U.S. patent application number 14/775924 was filed with the patent office on 2016-01-21 for kinase inhibitors.
The applicant listed for this patent is RESPIVERT LIMITED, TOPIVERT PHARMA LIMITED. Invention is credited to Matthew Colin Thor FYFE.
Application Number | 20160016934 14/775924 |
Document ID | / |
Family ID | 51535918 |
Filed Date | 2016-01-21 |
United States Patent
Application |
20160016934 |
Kind Code |
A1 |
FYFE; Matthew Colin Thor |
January 21, 2016 |
KINASE INHIBITORS
Abstract
There are provided compounds of formula I, ##STR00001## wherein:
Y represents NR.sup.2R.sup.3; one of R.sup.2 and R.sup.3 represents
--[C.sub.2-4 alkylene-O].sub.1-12--[C.sub.2-4 alkylene]-R.sup.2a
and the other of R.sup.2 and R.sup.3 has a meaning given in the
description; and R, R.sup.1, R.sup.2a, R.sup.a, R.sup.b, Q, X and Y
have meanings given in the description, which compounds have
antiinflammatory activity (e.g., through inhibition of one or more
of members of: the family of p38 mitogen-activated protein kinase
enzymes; Syk kinase; and members of the Src family of tyrosine
kinases) and have use in therapy, including in pharmaceutical
combinations, especially in the treatment of inflammatory diseases,
including inflammatory diseases of the lung, eye and
intestines.
Inventors: |
FYFE; Matthew Colin Thor;
(London, GB) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
RESPIVERT LIMITED
TOPIVERT PHARMA LIMITED |
Buckinghamshire
London |
|
GB
GB |
|
|
Family ID: |
51535918 |
Appl. No.: |
14/775924 |
Filed: |
March 13, 2014 |
PCT Filed: |
March 13, 2014 |
PCT NO: |
PCT/GB2014/050753 |
371 Date: |
September 14, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61782793 |
Mar 14, 2013 |
|
|
|
Current U.S.
Class: |
514/272 ;
514/341; 544/321; 546/275.4 |
Current CPC
Class: |
C07D 401/14 20130101;
A61K 31/5377 20130101; A61P 11/00 20180101; C07D 403/12 20130101;
A61K 31/506 20130101; A61K 31/675 20130101; A61K 31/4439 20130101;
A61P 29/00 20180101; C07D 401/12 20130101; A61K 45/06 20130101;
A61P 31/16 20180101; C07F 9/46 20130101 |
International
Class: |
C07D 401/12 20060101
C07D401/12; A61K 31/506 20060101 A61K031/506; A61K 31/4439 20060101
A61K031/4439; C07D 403/12 20060101 C07D403/12 |
Foreign Application Data
Date |
Code |
Application Number |
Aug 16, 2013 |
GB |
1314700.4 |
Dec 20, 2013 |
GB |
1322684.0 |
Claims
1. A compound of formula (I): ##STR00093## wherein: Q represents
thienyl, phenyl or pyridinyl, either of which may optionally bear 1
to 3 substituents independently selected from, hydroxyl, halogen,
C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 haloalkoxy, C.sub.1-6
hydroxyalkyl, NH.sub.2, N(H)--C.sub.1-6 alkyl, N(C.sub.1-6
alkyl).sub.2, -L-P(O)R'R'', C.sub.1-6 alkylene-5-10 membered
heterocycle and C.sub.0-3 alkylene-O--C.sub.0-6 alkylene-5-10
membered heterocycle; L is a direct bond or C.sub.1-2 alkylene; R'
represents C.sub.1-4 alkyl; R'' represents C.sub.1-4 alkyl,
C.sub.3-6 cycloalkyl, C.sub.1-4 alkoxy or hydroxy; or R' and R''
together combine to form C.sub.3-6 n-alkylene, wherein one CH.sub.2
of said n-alkylene group is optionally replaced by O, N(H) or
N(C.sub.1-4 alkyl); X represents CH or N, Y represents
NR.sup.2R.sup.3; R is C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.1-6
hydroxyalkyl, C.sub.1-6 haloalkyl, C.sub.1-6 alkyl substituted by
C.sub.2-3 alkynyl, C.sub.1-3 alkoxy or cyano, C.sub.0-2
alkylene-C.sub.3-8 cycloalkyl optionally substituted with C.sub.1-3
alkyl, a 4-5 membered heterocycle optionally substituted with
C.sub.1-3 alkyl or Si(R.sup.1a)(R.sup.1b)(R.sup.1c); R.sup.1a and
R.sup.1b independently represent C.sub.1-4 alkyl or C.sub.3-6
cycloalkyl, or R.sup.1a and R.sup.1b together combine to form
C.sub.2-6 alkylene; R.sup.1c represents C.sub.1-2 alkyl; R.sup.a
and R.sup.b, together with the C-atoms to which they are attached,
form a fused phenyl ring that is optionally substituted by one or
more substituents selected from C.sub.1-3 alkyl, C.sub.1-3
haloalkyl, cyano and halo, or one of R.sup.a and R.sup.b represents
H, halo, cyano, C.sub.1-3 alkyl or C.sub.1-3 haloalkyl and the
other independently represents halo, cyano, C.sub.1-3 alkyl or
C.sub.1-3 haloalkyl or R.sup.a and R.sup.b together represent
C.sub.3-5 n-alkylene, which alkylene group is optionally
substituted by one or more methyl substituents and/or which
alkylene group optionally contains one C--C double bond between two
C-atoms of the n-alkylene chain; R.sup.1 is selected from hydrogen,
OH, halogen, CN, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.0-3 alkylene-C.sub.3-6
cycloalkyl, C.sub.0-3 alkylene-O--C.sub.1-3 alkylene-C.sub.3-6
cycloalkyl, C.sub.1-6 alkoxy, C.sub.1-6 haloalkoxy, C.sub.1-6
hydroxyalkyl, C.sub.0-3 alkylene-SO.sub.2C.sub.1-3alkyl, C.sub.0-3
alkylene-SO.sub.2NR.sup.4R.sup.5, and C.sub.0-3
alkylene-NR.sup.6R.sup.7 and C.sub.0-3 alkylene-NCOR.sup.6R.sup.7;
one of R.sup.2 and R.sup.3 represents --[C.sub.2-4
alkylene-O].sub.1-12--[C.sub.2-4 alkylene]-R.sup.2a and the other
of R.sup.2 and R.sup.3 is selected from H, C.sub.1-8 alkyl,
C.sub.0-6 alkylene aryl, C.sub.0-6 alkylene heteroaryl,
--[C.sub.2-4 alkylene-O].sub.0-12--[C.sub.2-4 alkylene]-R.sup.2a,
C.sub.0-6 alkylene-4-10 membered heterocycle, and C.sub.0-3
alkylene-O--C.sub.0-6 alkylene-4-10 membered heterocycle with the
proviso that when the said heterocycle is linked through nitrogen
there are at least two C-atoms in the alkylene chain that links
that nitrogen atom to the essential O atom of the substituent,
wherein independently each alkyl or alkylene group optionally bears
1 oxo substituent, and optionally one or two carbon atoms in the
alkyl or alkylene chain may each be replaced by a heteroatom
selected from O, N or S(O).sub.p, such that when said alkyl or
alkylene comprises an amine said amino group is a tertiary amine,
wherein each 4-10 membered heterocycle is optionally substituted by
1 or 2 groups independently selected from halo, OH, C.sub.1-6
alkyl, C.sub.1-4 haloalkyl, C.sub.0-3 alkylene-O--C.sub.0-6 alkyl,
C.sub.0-3 alkylene-O--C.sub.1-3 haloalkyl, C.sub.0-6 alkylene aryl,
C.sub.0-3 alkylene-O--C.sub.0-3 alkylene aryl, C.sub.0-6 alkylene
heteroaryl, C.sub.0-3 alkylene-O--C.sub.0-3 alkylene heteroaryl,
C(O)C.sub.1-6 alkyl, SO.sub.2NR.sup.8R.sup.9, and C.sub.0-3
alkylene-NR.sup.8R.sup.9, C.sub.0-3
alkylene-NR.sup.8SO.sub.2R.sup.9 and C.sub.0-3
alkylene-NR.sup.8C(O)R.sup.9; R.sup.2a represents OR.sup.2b or
N(R.sup.2c) R.sup.2d; R.sup.2b to R.sup.2d independently represent
H or C.sub.1-4 alkyl optionally substituted by one or more halo
atoms, or R.sup.2C and R.sup.2d together represent C.sub.3-6
n-alkylene, C.sub.4-5 n-alkylene interrupted between C2 and C3 by
--O-- or --N(R.sup.2e)-- or C.sub.6 n-alkylene interrupted between
C2 and C3, or between C3 and C4, by --O-- or --N(R.sup.2e)--, any
of which n-alkylene groups are optionally substituted by one or
more substituents selected from halo, hydroxy, oxo, C.sub.1-4 alkyl
and C.sub.1-4 alkoxy; R.sup.2e represents H or C.sub.1-6 alkyl
optionally substituted by one or more substituents selected from
halo and hydroxy; R.sup.4 is H or C.sub.1-4 alkyl; R.sup.5 is H or
C.sub.1-4 alkyl, R.sup.6 is H or C.sub.1-4 alkyl,
C(O)C.sub.1-3alkyl and SO.sub.2C.sub.1-3 alkyl; R.sup.7 is H or
C.sub.1-4 alkyl, C(O)C.sub.1-3alkyl and SO.sub.2C.sub.1-3 alkyl;
R.sup.8 is H or C.sub.1-4 alkyl, and R.sup.9 is H or C.sub.1-4
alkyl, p is 0, 1 or 2 or a pharmaceutically acceptable salt
thereof, including all stereoisomers and tautomers thereof.
2. A compound according to claim 1 of formula (Id1) or formula
(Id2): ##STR00094## wherein R, R.sup.a, R.sup.b, R.sup.1, Q and Y
are as defined in claim 1.
3. A compound according to claim 1 of formula (If1) or formula
(If2): ##STR00095## wherein R, R.sup.a, R.sup.b, R.sup.1, Q and Y
are as defined in claim 1.
4. A compound according to claim 1 of formula (Ig1) or formula
(Ig2): ##STR00096## wherein R, R.sup.a, R.sup.b, R.sup.1, X, Q and
Y are as defined in claim 1.
5. A compound or salt according to claim 1, wherein R represents:
C.sub.1-6 n-alkyl, C.sub.3-6 branched alkyl, C.sub.2-6 alkenyl,
C.sub.1-6 hydroxyalkyl, C.sub.1-6 haloalkyl, C.sub.1-6 alkyl
substituted by C.sub.1-3 alkoxy or cyano, C.sub.0-2
alkylene-C.sub.3-8 cycloalkyl optionally substituted with C.sub.1-3
alkyl, or a 4-5 membered heterocycle optionally substituted with
C.sub.1-3 alkyl.
6. A compound according to claim 1, wherein: R.sup.1 represents
ethynyl or OCH.sub.3; R.sup.2 represents
--(CH.sub.2CH.sub.2O).sub.2-4CH.sub.3; and R.sup.3 is H.
7. A compound of formula (Ig2) ##STR00097## wherein: R represents
isopropyl, 1-methylcyclopropyl, propen-2-yl or tert-butyl; Q
represents phenyl substituted in the para position by methyl,
methoxy or dimethylamino; X represents CH or N; R.sup.1 represents
ethynyl or OCH.sub.3; Y is NR.sup.2R.sup.3; and one of R.sup.2 and
R.sup.3 represents --(CH.sub.2CH.sub.2O).sub.2-3CH.sub.3 and the
other of R.sup.2 and R.sup.3 is H, or a pharmaceutically acceptable
salt thereof, including all stereoisomers and tautomers
thereof.
8. A compound according to claim 1, wherein: Q represents phenyl
substituted in the para position by methyl, methoxy or
dimethylamino; and R represents isopropyl or tert-butyl.
9. A compound according to claim 1, wherein R represents
tert-butyl.
10. A compound according to claim 1 selected from the group
comprising or consisting of:
3-ethynyl-5-((4-((4-(3-(3-isopropyl-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)na-
phthalen-1-yl)oxy)pyrimidin-2-yl)amino)-N-(2-(2-(2-methoxyethoxy)ethoxy)et-
hyl)benzamide;
3-((4-((4-(3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthale-
n-1-yl)oxy)-pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-methoxyethoxy)ethox-
y)ethyl)benzamide;
3-((4-((4-(3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)ureido)n-
aphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-methoxyethox-
y)ethoxy)ethyl)-benzamide;
3-((4-((4-(3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthale-
n-1-yl)oxy)-pyridin-2-yl)amino)-5-methoxy-N-(2-(2-(2-methoxyethoxy)ethoxy)-
ethyl)benzamide;
3-((4-((4-(3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)ureido)--
naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-methoxyethoxy)-
ethyl)benzamide;
3-((4-((4-(3-(3-(tert-butyl)-1-(2,3,5,6-tetradeutero-4-(trideuteromethyl)-
phenyl)-1H-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-
-ethynyl-N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)benzamide;
3-((4-((4-(3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthale-
n-1-yl)oxy)-pyrimidin-2-yl)amino)-5-ethynyl-N-(2,5,8,11-tetraoxatridecan-1-
3-yl)benzamide;
3-((4-((4-(3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthale-
n-1-yl)oxy)-pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-methoxyethoxy)ethyl)be-
nzamide;
3-((4-((4-(3-(3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyraz-
ol-5-yl)ureido)-naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(-
2-(2-methoxyethoxy)-ethoxy)ethyl)benzamide;
3-((4-((4-(3-(3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)-
ureido)-naphthalen-1-yl)oxy)pyridin-2-yl)amino)-5-methoxy-N-(2-(2-(2-metho-
xyethoxy)-ethoxy)ethyl)benzamide;
3-((4-((4-(3-(3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)-
ureido)-naphthalen-1-yl)oxy)pyridin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-metho-
xyethoxy)-ethoxy)ethyl)benzamide;
3-((4-((4-(3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)-5,6,7,8--
tetrahydronaphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-m-
ethoxyethoxy)ethoxy)ethyl)benzamide;
3-((4-((4-(3-(3-(tert-butyl)-1-(2,4-dimethoxyphenyl)-1H-pyrazol-5-yl)urei-
do)naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-methoxye-
thoxy)ethoxy)ethyl)benzamide;
3-((4-((4-(3-(3-(tert-butyl)-1-(3-((dimethylphosphoryl)methyl)phenyl)-1H--
pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N--
(2-(2-(2-methoxyethoxy)ethoxy)ethyl)benzamide;
3-((4-((4-(3-(3-(tert-butyl)-1-(3-((dimethylphosphoryl)methyl)phenyl)-1H--
pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)pyridin-2-yl)amino)-5-methoxy-N-(2-
-(2-(2-methoxyethoxy)ethoxy)ethyl)benzamide;
3-((4-((4-(3-(3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)-
ureido)naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-methoxy-N-(2-(2-(2-meth-
oxyethoxy)ethoxy)ethyl)benzamide;
3-((4-((4-((3-(3-(tert-butyl)-1-(4-methoxy-2-methylphenyl)-1H-pyrazol-5-y-
l)ureido)naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-me-
thoxyethoxy)ethoxy)ethyl)benzamide, and pharmaceutically acceptable
salts thereof.
11. (canceled)
12. A compound according to claim 1 that is
3-((4-((4-(3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthale-
n-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-methoxyethoxy)ethoxy-
)ethyl)benzamide, or a pharmaceutically acceptable salt
thereof.
13. A pharmaceutical composition comprising a compound according to
claim 1, in combination with one or more pharmaceutically
acceptable diluents or carriers
14. A combination product comprising: (A) a compound according to
claim 1; and (B) another therapeutic agent, wherein each of
components (A) and (B) is formulated in admixture with a
pharmaceutically-acceptable adjuvant, diluent or carrier.
15. A medicament comprising a compound according to claim 1.
16. A method of treating a disease or condition in a subject
comprising administering to the subject a compound according to
claim 1, wherein the disease or condition is selected from the
group consisting of COPD, chronic bronchitis, emphysema, asthma,
pediatric asthma, cystic fibrosis, sarcoidosis, idiopathic
pulmonary fibrosis, allergic rhinitis, rhinitis, sinusitis,
allergic conjunctivitis, conjunctivitis, keratoconjunctivitis sicca
(dry eye), glaucoma, diabetic retinopathy, macular edema, diabetic
macular edema, central retinal vein occlusion (CRVO), dry and/or
wet age related macular degeneration (AMD), post-operative cataract
inflammation, uveitis, posterior uveitis, anterior uveitis, pan
uveitis, corneal graft and limbal cell transplant rejection, gluten
sensitive enteropathy (coeliac disease), eosinophilic esophagitis,
intestinal graft versus host disease, Crohn's disease, ulcerative
colitis, rheumatoid arthritis and osteoarthritis.
17. The method of claim 16, wherein the disease or condition is
selected from the group consisting of COPD, asthma,
keratoconjunctivitis sicca (dry eye), uveitis, posterior uveitis,
anterior uveitis, pan uveitis, Crohn's disease and ulcerative
colitis.
18. (canceled)
19. (canceled)
20. A process for the preparation of a compound of formula (I), as
defined in claim 1, which process comprises: (a) reacting a
compound of formula (II), with a compound of formula (III) wherein
LG.sup.II represents a leaving group and one of Z.sup.1 and Z.sup.2
is a structural fragment of formula (IV) wherein R and Q are as
defined in claim 1, and the other of Z.sup.1 and Z.sup.2 is a
structural fragment of formula (V) wherein R.sup.1, R.sup.a,
R.sup.b, X and Y are as defined in claim 1; (b) reacting a compound
of formula (VI), wherein R, R.sup.a, R.sup.b, Q and X are as
defined in claim 1 and LG.sup.VI represents a leaving group, with a
compound of formula (VII), wherein R.sup.1 and Y are as defined in
claim 1; (c) reacting a compound of formula (VIII), with a compound
of formula (III), wherein the compound of formula (III) and Z.sup.1
and Z.sup.2 are as defined above; (d) reacting a compound of
formula (IX), wherein Z.sup.1 is as defined above, with an
azide-forming agent, which reaction is followed, without isolation,
by thermal rearrangement of the intermediate acyl azide (of formula
Z.sup.1--C(O)--N.sub.3) to provide, in situ, a compound of formula
(VIII), which compound is then reacted with a compound of formula
(III), as defined above, to provide the compound of formula (I);
(e) reacting a compound of formula (X) wherein R, R.sup.1, R.sup.a,
R.sup.b, Q and X are as defined in claim 1 and R.sup.X represents H
or C.sub.1-4 alkyl, with a compound of formula (XI) wherein R.sup.2
and R.sup.3 are as hereinbefore defined; or (f) deprotecting a
protected derivative of a compound of formula (I).
21. A compound of formula (III), as defined in claim 20, or a salt
or protected derivative thereof, wherein Z.sup.2 represents a
structural fragment of formula (V), as defined in claim 20.
22. A compound of formula (VII), as defined in claim 20, or a salt
or protected derivative thereof.
Description
FIELD OF THE INVENTION
[0001] The invention relates to compounds which are inhibitors of
the family of p38 mitogen-activated protein kinase enzymes
(referred to herein as p38 MAP kinase inhibitors), for example the
alpha and gamma sub-types thereof, and of Syk kinase and the Src
family of tyrosine kinases, and to their use in therapy, including
in pharmaceutical combinations, especially in the treatment of
inflammatory diseases, in particular inflammatory diseases of the
lung, such as asthma and COPD, as well as those of the
gastrointestinal tract, such as ulcerative colitis and Crohn's
disease, and of the eye, such as uveitis.
BACKGROUND OF THE INVENTION
[0002] The listing or discussion of an apparently prior-published
document in this specification should not necessarily be taken as
an acknowledgement that the document is part of the state of the
art or is common general knowledge.
[0003] Four p38 MAPK isoforms (alpha, beta, gamma and delta
respectively), each displaying different patterns of tissue
expression, have been identified. The p38 MAPK alpha and beta
isoforms are found ubiquitously in the body, being present in many
different cell types. The alpha isoform is well characterized in
terms of its role in inflammation. Although studies using a
chemical genetic approach in mice indicate that the p38 MAPK beta
isoform does not play a role in inflammation (O'Keefe, S. J. et
al., J Biol Chem., 2007, 282(48):34663-71), it may be involved in
pain mechanisms through the regulation of COX2 expression
(Fitzsimmons, B. L. et al., Neuroreport, 2010, 21(4):313-7). These
isoforms are inhibited by a number of previously described small
molecular weight compounds. Early classes of inhibitors were highly
toxic due to the broad tissue distribution of these isoforms which
resulted in multiple off-target effects of the compounds.
Furthermore, development of a substantial number of inhibitors has
been discontinued due to unacceptable safety profiles in clinical
studies (Pettus, L. H. and Wurz, R. P., Curr. Top. Med. Chem.,
2008, 8(16):1452-67). As these adverse effects vary with chemotype,
and each of these compounds has distinct kinase selectivity
patterns, the toxicities observed may be structure--rather than p38
mechanism-based.
[0004] Less is known about the p38 MAPK gamma and delta isoforms,
which, unlike the alpha and beta isozymes are expressed in specific
tissues and cells. The p38 MAPK-delta isoform is expressed more
highly in the pancreas, testes, lung, small intestine and the
kidney. It is also abundant in macrophages and detectable in
neutrophils, CD4+ T cells and in endothelial cells (Shmueli, O. et
al., Comptes Rendus Biologies, 2003, 326(10-11):1067-1072; Smith,
S. J. Br. J. Pharmacol., 2006, 149:393-404; Hale, K. K., J.
Immunol., 1999, 162(7):4246-52; Wang, X. S. et al., J. Biol. Chem.,
1997, 272(38):23668-23674.) Very little is known about the
distribution of p38 MAPK gamma although it is expressed more highly
in brain, skeletal muscle and heart, as well as in lymphocytes and
macrophages. (Shmueli, O. et al., Comptes Rendus Biologies, 2003,
326(10-11):1067-1072, (2003)/; Hale, K. K., J. Immunol., 1999,
162(7):4246-52: Court, N. W. et al., J. Mol. Cell. Cardiol., 2002,
34(4):413-26; Mertens, S. et al., FEBS Lett., 1996,
383(3):273-6.)
[0005] Selective small molecule inhibitors of p38 MAPK gamma and
p38 MAPK delta are not currently available, although one previously
disclosed compound, BIRB 796, is known to possess pan-isoform
inhibitory activity. The inhibition of p38 MAPK gamma and delta
isoforms is observed at higher concentrations of the compound than
those required to inhibit p38 MAPK alpha and p38 beta (Kuma, Y. J.
Biol. Chem., 2005, 280:19472-19479). In addition BIRB 796 also
impaired the phosphorylation of p38 MAPKs or JNKs by the upstream
kinase MKK6 or MKK4. Kuma discussed the possibility that the
conformational change caused by the binding of the inhibitor to the
MAPK protein may affect the structure of both its phosphorylation
site and the docking site for the upstream activator, thereby
impairing the phosphorylation of p38 MAPKs or JNKs.
[0006] p38 MAP kinase is believed to play a pivotal role in many of
the signalling pathways that are involved in initiating and
maintaining chronic, persistent inflammation in human disease, for
example, in severe asthma, COPD (Chung, F., Chest, 2011,
139(6):1470-1479) and inflammatory bowel disease (IBD). There is
now an abundant literature which demonstrates that p38 MAP kinase
is activated by a range of pro-inflammatory cytokines and that its
activation results in the recruitment and release of additional
pro-inflammatory cytokines. Indeed, data from some clinical studies
demonstrate beneficial changes in disease activity in patients
during treatment with p38 MAP kinase inhibitors. For instance Smith
describes the inhibitory effect of p38 MAP kinase inhibitors on
TNF.alpha. (but not IL-8) release from human PBMCs.
[0007] The use of inhibitors of p38 MAP kinase in the treatment of
COPD and IBD has also been proposed. Small molecule inhibitors
targeted to p38 MAPK .alpha./.beta. have proved to be effective in
reducing various parameters of inflammation in: [0008] cells and
tissues obtained from patients with COPD, who are generally
corticosteroid insensitive, (Smith, S. J., Br. J. Pharmacol., 2006,
149:393-404); [0009] biopsies from IBD patients (Docena, G. et al.,
J. of Trans. Immunol., 2010, 162:108-115); and [0010] in vivo
animal models (Underwood, D. C. et al., Am. J. Physiol., 2000,
279:L895-902; Nath, P. et al., Eur. J. Pharmacol., 2006,
544:160-167).
[0011] Irusen and colleagues also suggested the possibility of
involvement of p38 MAPK.alpha./.beta. on corticosteroid
insensitivity via the reduction of binding affinity of the
glucocorticoid receptor (GR) in nuclei (Irusen, E. et al., J.
Allergy Clin. Immunol., 2002, 109:649-657). Clinical experience
with a range of p38 MAP kinase inhibitors, including AMG548, BIRB
796, VX702, SCIO469 and SCIO323 has been described (Lee, M. R. and
Dominguez, C., Current Med. Chem., 2005, 12:2979-2994). However,
the major obstacle hindering the utility of p38 MAP kinase
inhibitors in the treatment of human chronic inflammatory diseases
has been the toxicity observed in patients. This has been
sufficiently severe to result in the withdrawal from clinical
development of many of the compounds progressed, including all
those specifically mentioned above.
[0012] COPD is a condition in which the underlying inflammation is
reported to be substantially resistant to the anti-inflammatory
effects of inhaled corticosteroids. Consequently, a superior
strategy for treating COPD would be to develop an intervention
which has both inherent anti-inflammatory effects and the ability
to increase the sensitivity of the lung tissues of COPD patients to
inhaled corticosteroids. A recent publication of Mercado (Mercado,
N., et al., Mol. Pharmacol., 2011, 80(6):1128-1135) demonstrates
that silencing p38 MAPK gamma has the potential to restore
sensitivity to corticosteroids. Consequently there may be a dual
benefit for patients in the use of a p38 MAP kinase inhibitor for
the treatment of COPD and severe asthma.
[0013] Many patients diagnosed with asthma or with COPD continue to
suffer from uncontrolled symptoms and from exacerbations of their
medical condition that can result in hospitalization. This occurs
despite the use of the most advanced, currently available treatment
regimens, comprising of combination products of an inhaled
corticosteroid and a long acting .beta.-agonist. Data accumulated
over the last decade indicates that a failure to manage effectively
the underlying inflammatory component of the disease in the lung is
the most likely reason that exacerbations occur. Given the
established efficacy of corticosteroids as anti-inflammatory agents
and, in particular, of inhaled corticosteroids in the treatment of
asthma, these findings have provoked intense investigation.
Resulting studies have identified that some environmental insults
invoke corticosteroid-insensitive inflammatory changes in patients'
lungs. An example is the response arising from virally-mediated
upper respiratory tract infections (URTI), which have particular
significance in increasing morbidity associated with asthma and
COPD.
[0014] Epidemiologic investigations have revealed a strong
association between viral infections of the upper respiratory tract
and a substantial percentage of the exacerbations suffered by
patients already diagnosed with chronic respiratory diseases. Some
of the most compelling data in this regard derives from
longitudinal studies of children suffering from asthma
(Papadopoulos, N. G., Papi, A., Psarras, S. and Johnston, S. L.,
Paediatr. Respir. Rev., 2004, 5(3):255-260). A variety of
additional studies support the conclusion that a viral infection
can precipitate exacerbations and increase disease severity. For
example, experimental clinical infections with rhinovirus have been
reported to cause bronchial hyper-responsiveness to histamine in
asthmatics which is unresponsive to treatment with corticosteroids
(Grunberg, K., Sharon, R. F., et al., Am. J. Respir. Crit. Care
Med., 2001, 164(10):1816-1822). Further evidence derives from the
association observed between disease exacerbations in patients with
cystic fibrosis and HRV infections (Wat, D., Gelder, C., et al., J.
Cyst. Fibros., 2008, 7:320-328). Also consistent with this body of
data is the finding that respiratory viral infections, including
rhinovirus, represent an independent risk factor that correlates
negatively with the 12 month survival rate in pediatric, lung
transplant recipients (Liu, M., Worley, S., et al., Transpl.
Infect. Dis., 2009, 11(4):304-312).
[0015] Clinical research indicates that the viral load is
proportionate to the observed symptoms and complications and, by
implication, to the severity of inflammation. For example,
following experimental rhinovirus infection, lower respiratory
tract symptoms and bronchial hyper-responsiveness correlated
significantly with virus load (Message, S. D., Laza-Stanca, V., et
al., PNAS, 2008; 105(36):13562-13567). Similarly, in the absence of
other viral agents, rhinovirus infections were commonly associated
with lower respiratory tract infections and wheezing, when the
viral load was high in immunocompetent pediatric patients (Gerna,
G., Piralla, A., et al., J. Med. Virol., 2009,
81(8):1498-1507).
[0016] Interestingly, it has been reported recently that prior
exposure to rhinovirus reduced the cytokine responses evoked by
bacterial products in human alveolar macrophages (Oliver, B. G.,
Lim, S., et al., Thorax, 2008, 63:519-525). Additionally, infection
of nasal epithelial cells with rhinovirus has been documented to
promote the adhesion of bacteria, including S. aureus and H.
influenzae (Wang, J. H., Kwon, H. J. and Yong, J. J., The
Laryngoscope, 2009, 119(7):1406-1411). Such cellular effects may
contribute to the increased probability of patients suffering a
lower respiratory tract infection following an infection in the
upper respiratory tract. Accordingly, it is therapeutically
relevant to focus on the ability of novel interventions to decrease
viral load in a variety of in vitro systems, as a surrogate
predictor of their benefit in a clinical setting.
[0017] High risk groups, for whom a rhinovirus infection in the
upper respiratory tract can lead to severe secondary complications,
are not limited to patients with chronic respiratory disease. They
include, for example, the immune compromised who are prone to lower
respiratory tract infection, as well as patients undergoing
chemotherapy, who face acute, life-threatening fever. It has also
been suggested that other chronic diseases, such as diabetes, are
associated with a compromised immuno-defense response. This
increases both the likelihood of acquiring a respiratory tract
infection and of being hospitalized as a result (Peleg, A. Y.,
Weerarathna, T., et al., Diabetes Metab. Res. Rev., 2007,
23(1):3-13; Kornum, J. B., Reimar, W., et al., Diabetes Care, 2008,
31(8): 1541-1545).
[0018] Whilst upper respiratory tract viral infections are a cause
of considerable morbidity and mortality in those patients with
underlying disease or other risk factors; they also represent a
significant healthcare burden in the general population and are a
major cause of missed days at school and lost time in the workplace
(Rollinger, J. M. and Schmidtke, M., Med. Res. Rev., 2010, Doi
10.1002/med.20176). These considerations make it clear that novel
medicines, that possess improved efficacy over current therapies,
are urgently required to prevent and treat rhinovirus-mediated
upper respiratory tract infections. In general the strategies
adopted for the discovery of improved antiviral agents have
targeted various proteins produced by the virus, as the point of
therapeutic intervention. However, the wide range of rhinovirus
serotypes makes this a particularly challenging approach to pursue
and may explain why, at the present time, a medicine for the
prophylaxis and treatment of rhinovirus infections has yet to be
approved by any regulatory agency.
[0019] Viral entry into the host cell is associated with the
activation of a number of intracellular signalling pathways
controlled by the relative activation and inactivation of specific
kinases which are believed to play a prominent role in the
initiation of inflammatory processes (reviewed by Ludwig, S, 2007;
Signal Transduction, 7:81-88) and of viral propagation and
subsequent release.
[0020] It has been disclosed previously that compounds that inhibit
the activity of both c-Src and Syk kinases are effective agents
against rhinovirus replication (Charron, C. E. et al., WO
2011/158042) and that compounds that inhibit p59-HCK are effective
against influenza virus replication (Charron, C. E. et al., WO
2011/070369). For the reasons summarized above, in combination with
the inhibition of p38 MAPKs, these are particularly advantageous
inherent properties for compounds designed to treat chronic
respiratory diseases.
[0021] Certain p38 MAPK inhibitors have also been described as
inhibitors of the replication of respiratory syncytial virus (Cass,
L. et al., WO 2011/158039).
[0022] The precise etiology of IBD is uncertain, but is believed to
be governed by genetic and environmental factors that interact to
promote an excessive and poorly controlled mucosal inflammatory
response directed against components of the luminal microflora.
This response is mediated through infiltration of inflammatory
neutrophils, dendritic cells and T-cells from the periphery. Due to
the ubiquitous expression of p38 in inflammatory cells it has
become an obvious target for investigation in IBD models. Studies
investigating the efficacy of p38 inhibitors in animal models of
IBD and human biopsies from IBD patients indicated that p38 could
be a target for the treatment of IBD (Hove, T. ten et al., Gut,
2002, 50:507-512, Docena, G. et al., J. of Trans. Immunol., 2010,
162:108-115). However, these findings are not completely consistent
with other groups reporting no effect with p38 inhibitors (Malamut
G. et al., Dig. Dis. Sci, 2006, 51:1443-1453). A clinical study in
Crohn's patients using the p38 alpha inhibitor BIRB796 demonstrated
potential clinical benefit with an improvement in C-reactive
protein levels. However this improvement was transient, returning
to baseline by week 8 (Schreiber, S. et al., Clin. Gastro.
Hepatology, 2006, 4:325-334). A small clinical study investigating
the efficacy of CNI-1493, a p38 and Jnk inhibitor, in patients with
severe Crohn's disease showed significant improvement in clinical
score over 8 weeks (Hommes, D. et al. Gastroenterology. 2002
122:7-14).
[0023] T cells are known to play key role in mediating inflammation
of the gastrointestinal tract. Pioneering work by Powrie and
colleagues demonstrated that transfer of naive CD4+ cells into
severely compromised immunodeficient (SCID) animals results in the
development of colitis which is dependent on the presence of
commensal bacteria (Powrie F. et al. Int Immunol. 1993 5:1461-71).
Furthermore, investigation of mucosal membranes from IBD patients
showed an upregulation of CD4+ cells which were either Th1
(IFN.gamma./IL-2) or Th2 (IL5/TGF.beta.) biased depending on
whether the patient had Crohn's disease or ulcerative colitis (Fuss
I J. et al. J Immunol. 1996 157:1261-70). Similarly, T cells are
known to play a key role in inflammatory disorders of the eye with
several studies reporting increased levels of T cell associated
cytokines (IL-17 and IL-23) in sera of Behcets patients (Chi W. et
al. Invest Ophthalmol Vis Sci. 2008 49:3058-64). In support,
Direskeneli and colleagues demonstrated that Behcets patients have
increased Th17 cells and decreased Treg cells in their peripheral
blood (Direskeneli H. et al. J Allergy Clin Immunol. 2011
128:665-6).
[0024] One approach to inhibit T cell activation is to target
kinases which are involved in activation of the T cell receptor
signalling complex. Syk and Src family kinases are known to play a
key role in this pathway, where Src family kinases, Fyn and Lck,
are the first signalling molecules to be activated downstream of
the T cell receptor (Barber E K. et al. PNAS 1989 86:3277-81). They
initiate the tyrosine phosphorylation of the T cell receptor
leading to the recruitment of the Syk family kinase, ZAP-70. Animal
studies have shown that ZAP-70 knockout results in a SCID phenotype
(Chan A C. et al. Science. 1994 10; 264(5165):1599-601).
[0025] A clinical trial in rheumatoid arthritis patients with the
Syk inhibitor Fostamatinib demonstrated the potential of Syk as an
anti-inflammatory target with patients showing improved clinical
outcome and reduced serum levels of IL-6 and MMP-3 (Weinblatt M E.
et al. Arthritis Rheum. 2008 58:3309-18). Syk kinase is widely
expressed in cells of the hematopoietic system, most notably in B
cells and mature T cells. Through interaction with immunoreceptor
tyrosine-based activation (ITAM) motifs it plays an important role
in regulating T cell and B cell expansion as well as mediating
immune-receptor signalling in inflammatory cells. Syk activation
leads to IL-6 and MMP release--inflammatory mediators commonly
found upregulated in inflammatory disorders including IBD and
rheumatoid arthritis (Wang Y D. et al World J Gastroenterol 2007;
13: 5926-5932, Litinsky I et al. Cytokine. 2006 January
33:106-10).
[0026] In addition to playing key roles in cell signalling events
which control the activity of pro-inflammatory pathways, kinase
enzymes are now also recognised to regulate the activity of a range
of cellular functions. Among those which have been discussed
recently are the maintenance of DNA integrity (Shilo, Y. Nature
Reviews Cancer, 2003, 3:155-168) and co-ordination of the complex
processes of cell division. An illustration of recent findings is a
publication describing the impact of a set of inhibitors acting
upon the so-called "Olaharsky kinases" on the frequency of
micronucleus formation in vitro (Olaharsky, A. J. et al., PLoS
Comput. Biol., 2009, 5(7):e1000446). Micronucleus formation is
implicated in, or associated with, disruption of mitotic processes
and is therefore an undesirable manifestation of potential
toxicity. Inhibition of glycogen synthase kinase 3.alpha.
(GSK3.alpha.) was found to be a particularly significant factor
that increases the likelihood of a kinase inhibitor promoting
micronucleus formation. Recently, inhibition of the kinase
GSK3.beta. with RNAi was also reported to promote micronucleus
formation (Tighe, A. et al., BMC Cell Biology, 2007, 8:34).
[0027] It may be possible to attenuate the adverse effects arising
from drug interactions with Olaharsky kinases, such as GSK3.alpha.,
by optimisation of the dose and/or by changing the route of
administration. However, it would be more advantageous to identify
therapeutically useful molecules that demonstrate low or
undetectable activity against these off-target enzymes and
consequently elicit little or no disruption of mitotic processes,
as measured in mitosis assays.
[0028] It is evident from consideration of the literature cited
hereinabove that there remains a need to identify and develop new
p38 MAP kinase inhibitors that have improved therapeutic potential
over currently available treatments. Desirable compounds are those
that exhibit a superior therapeutic index by exerting, at the
least, an equally efficacious effect as previous agents but, in one
or more respects, are less toxic at the relevant therapeutic dose.
The present invention therefore, inter alia, provides such novel
compounds that inhibit the enzyme activity of p38 MAP kinase, for
example with certain sub-type specificities, optionally together
with Syk kinase and tyrosine kinases within the Src family
(particularly c-Src) thereby possessing good anti-inflammatory
properties, and suitable for use in therapy.
[0029] In one or more embodiments the compounds exhibit a long
duration of action and/or persistence of action.
SUMMARY OF THE INVENTION
[0030] In a first aspect, the invention provides a compound of
formula (I),
##STR00002##
wherein: Q represents thienyl, phenyl or pyridinyl, either of which
may optionally bear 1 to 3 substituents independently selected
from, hydroxyl, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy,
C.sub.1-6 haloalkoxy, C.sub.1-6 hydroxyalkyl, NH.sub.2,
N(H)--C.sub.1-6 alkyl, N(C.sub.1-6 alkyl).sub.2, -L-P(O)R'R'',
C.sub.1-6 alkylene-5-10 membered heterocycle and C.sub.0-3
alkylene-O--C.sub.0-6 alkylene-5-10 membered heterocycle; L is a
direct bond or C.sub.1-2 alkylene; R' represents C.sub.1-4 alkyl;
R'' represents C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, C.sub.1-4
alkoxy or hydroxy; or R' and R'' together combine to form C.sub.3-6
n-alkylene, wherein one CH.sub.2 of said n-alkylene group is
optionally replaced by O, N(H) or N(C.sub.1-4 alkyl); X represents
CH or N, Y represents NR.sup.2R.sup.3;
R is
[0031] C.sub.1-6 alkyl, [0032] C.sub.2-6 alkenyl, [0033] C.sub.1-6
hydroxyalkyl, [0034] C.sub.1-6 haloalkyl, [0035] C.sub.1-6 alkyl
substituted by C.sub.2-3 alkynyl, C.sub.1-3 alkoxy or cyano, [0036]
C.sub.0-2 alkylene-C.sub.3-8 cycloalkyl optionally substituted with
C.sub.1-3 alkyl, [0037] a 4-5 membered heterocycle optionally
substituted with C.sub.1-3 alkyl or [0038]
Si(R.sup.1a)(R.sup.1b)(R.sup.1c); R.sup.1a and R.sup.1b
independently represent C.sub.1-4 alkyl or C.sub.3-6 cycloalkyl, or
R.sup.1a and R.sup.1b together combine to form C.sub.2-6 alkylene;
R.sup.1c represents C.sub.1-2 alkyl; R.sup.a and R.sup.b, together
with the C-atoms to which they are attached, form a fused phenyl
ring that is optionally substituted by one or more substituents
selected from C.sub.1-3 alkyl, C.sub.1-3 haloalkyl, cyano and halo,
or one of R.sup.a and R.sup.b represents H, halo, cyano, C.sub.1-3
alkyl or C.sub.1-3 haloalkyl and the other independently represents
halo, cyano, C.sub.1-3 alkyl or C.sub.1-3 haloalkyl or R.sup.a and
R.sup.b together represent C.sub.3-5 n-alkylene, which alkylene
group is optionally substituted by one or more methyl substituents
and/or which alkylene group optionally contains one C--C double
bond between two C-atoms of the n-alkylene chain; R.sup.1 is
selected from hydrogen, OH, halogen, CN, C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.0-3
alkylene-C.sub.3-6 cycloalkyl, C.sub.0-3 alkylene-O--C.sub.1-3
alkylene-C.sub.3-6 cycloalkyl, C.sub.1-6 alkoxy, C.sub.1-6
haloalkoxy, C.sub.1-6 hydroxyalkyl, C.sub.0-3
alkylene-SO.sub.2C.sub.1-3alkyl, C.sub.0-3
alkylene-SO.sub.2NR.sup.4R.sup.5, and C.sub.0-3
alkylene-NR.sup.6R.sup.7 and C.sub.0-3 alkylene-NCOR.sup.6R.sup.7;
one of R.sup.2 and R.sup.3 represents --[C.sub.2-4
alkylene-O].sub.1-12--[C.sub.2-4 alkylene]-R.sup.2a and the other
of R.sup.2 and R.sup.3 is selected from H, C.sub.1-8 alkyl,
C.sub.0-6 alkylene aryl, C.sub.0-6 alkylene heteroaryl,
--[C.sub.2-4 alkylene-O].sub.0-12--[C.sub.2-4 alkylene]-R.sup.2a,
C.sub.0-6 alkylene-4-10 membered heterocycle, and C.sub.0-3
alkylene-O--C.sub.0-6 alkylene-4-10 membered heterocycle with the
proviso that when the said heterocycle is linked through nitrogen
there are at least two C-atoms in the alkylene chain that links
that nitrogen atom to the essential O atom of the substituent,
wherein independently each alkyl or alkylene group optionally bears
1 oxo substituent, and optionally one or two carbon atoms in the
alkyl or alkylene chain may each be replaced by a heteroatom
selected from O, N or S(O).sub.p, such that when said alkyl or
alkylene comprises an amine said amino group is a tertiary amine,
wherein each 4-10 membered heterocycle is optionally substituted by
1 or 2 groups independently selected from halo, OH, C.sub.1-6
alkyl, C.sub.1-4 haloalkyl, C.sub.0-3 alkylene-O--C.sub.0-6 alkyl,
C.sub.0-3 alkylene-O--C.sub.1-3 haloalkyl, C.sub.0-6 alkylene aryl,
C.sub.0-3 alkylene-O--C.sub.0-3 alkylene aryl, C.sub.0-6 alkylene
heteroaryl, C.sub.0-3 alkylene-O--C.sub.0-3 alkylene heteroaryl,
C(O)C.sub.1-6 alkyl, SO.sub.2NR.sup.8R.sup.9, and C.sub.0-3
alkylene-NR.sup.8R.sup.9, C.sub.0-3
alkylene-NR.sup.8SO.sub.2R.sup.9 and C.sub.0-3
alkylene-NR.sup.8C(O)R.sup.9; R.sup.2a represents OR.sup.2b or
N(R.sup.2c)R.sup.2d; R.sup.2b to R.sup.2d independently represent H
or C.sub.1-4 alkyl optionally substituted by one or more halo
atoms, or R.sup.2c and R.sup.2d together represent [0039] C.sub.3-6
n-alkylene, [0040] C.sub.4-6 n-alkylene interrupted between C2 and
C3 by --O-- or --N(R.sup.2e)-- or [0041] C.sub.6 n-alkylene
interrupted between C2 and C3, or between C3 and C4, by --O-- or
--N(R.sup.2e)--, any of which n-alkylene groups are optionally
substituted by one or more substituents selected from halo,
hydroxy, oxo, C.sub.1-4 alkyl and C.sub.1-4 alkoxy; R.sup.2e
represents H or C.sub.1-6 alkyl optionally substituted by one or
more substituents selected from halo and hydroxy; R.sup.4 is H or
C.sub.1-4 alkyl; R.sup.5 is H or C.sub.1-4 alkyl, R.sup.6 is H or
C.sub.1-4 alkyl, C(O)C.sub.1-3alkyl and SO.sub.2C.sub.1-3 alkyl;
R.sup.7 is H or C.sub.1-4 alkyl, C(O)C.sub.1-3alkyl and
SO.sub.2C.sub.1-3 alkyl; R.sup.8 is H or C.sub.1-4 alkyl, and
R.sup.9 is H or C.sub.1-4 alkyl, p is 0, 1 or 2 or a
pharmaceutically acceptable salt thereof, including all
stereoisomers and tautomers thereof.
[0042] Compounds of the invention are inhibitors of p38 MAP kinase
especially of the alpha sub-type.
[0043] In at least some embodiments compounds of the present
invention have low B-Raf binding, for example less than 40%
inhibition of the kinase binding at 500 nM, such as 30% inhibition
or less in an assay such as the Kinomescan method.
[0044] B-Raf is a member of the Raf kinase family of
serine/threonine-specific protein kinases. This protein plays a
role in regulating the MAP kinase/ERKs signalling pathway, which
affects cell division, differentiation, and secretion. A mutation
of the gene has been associated with cancer in humans (Davies, H.
et al., Nature, 2002, 417(6892):949-54).
[0045] Cell signalling can bypass selective inhibition of B-Raf
with undesirable consequences (Lo, R. S., Cell Research, advance
online publication 8 May 2012; doi: 10.1038/cr.2012.78). It is
therefore preferable that kinase inhibitors intended for use as
anti-inflammatory medicines should have minimal potential to
interact with B-Raf.
[0046] The present compounds also display low affinity for
GSK3.alpha. kinase in binding assays, which is considered to be
beneficial in a therapeutic context, in particular in relation to
minimising toxicity in vivo.
[0047] In at least some embodiments, compounds of the present
invention have p59-HCK inhibitory activity which may also augment
their advantageous therapeutic profile.
DETAILED DESCRIPTION OF THE INVENTION
[0048] Alkyl as used herein refers to straight chain or branched
chain alkyl, such as, without limitation, methyl, ethyl, n-propyl,
iso-propyl, butyl, n-butyl and tert-butyl. In one embodiment alkyl
refers to straight chain alkyl.
[0049] Alkoxy as used herein refers to straight or branched chain
alkoxy, for example methoxy, ethoxy, propoxy, butoxy. Alkoxy as
employed herein also extends to embodiments in which the or an
oxygen atom (e.g. a single oxygen atom) is located within the alkyl
chain, for example --C.sub.1-3 alkylOC.sub.1-3 alkyl, such as
--CH.sub.2CH.sub.2OCH.sub.3 or --CH.sub.2OCH.sub.3. Thus in one
embodiment the alkoxy is linked through carbon to the remainder of
the molecule, for example --C.sub.6-nalkyl-O--C.sub.6-malkyl in
which n=1-5, m=1-5 and n+m=6-10. In one embodiment the alkoxy is
linked through oxygen to the remainder of the molecule, for example
--OC.sub.1-6 alkyl. In one embodiment the disclosure relates to
straight chain alkoxy. In one embodiment the alkoxy is linked
through oxygen to the remainder of the molecule but the alkoxy
group contains a further oxygen atom, for example
--OCH.sub.2CH.sub.2OCH.sub.3.
[0050] Halo or halogen includes fluoro, chloro, bromo or iodo, in
particular fluoro, chloro or bromo, especially fluoro or
chloro.
[0051] Alkyl substituted by halo (haloalkyl) as employed herein
refers to alkyl groups having 1 to 6 halogen atoms, for example 1
to 5 halogens, such as per haloalkyl, in particular perfluoroalkyl,
more specifically --CF.sub.2CF.sub.3 or CF.sub.3.
[0052] Alkyl substituted by hydroxy (hydroxyalkyl) as employed
herein refers to alkyl groups having 1 to 3 hydroxy groups, for
example 1 or 2 hydroxy substituents thereon, for example
--CH.sub.2CH.sub.2OH, --C(CH.sub.3)CH.sub.2OH,
--C(CH.sub.3).sub.2CH.sub.2OH or similar.
[0053] Alkoxy substituted by halo (haloalkoxy) as employed herein
refers to alkoxy groups having 1 to 6 halogen atoms, for example 1
to 5 halogens, such as per haloalkoxy, in particular
perfluoroalkoxy, more specifically --OCF.sub.2CF.sub.3 or
--OCF.sub.3.
[0054] Unless otherwise specified, alkylene as employed herein is a
straight chain or branched chain carbon linking group, for example
comprising methylenes, between two other moieties. It will be clear
to those skilled in the art that groups defined as, for example
C.sub.2-8 alkenyl and C.sub.2-8 alkynyl may comprise an alkylene
portion. For the avoidance of doubt, the term "n-alkylene", when
used herein, refers to straight chain alkylene.
[0055] It will be clear to persons skilled in the art that the
heteroatom may replace a primary, secondary or tertiary carbon,
that is a CH.sub.3, --CH.sub.2-- or a --CH--, group, as technically
appropriate and hydrogen or branching in the alkyl or alkylene
chain will fill the valency of the heteroatom as appropriate to the
location, for example where a terminal primary carbon is replaced
by an oxygen heteroatom the terminal group will be an alcohol.
[0056] C.sub.1-6 alkyl includes C.sub.1, C.sub.2, C.sub.3, C.sub.4,
C.sub.5 and C.sub.6.
[0057] C.sub.1-6 alkoxy includes C.sub.1, C.sub.2, C.sub.3,
C.sub.4, C.sub.5 and C.sub.6.
[0058] The term 5-10 membered heterocycle, as employed herein
refers to a 5 to 10 membered saturated or partially unsaturated
non-aromatic ring comprising one or more, for example 1, 2, 3 or 4
heteroatoms independently selected from O, N and S, wherein
optionally one or two carbons in the ring may bear an oxo
substituent. Any valencies of a heteroatom not employed in forming
or retaining the ring structure may be filled by hydrogen or a
substituent, as appropriate. Thus the optional substituents on the
heterocycles may be attached to a carbon or on a heteroatom, such
as nitrogen as appropriate. Examples of 5-10 membered heterocycles
include, pyrroline, pyrrolidine, tetrahydrofuran, thiepane, oxepane
piperidine, piperazine, morpholine, thiomorpholine, dioxane,
tetrahydrothiophene, pyrazoline, imidazoline, pyrazolidine,
oxoimidazolidine, dioxolane, thiazolidine, isoxazolidine,
dihydropyran, dihydroindene, dihydroisobenzofuran,
isoindolin-1-one, chroman, 1,2,3,4-tetrahydroquinoline,
2,3-dihydrobenzo[b][1,4]dioxineazocane, and the like.
[0059] The term 5-6 membered heterocycle as employed herein refers
to a 5 to 6 membered saturated or partially unsaturated
non-aromatic ring comprising one or more, for example 1, 2, 3 or 4
heteroatoms independently selected from O, N and S wherein
optionally one or two carbons in the ring may bear an oxo
substituent. The definition of C.sub.5-6 heterocycle as employed
herein refers to a 5 to 6 membered saturated or partially
unsaturated non-aromatic carbocyclic ring comprising one or more,
for example 1, 2, 3 or 4 heteroatoms independently selected from O,
N and S, wherein each heteroatom replaces a carbon atom and
optionally one or two carbons may bear an oxo substituent. Clearly
any valencies of a heteroatom not employed in forming or retaining
the ring structure may be filled by hydrogen or a substituent, as
appropriate. Thus substituents on heterocycles may be on carbon or
on a heteroatom, such as N as appropriate. Examples of heterocycles
and C.sub.5-6 heterocycles include pyrroline, pyrrolidine,
tetrahydrofuran, tetrahydrothiophene, pyrazoline, imidazoline,
pyrazolidine, imidazolidine, oxoimidazolidine, dioxolane,
thiazolidine, isoxazolidine, pyran, dihydropyran, piperidine,
piperazine, morpholine, dioxane, thiomorpholine and oxathiane.
[0060] When employed herein, the group morpholinyl suitably
represents N-morpholinyl.
[0061] In one embodiment there is provided a compound of formula
(Ia1) or, particularly, formula (Ia2):
##STR00003##
wherein R, R.sup.a, R.sup.b, R.sup.1, Q and Y are defined as above
for compounds of formula (I).
[0062] In one embodiment there is provided a compound of formula
(Ib1) or, particularly, formula (Ib2):
##STR00004##
wherein R, R.sup.a, R.sup.b, R.sup.1, Q, X and Y are defined above
for compounds of formula (I)
[0063] In one embodiment there is provided a compound of formula
(Ic1) or, particularly, formula (Ic2):
##STR00005##
wherein R, R.sup.a, R.sup.b, R.sup.1, Q and Y are defined above for
compounds of formula (I).
[0064] In one embodiment there is provided a compound of formula
(Id1) or, particularly, formula (Id2):
##STR00006##
wherein R, R.sup.a, R.sup.b, R.sup.1, Q and Y are defined above for
compounds of formula (I).
[0065] In one embodiment there is provided a compound of formula
(Ie1) or, particularly, formula (Ie2):
##STR00007##
wherein R, R.sup.a, R.sup.b, R.sup.1, Q and Y are defined above for
compounds of formula (I).
[0066] In one embodiment there is provided a compound of formula
(If1) or, particularly, formula (If2):
##STR00008##
wherein R, R.sup.a, R.sup.b, R.sup.1, Q and Y are defined above for
compounds of formula (I).
[0067] In one embodiment there is provided a compound of formula
(Ig1) or, particularly, formula (Ig2):
##STR00009##
wherein R, R.sup.a, R.sup.b, R.sup.1, X, Q and Y are as defined
above for compounds of formula (I).
[0068] In one embodiment there is provided a compound of formula
(Ih1) or, particularly, formula (Ih2):
##STR00010##
wherein R, R.sup.a, R.sup.b, R.sup.1, X, Q and Y are as defined
above for compounds of formula (I).
[0069] Generally in substituents such C.sub.0-3
alkylene-O--C.sub.0-6 alkylene-5-10 membered heterocycle, for
example as defined for R.sup.2 or R.sup.3, when the said
heterocycle is linked through nitrogen the group will then be
defined as C.sub.0-3 alkylene-O--C.sub.2-6 alkylene-5-10 membered
heterocycle.
[0070] Generally when Q comprises a phenyl or pyridine substituted
with a C.sub.1-6 alkylene-5-10 membered heterocycle or C.sub.0-3
alkylene-O--C.sub.0-6 alkylene-5-10 membered heterocycle then
R.sup.2 and R.sup.3 are independently selected from H, C.sub.1-8
alkyl, wherein independently each alkyl or alkylene group
optionally bears 1 oxo substituent, and optionally up to two carbon
atoms in the alkyl or alkylene chain may be replaced by a
heteroatom selected from O, N or S(O).sub.p, such that when alkyl
or alkylene comprises an amine said amino group is a tertiary
amine.
[0071] In one embodiment Q represents phenyl bearing one or two
substituents independently selected from hydroxyl, halogen,
C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 haloalkoxy, C.sub.1-6
hydroxyalkyl, N(C.sub.1-6 alkyl).sub.2, C.sub.1-6 alkylene-5-10
membered heterocycle and C.sub.0-3 alkylene-O--C.sub.1-6
alkylene-5-10 membered heterocycle (e.g. one or two substituents
independently selected from hydroxyl, halogen, C.sub.1-6 alkyl,
C.sub.1-6 alkoxy, C.sub.1-6 haloalkoxy, C.sub.1-6 hydroxyalkyl,
C.sub.1-6 alkylene-5-10 membered heterocycle and C.sub.0-3
alkylene-O--C.sub.1-6 alkylene-5-10 membered heterocycle).
[0072] In one embodiment Q represents phenyl bearing a methyl,
methoxy, --N(CH.sub.3).sub.2 or --OCH.sub.2CH.sub.2OCH.sub.3 (e.g.
methyl, methoxy, or --OCH.sub.2CH.sub.2OCH.sub.3), for example one
of said substituents, in particular in the para position.
[0073] In one embodiment Q is dimethyl phenyl, for example where
the methyl substituents are in the meta and para position.
[0074] In one embodiment Q represents pyridinyl bearing one
substituent independently selected from hydroxyl, halogen,
C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 haloalkoxy, C.sub.1-6
hydroxyalkyl, C.sub.1-6 alkylene-5-10 membered heterocycle and
C.sub.0-3 alkylene-O--C.sub.1-6 alkylene-5-10 membered
heterocycle.
[0075] In one embodiment Q is methoxypyridinyl, for example
6-methoxypyridin-3-yl.
[0076] In one embodiment Q represents thienyl optionally bearing
one substituent independently selected from hydroxyl, halogen,
C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 haloalkoxy, C.sub.1-6
hydroxyalkyl, C.sub.1-6 alkylene-5-10 membered heterocycle and
C.sub.0-3 alkylene-O--C.sub.1-6 alkylene-5-10 membered
heterocycle.
[0077] In one embodiment R is ethyl, isopropyl, tert-butyl,
cyclopropyl, 1-methylcyclopropyl, propen-2-yl, CF.sub.3,
C.sub.2F.sub.5, oxetanyl, (methyl)oxetanyl or tetrahydrofuranyl
(e.g. ethyl, isopropyl, tert-butyl, cyclopropyl,
1-methylcyclopropyl, CF.sub.3, C.sub.2F.sub.5, oxetanyl,
(methyl)oxetanyl or tetrahydrofuranyl), such as isopropyl or
tert-butyl.
[0078] In one embodiment R is C(CH.sub.3).sub.2CH.sub.2OH or
CH(CH.sub.3)CH.sub.2OH.
[0079] In one embodiment R is 1-hydroxy-2-methylpropan-2-yl.
[0080] In one embodiment R.sup.1 is H, Br, Cl, CH.sub.3,
CH.sub.2CH.sub.3, CN, N(CH.sub.3).sub.2, CF.sub.3, ethynyl,
OCH.sub.3, OCHF.sub.2, OCH.sub.2CH.sub.3 or
OCH.sub.2(CH.sub.3).sub.2 (e.g. R.sup.1 is H, Br, Cl, CH.sub.3, CN,
N(CH.sub.3).sub.2, CF.sub.3, ethynyl, OCH.sub.3, OCH.sub.2CH.sub.3
or OCH.sub.2(CH.sub.3).sub.2).
[0081] In one embodiment R.sup.4 is H or methyl.
[0082] In one embodiment R.sup.5 is H or methyl.
[0083] In one embodiment R.sup.6 is H or methyl.
[0084] In one embodiment R.sup.7 is H or methyl.
[0085] In one embodiment R.sup.8 is H or methyl.
[0086] In one embodiment R.sup.9 is H or methyl.
[0087] Embodiments of the invention that may be mentioned include
compounds of formulae (I), (Ia1), (Ia2), (Ib1), (Ib2), (Ic1),
(Ic2), (Id1), (Id2), (Ie1), (Ie2), (If1), (If2), (Ig1), (Ig2),
(Ih1) and (Ih2) wherein:
[0088] Q represents phenyl substituted by -L-P(O)R'R'' or,
particularly, phenyl bearing one or two substituents independently
selected from hydroxyl, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy,
C.sub.1-6 haloalkoxy, C.sub.1-6 hydroxyalkyl, N(C.sub.1-6
alkyl).sub.2, C.sub.1-6 alkylene-5-10 membered heterocycle and
C.sub.0-3 alkylene-O--C.sub.1-6 alkylene-5-10 membered heterocycle
(e.g. Q represents phenyl mono-substituted (e.g. in the para
position) by methyl, methoxy, --N(CH.sub.3).sub.2 or
--OCH.sub.2CH.sub.2OCH.sub.3 or di-substituted (e.g. in the meta
and para positions) by methyl),
or Q represents pyridinyl bearing one substituent independently
selected from hydroxyl, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy,
C.sub.1-6 haloalkoxy, C.sub.1-6 hydroxyalkyl, C.sub.1-6
alkylene-5-10 membered heterocycle and C.sub.0-3
alkylene-O--C.sub.1-6 alkylene-5-10 membered heterocycle (e.g. Q
represents methoxypyridinyl, such as 6-methoxypyridin-3-yl);
L is CH.sub.2;
[0089] R' and R'' both represent C.sub.1-4 alkyl (e.g. C.sub.1-2
alkyl, such as methyl); R.sup.a and R.sup.b together represent
--(CH.sub.2).sub.3-5- or, particularly, R.sup.a and R.sup.b,
together with the C-atoms to which they are attached, form a fused
phenyl ring, or one of R.sup.a and R.sup.b represents halo,
C.sub.1-3 alkyl or C.sub.1-3 haloalkyl and the other independently
represents halo, cyano, C.sub.1-3 alkyl or C.sub.1-3 haloalkyl
(e.g. R.sup.a and R.sup.b both represent methyl, fluoro or chloro);
Y represents NR.sup.2R.sup.3; R.sup.2 represents --[C.sub.2-4
alkylene-O].sub.1-6--[C.sub.2-4 alkylene]-R.sup.2a (e.g.
--[C.sub.2-4 alkylene-O].sub.1-3--[C.sub.2-4 alkylene]- R.sup.2a,
such as --[CH.sub.2CH.sub.2O].sub.1-2--CH.sub.2CH.sub.2R.sup.2a);
R.sup.3 represents methyl or, particularly, H; R.sup.2a represents
OR.sup.2b or N(R.sup.2c)R.sup.2d; R.sup.2b represents H or
C.sub.1-4 alkyl (e.g. R.sup.2b represents methyl); R.sup.2 and
R.sup.2d independently represent H or C.sub.1-4 alkyl (e.g. methyl)
or R.sup.2c and R.sup.2d together represent C.sub.4-5 n-alkylene,
which n-alkylene group is optionally interrupted between C2 and C3
by --O-- or --N(R.sup.2e)-- (e.g. R.sup.2c and R.sup.2d either both
represent methyl or together represent
--CH.sub.2CH.sub.2--O--CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2--NH--CH.sub.2CH.sub.2-- or
--CH.sub.2CH.sub.2--N(CH.sub.3)--CH.sub.2CH.sub.2--); R.sup.2e
represents H or C.sub.1-4 alkyl (e.g. methyl); R represents [0090]
Si(C.sub.1-2 alkyl).sub.3 (e.g. Si(CH.sub.3).sub.3), [0091]
--C(C.sub.1-2 alkyl).sub.2-C.sub.2-3 alkynyl (e.g.
--C(CH.sub.3).sub.2--C.ident.C--H) or, particularly, [0092]
C.sub.1-6 alkyl optionally substituted by hydroxy, cyano or methoxy
or by one or more fluoro groups, [0093] C.sub.2-6 alkenyl or [0094]
C.sub.3-4 cycloalkyl, which latter group is optionally substituted
by C.sub.1-3 alkyl (e.g. R represents ethyl, isopropyl, n-propyl,
tert-butyl, cyclopropyl, 1-methylcyclopropyl, CF.sub.3,
C.sub.2F.sub.5, --C(CH.sub.3).sub.2CF.sub.3 oxetanyl,
(methyl)oxetanyl, tetrahydrofuranyl or propen-2-yl, such as
isopropyl, propen-2-yl or tert-butyl); and/or R.sup.1 represents H,
halogen (e.g. F, Br or Cl), CN, C.sub.1-4 alkyl (e.g. methyl or
ethyl), C.sub.2-4 alkynyl (e.g. ethynyl), C.sub.1-4 fluoroalkyl
(e.g. CF.sub.3), C.sub.1-4 alkoxy (e.g. OCH.sub.3,
OCH.sub.2CH.sub.3 or OCH.sub.2(CH.sub.3).sub.2), C.sub.1-4
haloalkoxy (e.g. OCHF.sub.2) or NR.sup.6R.sup.7 (e.g.
N(CH.sub.3).sub.2) (e.g. R.sup.1 represents H, halogen (e.g. F, Br
or Cl), CN, C.sub.1-4 alkyl (e.g. methyl or ethyl), C.sub.2-4
alkynyl (e.g. ethynyl), C.sub.1-4 fluoroalkyl (e.g. CF.sub.3),
C.sub.1-4 alkoxy (e.g. OCH.sub.3, OCH.sub.2CH.sub.3 or
OCH.sub.2(CH.sub.3).sub.2), or NR.sup.6R.sup.7 (e.g.
N(CH.sub.3).sub.2), in particular R.sup.1 represents ethynyl or
OCH.sub.3).
[0095] More particular embodiments of the invention that may be
mentioned include compounds of formulae (I), (Ia1), (Ia2), (Ib1),
(Ib2), (Ic1), (Ic2), (Id1), (Id2), (Ie1), (Ie2), (If1), (If2),
(Ig1), (Ig2), (Ih1) and (Ih2) wherein:
Q represents phenyl mono-substituted (e.g. in the meta position) by
--CH.sub.2--P(O)(C.sub.1-2 alkyl).sub.2 or, particularly, phenyl
mono-substituted (e.g. in the para position) by C.sub.1-6 alkyl
(e.g. methyl), C.sub.1-6 alkoxy (e.g. methoxy), C.sub.1-6
haloalkoxy or N(C.sub.1-6 alkyl).sub.2 (e.g. N(CH.sub.3).sub.2)
(for example, Q represents phenyl substituted in the para position
by methyl, methoxy or dimethylamino); R.sup.a and R.sup.b together
represent --(CH.sub.2).sub.4-- or, particularly, R.sup.a and
R.sup.b, together with the C-atoms to which they are attached, form
a fused phenyl ring; Y represents NR.sup.2R.sup.3; R.sup.2
represents --[C.sub.2-3 alkylene-O].sub.1-3--[C.sub.2-3
alkylene]-R.sup.2a (e.g. R.sup.2 represents
--[CH.sub.2CH.sub.2O].sub.1-2--
CH.sub.2CH.sub.2R.sup.2a);
[0096] R.sup.3 represents H; R.sup.2a represents --O--(C.sub.1-3
alkyl) (e.g. --OCH.sub.3) or N(R.sup.2c)R.sup.2d; R.sup.2c and
R.sup.2d independently represent H or C.sub.1-3 alkyl (e.g. methyl)
or R.sup.2c and R.sup.2d together represent C.sub.4 n-alkylene,
which n-alkylene group is optionally interrupted between C2 and C3
by --O-- or --N(R.sup.2e)-- (e.g. R.sup.2c and R.sup.2d either both
represent methyl or together represent
--CH.sub.2CH.sub.2--N(CH.sub.3)--CH.sub.2CH.sub.2-- or,
particularly, --CH.sub.2CH.sub.2--O--CH.sub.2CH.sub.2--); R
represents C.sub.1-4 alkyl optionally substituted by one or more
fluoro groups, C.sub.3-4 alkenyl or C.sub.3-4 cycloalkyl, which
latter group is optionally substituted by methyl (e.g. R represents
ethyl, cyclopropyl, CF.sub.3, C.sub.2F.sub.5,
--C(CH.sub.3).sub.2CF.sub.3 or, particularly, isopropyl,
1-methylcyclopropyl, propen-2-yl or tert-butyl); and/or R.sup.1
represents Br, Cl, CN, methyl, ethyl, CF.sub.3, OCHF.sub.2,
OCH.sub.2CH.sub.3, OCH.sub.2(CH.sub.3).sub.2, N(CH.sub.3).sub.2 or,
particularly, ethynyl or OCH.sub.3 (e.g. R.sup.1 represents Br, Cl,
CN, methyl, ethyl, CF.sub.3, OCH.sub.2CH.sub.3,
OCH.sub.2(CH.sub.3).sub.2, N(CH.sub.3).sub.2 or, particularly,
ethynyl or OCH.sub.3).
[0097] Particular embodiments of the invention include the
following. [0098] (1) A compound of formula (I), (Ia1), (Ia2),
(Ib1), (Ib2), (Ic1), (Ic2), (Id1), (Id2), (Ie1), (Ie2), (If1),
(If2), (Ig1), (Ig2), (Ih1) or (Ih2) as defined above, or a
pharmaceutically acceptable salt thereof. [0099] (2) A compound or
salt according to Embodiment (1), wherein Q represents phenyl
bearing one or two substituents independently selected from
hydroxyl, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6
haloalkoxy, C.sub.1-6 hydroxyalkyl, N(C.sub.1-6 alkyl).sub.2,
C.sub.1-6 alkylene-5-10 membered heterocycle and C.sub.0-3
alkylene-O--C.sub.1-6 alkylene-5-10 membered heterocycle (e.g. one
or two substituents independently selected from hydroxyl, halogen,
C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 haloalkoxy, C.sub.1-6
hydroxyalkyl, C.sub.1-6 alkylene-5-10 membered heterocycle and
C.sub.0-3 alkylene-O--C.sub.1-6 alkylene-5-10 membered
heterocycle). [0100] (3) A compound or salt according to Embodiment
(1) or Embodiment (2), wherein Q represents phenyl bearing a
methyl, methoxy, --N(CH.sub.3).sub.2 or
--OCH.sub.2CH.sub.2OCH.sub.3 (e.g. a methyl, methoxy or
--OCH.sub.2CH.sub.2OCH.sub.3). [0101] (4) A compound or salt
according to any one of Embodiments (1) to (3), wherein Q
represents phenyl substituted in the para position by methyl,
methoxy, --N(CH.sub.3).sub.2 or --OCH.sub.2CH.sub.2OCH.sub.3 (e.g.
by methyl, methoxy or --OCH.sub.2CH.sub.2OCH.sub.3). [0102] (5) A
compound or salt according to any one of Embodiments (1) to (3),
wherein Q is dimethyl phenyl, for example where the methyl
substituents are in the meta and para position. [0103] (7) A
compound or salt according to Embodiment (1), wherein Q represents
pyridinyl bearing one substituent independently selected from
hydroxyl, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6
haloalkoxy, C.sub.1-6 hydroxyalkyl, C.sub.1-6 alkylene-5-10
membered heterocycle and C.sub.0-3 alkylene-O--C.sub.1-6
alkylene-5-10 membered heterocycle. [0104] (8) A compound or salt
according to Embodiment (7), wherein Q is methoxypyridinyl, for
example 6-methoxypyridin-3-yl. [0105] (9) A compound or salt
according to Embodiment (1), wherein Q represents thienyl
optionally bearing one substituent independently selected from
hydroxyl, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6
haloalkoxy, C.sub.1-6 hydroxyalkyl, C.sub.1-6 alkylene-5-10
membered heterocycle and C.sub.0-3 alkylene-O--C.sub.1-6
alkylene-5-10 membered heterocycle. [0106] (10) A compound or salt
according to any one of Embodiments (1) to (9), wherein R is ethyl,
isopropyl, tert-butyl, cyclopropyl, 1-methylcyclopropyl, CF.sub.3,
C.sub.2F.sub.5, oxetanyl, (methyl)oxetanyl or tetrahydrofuranyl,
such as isopropyl or tert-butyl. [0107] (11) A compound or salt
according to any one of Embodiments (1) to (9), wherein R is
C(CH.sub.3).sub.2CH.sub.2OH or CH(CH.sub.3)CH.sub.2OH. [0108] (12)
A compound or salt according to any one of Embodiments (1) to (9),
wherein R is 1-hydroxy-2-methylpropan-2-yl. [0109] (13) A compound
or salt according to any one of Embodiments (1) to (12), wherein
R.sup.1 is H, Br, Cl, CH.sub.3, CH.sub.2CH.sub.3, CN,
N(CH.sub.3).sub.2, CF.sub.3, ethynyl, OCH.sub.3, OCHF.sub.2,
OCH.sub.2CH.sub.3 or OCH.sub.2(CH.sub.3).sub.2 (e.g. R.sup.1 is H,
Br, Cl, CH.sub.3, CN, N(CH.sub.3).sub.2, CF.sub.3, ethynyl,
OCH.sub.3, OCH.sub.2CH.sub.3 or OCH.sub.2(CH.sub.3).sub.2). [0110]
(14) A compound or salt according to any one of Embodiments (1) to
(13), wherein R.sup.4 is H or methyl. [0111] (15) A compound or
salt according to any one of Embodiments (1) to (14), wherein
R.sup.5 is H or methyl. [0112] (16) A compound or salt according to
any one of Embodiments (1) to (15), wherein R.sup.6 is H or methyl.
[0113] (17) A compound or salt according to any one of Embodiments
(1) to (16), wherein R.sup.7 is H or methyl. [0114] (18) A compound
or salt according to any one of Embodiments (1) to (17), wherein
R.sup.8 is H or methyl. [0115] (19) A compound or salt according to
any one of Embodiments (1) to (18), wherein R.sup.9 is H or methyl.
[0116] (20) A compound or salt according to any one of Embodiments
(1) and (10) to (19), wherein Q represents phenyl mono-substituted
(e.g. in the para position) by C.sub.1-6 alkyl (e.g. methyl),
C.sub.1-6 alkoxy (e.g. methoxy), C.sub.1-6 haloalkoxy or
N(C.sub.1-6 alkyl).sub.2 (e.g. N(CH.sub.3).sub.2). [0117] (21) A
compound or salt according to Embodiment (20), wherein Q represents
phenyl substituted in the para position by methyl, methoxy or
dimethylamino. [0118] (22) A compound or salt according to any one
of Embodiments (1) to (21), wherein R.sup.a and R.sup.b, together
with the C-atoms to which they are attached, form a fused phenyl
ring. [0119] (23) A compound or salt according to any one of
Embodiments (1) to (22) (e.g. any one of Embodiments (1) to (21)),
wherein R.sup.2 represents --[C.sub.2-3
alkylene-O].sub.1-3--[C.sub.2-3 alkylene]-R.sup.2a (e.g. R.sup.2
represents
--[CH.sub.2CH.sub.2O].sub.1-2--CH.sub.2CH.sub.2R.sup.2a). [0120]
(24) A compound or salt according to any one of Embodiments (1) to
(23), wherein R.sup.3 represents H. [0121] (25) A compound or salt
according to any one of Embodiments (1) to (24), wherein R.sup.2a
represents --O--(C.sub.1-3 alkyl) (e.g. --OCH.sub.3) or
N(R.sup.2c)R.sup.2d. [0122] (26) A compound or salt according to
any one of Embodiments (1) to (25), wherein R.sup.2 and R.sup.2d
independently represent H or C.sub.1-3 alkyl (e.g. methyl) or
R.sup.2c and R.sup.2d together represent C.sub.4 n-alkylene, which
n-alkylene group is optionally interrupted between C2 and C3 by
--O-- or --N(R.sup.2e)-- (e.g. R.sup.2c and R.sup.2d either both
represent methyl or together represent
--CH.sub.2CH.sub.2--N(CH.sub.3)--CH.sub.2CH.sub.2-- or,
particularly, --CH.sub.2CH.sub.2--O--CH.sub.2CH.sub.2--). [0123]
(27) A compound or salt according to any one of Embodiments (1) to
(9) and (13) to (26), wherein R represents C.sub.1-4 alkyl
optionally substituted by one or more fluoro groups, C.sub.3-4
alkenyl or C.sub.3-4 cycloalkyl, which latter group is optionally
substituted by methyl (e.g. R represents ethyl, cyclopropyl,
CF.sub.3, C.sub.2F.sub.5, --C(CH.sub.3).sub.2CF.sub.3 or,
particularly, isopropyl, 1-methylcyclopropyl, propen-2-yl or
tert-butyl). [0124] (28) A compound or salt according to any one of
Embodiments (1) to (12) and (14) to (27), wherein R.sup.1
represents Br, Cl, CN, methyl, ethyl, CF.sub.3, OCHF.sub.2,
OCH.sub.2CH.sub.3, OCH.sub.2(CH.sub.3).sub.2, N(CH.sub.3).sub.2,
ethynyl or OCH.sub.3 (e.g. R.sup.1 represents Br, Cl, CN, methyl,
ethyl, CF.sub.3, OCH.sub.2CH.sub.3, OCH.sub.2(CH.sub.3).sub.2,
N(CH.sub.3).sub.2, ethynyl or OCH.sub.3). [0125] (29) A compound or
salt according to Embodiment (28), wherein R.sup.1 represents
ethynyl or OCH.sub.3. [0126] (30) A compound or salt according to
any one of Embodiments (1) to (29) above, wherein: [0127] Q
represents thienyl, phenyl or pyridinyl, either of which is
substituted by NH.sub.2, N(H)--C.sub.1-6 alkyl, N(C.sub.1-6
alkyl).sub.2 or, particularly, -L-P(O)R'R'' and is optionally
further substituted by 1 or 2 substituents independently selected
from, hydroxyl, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy,
C.sub.1-6 haloalkoxy, C.sub.1-6 hydroxyalkyl, NH.sub.2,
N(H)--C.sub.1-6 alkyl, N(C.sub.1-6 alkyl).sub.2, -L-P(O)R'R'',
C.sub.1-6 alkylene-5-10 membered heterocycle and C.sub.0-3
alkylene-O--C.sub.0-6 alkylene-5-10 membered heterocycle; [0128] R
represents C.sub.2-6 alkenyl (e.g. C.sub.3-4 alkenyl, such as
propen-2-yl), C.sub.1-6 alkyl substituted by C.sub.1-3 alkoxy or
cyano (e.g. secondary C.sub.3-6 alkyl substituted by methoxy or
cyano, such as --C(CH.sub.3).sub.2OCH.sub.3 or
--C(CH.sub.3).sub.2CN) or, particularly, C.sub.1-6 alkyl
substituted by C.sub.2-3 alkynyl (e.g. --C(C.sub.1-2
alkyl).sub.2-C.sub.2-3 alkynyl, such as
--C(CH.sub.3).sub.2--C.ident.C--H) or
Si(R.sup.1a)(R.sup.1b)(R.sup.1c)(e.g. Si(C.sub.1-2 alkyl).sub.3,
such as Si(CH.sub.3).sub.3); and/or [0129] R.sup.a and R.sup.b,
together with the C-atoms to which they are attached, form a fused
phenyl ring that is substituted by one or more substituents
selected from C.sub.1-3 alkyl, C.sub.1-3 haloalkyl, cyano and halo,
[0130] or one of R.sup.a and R.sup.b represents H, halo, cyano,
C.sub.1-3 alkyl or C.sub.1-3 haloalkyl and the other independently
represents halo, cyano, C.sub.1-3 alkyl or C.sub.1-3 haloalkyl, or,
particularly, R.sup.a and R.sup.b together represent C.sub.3-5
n-alkylene, which alkylene group is optionally substituted by one
or more methyl substituents and/or which alkylene group optionally
contains one C--C double bond between two C-atoms of the n-alkylene
chain (e.g. R.sup.a and R.sup.b together represent C.sub.3-4
n-alkylene, such as --(CH.sub.2).sub.4--). [0131] (31) A compound
or salt according to any one of Embodiments (1) to (30) above,
wherein: [0132] Q represents phenyl substituted by -L-P(O)R'R''
(e.g. in the para- or, particularly, the meta-position relative to
the point of attachment of the phenyl group to the pyrazole group);
[0133] L is CH.sub.2 or a direct bond; [0134] R' represents
C.sub.1-2 alkyl (e.g. methyl); [0135] R'' represents C.sub.1-2
alkyl (e.g. methyl); [0136] or R' and R'' together combine to form
C.sub.4-5 n-alkylene; [0137] R is --C(C.sub.1-2
alkyl).sub.2-C.sub.2-3 alkynyl (e.g.
--C(CH.sub.3).sub.2--C.ident.C--H) or Si(C.sub.1-2 alkyl).sub.3
(e.g. Si(CH.sub.3).sub.3); and/or [0138] R.sup.a and R.sup.b
together represent C.sub.3-4 n-alkylene (e.g.
--(CH.sub.2).sub.4--). [0139] (32) A compound or salt according to
any one of Embodiments (1) to (29) above, wherein: [0140] Q
represents thienyl, phenyl or pyridinyl, either of which may
optionally bear 1 to 3 substituents independently selected from,
hydroxyl, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6
haloalkoxy, C.sub.1-6 hydroxyalkyl, NH.sub.2, N(H)--C.sub.1-6
alkyl, N(C.sub.1-6 alkyl).sub.2, C.sub.1-6 alkylene-5-10 membered
heterocycle and C.sub.0-3 alkylene-O--C.sub.0-6 alkylene-5-10
membered heterocycle; [0141] R is C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.1-6 hydroxyalkyl, C.sub.1-6 haloalkyl, C.sub.1-6
alkyl substituted by C.sub.1-3 alkoxy or cyano, C.sub.0-2
alkylene-C.sub.3-8 cycloalkyl optionally substituted with C.sub.1-3
alkyl or a 4-5 membered heterocycle optionally substituted with
C.sub.1-3 alkyl; and [0142] R.sup.a and R.sup.b, together with the
C-atoms to which they are attached, form a fused phenyl ring that
is optionally substituted by one or more substituents selected from
C.sub.1-3 alkyl, C.sub.1-3 haloalkyl, cyano and halo, or one of
R.sup.a and R.sup.b represents H, halo, cyano, C.sub.1-3 alkyl or
C.sub.1-3 haloalkyl and the other independently represents halo,
cyano, C.sub.1-3 alkyl or C.sub.1-3 haloalkyl. [0143] (33) A
compound or salt according to any one of Embodiments (1) to (32)
above, wherein one of R.sup.2 and R.sup.3 represents --[C.sub.2-3
alkylene-O].sub.1-3--[C.sub.2-3 alkylene]-R.sup.2a, such as
--(CH.sub.2CH.sub.2O).sub.2-3CH.sub.3) and the other of R.sup.2 and
R.sup.3 is as defined above in any of Embodiments (1) to (32) (e.g.
the other of R.sup.2 and R.sup.3 is H). [0144] (34) A compound or
salt according to any one of Embodiments (1) to (33) above, wherein
[0145] R represents: [0146] C.sub.1-6 n-alkyl, [0147] C.sub.3-6
branched alkyl (e.g. C.sub.4-6 branched alkyl), [0148] C.sub.2-6
alkenyl, [0149] C.sub.1-6 hydroxyalkyl, [0150] C.sub.1-6 haloalkyl,
[0151] C.sub.1-6 alkyl substituted by C.sub.1-3 alkoxy or cyano,
[0152] C.sub.0-2 alkylene-C.sub.3-8 cycloalkyl optionally
substituted with C.sub.1-3 alkyl, or [0153] a 4-5 membered
heterocycle optionally substituted with C.sub.1-3 alkyl [0154]
(e.g. R represents ethyl, cyclopropyl, CF.sub.3, C.sub.2F.sub.5,
--C(CH.sub.3).sub.2CF.sub.3 or, particularly, 1-methylcyclopropyl,
propen-2-yl or tert-butyl). [0155] (35) A compound or salt
according to any one of Embodiments (1) to (32) above, wherein one
of R.sup.2 and R.sup.3 represents --[C.sub.2-3
alkylene-O].sub.1-5--[C.sub.2-3 alkylene]-R.sup.2a (e.g.
--[C.sub.2-3 alkylene-O].sub.1-4--[C.sub.2-3 alkylene]-R.sup.2a,
such as --(CH.sub.2CH.sub.2O).sub.2-4CH.sub.3) and the other of
R.sup.2 and R.sup.3 is as defined above in any of Embodiments (1)
to (32) (e.g. the other of R.sup.2 and R.sup.3 is H). [0156] (36) A
compound or salt according to Embodiment (35) above, wherein
R.sup.1 represents ethynyl or OCH.sub.3. [0157] (37) A compound or
salt according to Embodiment (35) or Embodiment (36) above, wherein
R.sup.2 represents --(CH.sub.2CH.sub.2O).sub.2-4CH.sub.3 and
R.sup.3 is H. [0158] (38) A compound or salt according to any one
of Embodiments (1) to (37) above, wherein [0159] Q represents
phenyl substituted in the para position by methyl, methoxy or
dimethylamino and R represents isopropyl or, particularly,
tert-butyl.
[0160] Exemplary compounds of formula (I) are selected from the
group consisting of: [0161]
3-ethynyl-5-((4-((4-(3-(3-isopropyl-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)na-
phthalen-1-yl)oxy)pyrimidin-2-yl)amino)-N-(2-(2-(2-methoxyethoxy)ethoxy)et-
hyl)benzamide; [0162]
3-((4-((4-(3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthale-
n-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-methoxyethoxy)ethoxy-
)ethyl)benzamide; [0163]
3-((4-((4-(3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)ureido)n-
aphthalen-1-yl)oxy)-pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-methoxyetho-
xy)ethoxy)ethyl)benzamide; [0164]
3-((4-((4-(3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthale-
n-1-yl)oxy)pyridin-2-yl)amino)-5-methoxy-N-(2-(2-(2-methoxyethoxy)ethoxy)e-
thyl)benzamide; [0165]
3-((4-((4-(3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)ureido)--
naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-methoxyethoxy)-
ethyl)benzamide; [0166]
3-((4-((4-(3-(3-(tert-butyl)-1-(2,3,5,6-tetradeutero-4-(trideuteromethyl)-
phenyl)-1H-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-
-ethynyl-N-(2-(2-(2-methoxyethoxy)-ethoxy)ethyl)benzamide; [0167]
3-((4-((4-(3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthale-
n-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2,5,8,11-tetraoxatridecan-13-
-yl)benzamide; [0168]
3-((4-((4-(3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthale-
n-1-yl)oxy)-pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-methoxyethoxy)ethyl)be-
nzamide; [0169]
3-((4-((4-(3-(3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)-
ureido)-naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-met-
hoxyethoxy)-ethoxy)ethyl)benzamide; [0170]
3-((4-((4-(3-(3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)-
ureido)-naphthalen-1-yl)oxy)pyridin-2-yl)amino)-5-methoxy-N-(2-(2-(2-metho-
xyethoxy)-ethoxy)ethyl)benzamide; [0171]
3-((4-((4-(3-(3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)-
ureido)-naphthalen-1-yl)oxy)pyridin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-metho-
xyethoxy)-ethoxy)ethyl)benzamide; [0172]
3-((4-((4-(3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)-5,6,7,8--
tetrahydronaphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-m-
ethoxyethoxy)ethoxy)ethyl)benzamide; [0173]
3-((4-((4-(3-(3-(tert-butyl)-1-(2,4-dimethoxyphenyl)-1H-pyrazol-5-yl)urei-
do)naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-methoxye-
thoxy)ethoxy)ethyl)benzamide; [0174]
3-((4-((4-(3-(3-(tert-butyl)-1-(3-((dimethylphosphoryl)methyl)phenyl)-1H--
pyrazol-5-yl)ureido)
naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-methoxyeth-
oxy)ethoxy)ethyl)benzamide; [0175]
3-((4-((4-(3-(3-(tert-butyl)-1-(3-((dimethylphosphoryl)methyl)phenyl)-1H--
pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)pyridin-2-yl)amino)-5-methoxy-N-(2-
-(2-(2-methoxyethoxy)ethoxy)ethyl)benzamide; [0176]
3-((4-((4-(3-(3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)-
ureido)naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-methoxy-N-(2-(2-(2-meth-
oxyethoxy)ethoxy)ethyl)benzamide; [0177]
3-((4-((4-(3-(3-(tert-butyl)-1-(4-methoxy-2-methylphenyl)-1H-pyrazol-5-yl-
)ureido)naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-met-
hoxyethoxy)ethoxy)ethyl)benzamide, and pharmaceutically acceptable
salts thereof.
[0178] Thus in one embodiment the compound of the invention is
3-((4-((4-(3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthale-
n-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-methoxyethoxy)ethoxy-
)ethyl)benzamide or a pharmaceutically acceptable salt thereof.
[0179] In an alternative embodiment, there is provided a compound
of formula (I), (Ib1), (Ib2), (Ic1), (Ic2), (Id1), (Id2), (Ig1) or
(Ig2) as defined above, or a pharmaceutically acceptable salt
thereof, wherein the compound is not a compound of the formula:
##STR00011##
or a pharmaceutically acceptable salt thereof, including all
tautomers thereof.
[0180] In certain embodiments, there is provided a compound of
formula (I), (Ib1), (Ib2), (Ic1), (Ic2), (Id1), (Id2), (Ig1) or
(Ig2) as defined above, or a pharmaceutically acceptable salt
thereof, wherein the compound is not: [0181]
3-((4-((4-(3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthale-
n-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-methoxyethoxy)ethoxy-
)ethyl)benzamide; and/or [0182]
3-((4-((4-(3-(3-(tert-butyl)-1-(2,3,5,6-tetradeutero-4-(trideuteromethyl)-
phenyl)-1H-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-
-ethynyl-N-(2-(2-(2-methoxyethoxy)-ethoxy)ethyl)benzamide, or a
pharmaceutically acceptable salt thereof.
[0183] The pharmaceutically acceptable acid addition salts of
compounds of formula (I) are meant to comprise the therapeutically
active non-toxic acid addition salts that the compounds of formula
(I) are able to form. These pharmaceutically acceptable acid
addition salts can conveniently be obtained by treating the free
base form with such appropriate acids in a suitable solvent or
mixture of solvents. Appropriate acids comprise, for example,
inorganic acids such as hydrohalic acids, e.g. hydrochloric or
hydrobromic acid, sulfuric, nitric, phosphoric acids and the like;
or organic acids such as, for example, acetic, propanoic,
hydroxyacetic, lactic, pyruvic, malonic, succinic, maleic, fumaric,
malic, tartaric, citric, methanesulfonic, ethanesulfonic,
benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic,
p-aminosalicylic, pamoic acid and the like.
[0184] Conversely said salt forms can be converted by treatment
with an appropriate base into the free base form.
[0185] Stereoisomers as employed herein refers to isomeric
molecules that have the same molecular formula and sequence of
bonded atoms (constitution), but that differ only in the
three-dimensional orientations of their atoms in space. This
contrasts with structural isomers, which share the same molecular
formula, but the bond connections and/or their order differ(s)
between different atoms/groups. In stereoisomers, the order and
bond connections of the constituent atoms remain the same, but
their orientation in space differs.
[0186] As employed herein below the definition of compounds of
formula (I) is intended to include all tautomers of said compounds,
and solvates of said compounds (including solvates of salts of said
compounds) unless the context specifically indicates otherwise.
Examples of solvates include hydrates.
[0187] The invention provided herein extends to prodrugs of the
compound of formula (I), that is to say compounds which break down
and/or are metabolised in vivo to provide an active compound of
formula (I). General examples of prodrugs include simple esters,
and other esters such as mixed carbonate esters, carbamates,
glycosides, ethers, acetals and ketals.
[0188] In a further aspect of the invention there is provided one
or more metabolites of the compound of formula (I), in particular a
metabolite that retains one or more of the therapeutic activities
of the compound of formula (I). A metabolite, as employed herein,
is a compound that is produced in vivo from the metabolism of the
compound of formula (I), such as, without limitation, oxidative
metabolites and/or metabolites generated, for example, from
0-dealkylation.
[0189] The compounds of the disclosure include those where the atom
specified is a naturally occurring or non-naturally occurring
isotope. In one embodiment the isotope is a stable isotope. Thus
the compounds of the disclosure include, for example deuterium
containing compounds and the like.
[0190] The disclosure also extends to all polymorphic forms of the
compounds herein defined.
[0191] Generic routes by which compound examples of the invention
may be conveniently prepared are summarized below. Those routes are
specifically exemplified for compounds of formula (I) in which
R.sup.a and R.sup.b, together with the C-atoms to which they are
attached, form a fused phenyl ring. However, compounds of formula
(I) having other definitions of R.sup.a and R.sup.b may be prepared
by analogous routes.
[0192] Thus, for example, compounds of formula (I) may be obtained
by a general process (Scheme 1, Route A) whereby a naphthylamine
precursor represented by Intermediate B is coupled with an
activated, electrophilic derivative Intermediate A* prepared from
the corresponding amine precursor, Intermediate A (G=H). The amine
radical NR.sup.aR.sup.b in compounds of Intermediate B either
comprise the group Y, as defined for compounds of formula (I) above
or a protected derivative of the same. The fragment LG.sub.1 in
Intermediate A* is a suitable leaving group such as an imidazolyl
(C.sub.3H.sub.3N.sub.2) or an aryloxy radical such as a phenoxy
(C.sub.6H.sub.5O) group. It will be understood by persons skilled
in the art that, in some instances, the compound represented by
Intermediate A* may be isolated or in other cases may be a
transient intermediate, that is not isolated, but generated in situ
and used directly.
##STR00012##
[0193] In the case wherein LG.sub.1 is imidazolyl, compounds
represented by Intermediate A* are obtained by reaction of the
corresponding amine with an activating agent such as CDI in a
non-polar aprotic solvent, such as DCM and are conveniently
generated in situ at RT and then reacted without isolation with
compounds represented by Intermediate B.
[0194] In the case wherein LG.sub.1 is aryloxy the required
activated amine may be generated by treatment of the amine
precursor with a suitable chloroformate, such as, for example,
phenyl chloroformate, in the presence of a base. In some instances
it is advantageous to conduct the activation process under
Schotten-Baumann type conditions, that is using an aqueous base,
such as aq sodium carbonate under biphasic conditions. The
activated amine derivatives represented by Intermediate A* wherein
LG.sub.1 is aryloxy, for example phenoxy, may thereby be generated
optionally in situ and then reacted without isolation with
compounds represented by Intermediate B to provide compound
examples of formula (I).
[0195] Compounds of formula (I) may include those in which the
substituent Y incorporates one or more functional groups that have
been protected during the coupling process and therefore require(s)
subsequent deprotection. An example of such a procedure is the
removal of a tert-butoxycarbonyl (Boc) group from a secondary
amine, by treatment with an appropriate acid.
[0196] Alternatively, compound examples of formula (I) may be
generated by an S.sub.NAr displacement reaction between an
electrophilic heteroaryloxy fragment represented by Intermediate C,
wherein LG.sub.2 is a suitable leaving group, typically a halogen
atom, for example chlorine, with an aniline component represented
by Intermediate D (Scheme 2, Route B). The reaction proceeds under
acidic conditions, for example in the presence of p-TSA and in a
polar aprotic solvent such as THF and typically at elevated
temperatures, for example at 70.degree. C.
##STR00013##
[0197] Optionally, compound examples of the invention may be
prepared by a general synthetic process comprising of an amide bond
forming reaction between a carboxylic acid derivative with an amine
R.sup.aR.sup.bNH (Scheme 3, Routes C.sub.1 and C.sub.2) whereby
NR.sup.aR.sup.b comprises Y or a protected derivative thereof, in
which latter case the compounds of formula (I) are revealed
following an appropriate deprotection step(s). The amide coupling
may be conducted on an alkyl ester represented by Intermediate E
(R.sup.c=alkyl), for example a methyl ester, with the amine, in the
presence of a trialkylaluminium, for example trimethylaluminium
(Scheme 3, Route C.sub.1). The reaction is conveniently carried out
in an aprotic solvent such as THF and at ambient or slightly
elevated temperatures, typically RT to 40.degree. C.
##STR00014##
[0198] Alternatively the amide products of formula (I) may be
derived from the parent carboxylic acids represented by
Intermediate F (R.sup.c.dbd.H) by reaction with the amine
R.sup.aR.sup.bNH under the influence of an amide (peptide) coupling
reagent, and in the presence a non-nucleophilic base (Scheme 3,
Route C.sub.2). An example of a reagent that is frequently employed
for these transformations is HATU and suitable bases include DIPEA
and N-methylmorpholine and the like. The amidation reaction is
typically conducted in polar aprotic solvents such as THF and at
ambient temperature.
[0199] The above and other routes may be used to prepare the
compound of formula (I). Thus, according to a further aspect of the
invention, there is provided a process for the preparation of a
compound of formula (I) which process comprises:
(a) reaction of a compound of formula (II),
##STR00015##
with a compound of formula (III)
##STR00016##
wherein LG.sup.II represents a suitable leaving group (e.g.
imidazolyl, halo (such as chloro) or, particularly, aryloxy (such
as phenoxy)) and one of Z.sup.1 and Z.sup.2 is a structural
fragment of formula (IV)
##STR00017##
wherein R and Q are as hereinbefore defined, and the other of
Z.sup.1 and Z.sup.2 is a structural fragment of formula (V)
##STR00018##
wherein R.sup.1, R.sup.a, R.sup.b, X and Y are as hereinbefore
defined (e.g. in one particular embodiment, Z.sup.1 is a structural
fragment of formula (IV) and Z.sup.2 is a structural fragment of
formula (V)), for example under conditions known to those skilled
in the art, such as from ambient temperature to about 80.degree. C.
(e.g. from 50 to 60.degree. C.), optionally in the presence of an
amine base (e.g. a trialkylamine such as N,N-diisopropylethylamine
or, particularly, triethylamine) and a suitable organic solvent
(e.g. an aprotic solvent, such as dichloromethane or, particularly,
an ester such as isopropyl acetate); (b) reaction of a compound of
formula (VII
##STR00019##
wherein R, R.sup.a, R.sup.b, Q and X are as hereinbefore defined
and LG.sup.VI represents a suitable leaving group (e.g. a halo
group such as bromo or, particularly, chloro), with a compound of
formula (VII),
##STR00020##
wherein R.sup.1 and Y are as hereinbefore defined, under conditions
known to those skilled in the art (e.g. as described in J. Am.
Chem. Soc. 2011, 133, 15686-15696), such as at elevated temperature
(e.g. from 50 to 110.degree. C., such as at about 60.degree. C.) in
the presence of a suitable organic solvent (e.g. a polar aprotic
solvent such as DMF, THF, 1,4-dioxane, or mixtures thereof) and,
optionally, an acidic catalyst (e.g. a sulfonic acid such as
para-toluenesulfonic acid); (c) reaction of a compound of formula
(VIII),
##STR00021##
with a compound of formula (III), wherein the compound of formula
(III) and Z.sup.1 and Z.sup.2 are as hereinbefore defined, under
conditions known to those skilled in the art, for example at a
temperature from ambient (e.g. 15 to 30.degree. C.) to about
110.degree. C. in the presence of a suitable organic solvent (e.g.
a polar aprotic solvent such as DMF, THF, 1,4-dioxane, or mixtures
thereof); (d) reaction of a compound of formula (IX),
##STR00022##
wherein Z.sup.1 is as defined above, with a suitable azide-forming
agent (i.e. a suitable source of a leaving group and activated
azide ion, such as diphenyl phosphorazidate; see, for example,
Tetrahedron 1974, 30, 2151-2157) under conditions known to those
skilled in the art, such as at sub-ambient to ambient temperature
(e.g. from an initial temperature of about -5 to 5.degree. C. to
ambient temperature post-reaction) in the presence of an amine base
(e.g. triethylamine or a sterically hindered base such as
N,N-diisopropylethylamine) and a suitable organic solvent (e.g. a
polar aprotic solvent such as DMF, THF, 1,4-dioxane, or mixtures
thereof), which reaction is followed, without isolation, by thermal
rearrangement (e.g. under heating) of the intermediate acyl azide
(of formula Z.sup.1--C(O)--N.sub.3) e.g. at ambient temperature
(such as from 15 to 30.degree. C.) to provide, in situ, a compound
of formula (VIII), which compound is then reacted with a compound
of formula (III), as defined above, to provide the compound of
formula (I); (e) reaction of a compound of formula (X)
##STR00023##
wherein R, R.sup.1, R.sup.a, R.sup.b, Q and X are as hereinbefore
defined and R.sup.X represents H or C.sub.1-4 alkyl, with a
compound of formula (XI)
##STR00024##
wherein R.sup.2 and R.sup.3 are as hereinbefore defined, under
conditions known to those skilled in the art, for example [0200]
when R.sup.X represents H, reaction in the presence of a suitable
solvent, a base (e.g. triethylamine or N,N-diisopropylethylamine)
and an amide (peptide) coupling reagent, such as HATU, CDI,
N,N'-dicyclohexylcarbodiimide, N,N'-diisopropylcarbodiimide BOP or
PyBOP, optionally in combination with an activated ester-forming
agent such as HOBt or 1-hydroxy-7-azabenzotriazole, [0201] when
R.sup.X represents H, conversion of the carboxylic acid to an acid
halide (e.g. by reaction with a halogenating agent such as thionyl
chloride), followed by reaction with the compound of formula (XI)
in the presence of a suitable solvent and a base (e.g.
triethylamine or N,N-diisopropylethylamine), or [0202] when R.sup.X
represents C.sub.1-4 alkyl (e.g. methyl), reaction in the presence
of a trialkylaluminium (e.g. trimethylaluminium) and an aprotic
solvent (e.g. THF); or (f) deprotection of a protected derivative
of a compound of formula (I), under conditions known to those
skilled in the art, wherein the protected derivative bears a
protecting group on an O- or N-atom of the compound of formula (I)
(and, for the avoidance of doubt, a protected derivative of one
compound of formula (I) may or may not represent another compound
of formula I).
[0203] Compounds represented by Intermediate A are either
commercially available, or may be prepared by synthetic approaches
that are well established in the art. For example compounds of this
general structure may be prepared by condensation of the
appropriate hydrazine, optionally in the form of a protected
derivative thereof or a suitable salt, with the relevant
ketonitrile (Scheme 4). An example of an appropriate salt is a
hydrochloride salt, and a suitable protective group for this
transformation is an acid labile carbamate, for example a Boc group
(R.sup.d=tert-Bu) that is readily removed under the cyclisation
conditions
##STR00025##
to generate the parent hydrazine in situ. The
condensation/cyclisation reaction is suitably conducted in a polar
protic solvent such as ethanol and in the presence of a strong acid
for example concentrated hydrochloric acid and at elevated
temperatures, typically at reflux.
[0204] In some instances it may be advantageous to prepare such
intermediates by one or other alternative methodologies, as best
suits the availability of starting materials and/or the
functionality represented in the compounds and/or the need to
protect one or more of them, during the synthetic processes in
question or in subsequent transformations. For example compounds
represented by Intermediate A may also be accessed via a copper (I)
mediated coupling reaction between a 1H-pyrazol-5-amine and a
suitable arene Q-LG.sub.3 in which Q is an optionally substituted
aromatic nucleus as defined for compounds of formula (I) and
LG.sub.3 is a halide such as an iodine atom (Scheme 5). The
reaction is conveniently conducted in an
##STR00026##
aprotic non-polar solvent such as toleune, employing a copper (I)
salt as the catalyst, for example copper (I) iodide and in the
presence of a copper co-ordinating ligand such as
N.sup.1,N.sup.2-dimethylcyclohexane-1,2-diamine and in the presence
of a base, for example potassium carbonate and typically at
elevated temperature for example at reflux.
[0205] It will be evident to those skilled in the art that it may
be advantageous to convert one intermediate described herein into
another example of the same by one or more transformations that are
well known and precedented and thereby gain access to additional
compounds of the invention. As an example of such a process those
compounds represented by Intermediate A wherein Q is a phenyl ring
substituted with an alkoxy group (OR.sup.e wherein R.sup.e is
alkyl), such as a methoxy group, may be converted into the
corresponding phenol by an O-dealkylation reaction (Scheme 6). This
type of transformation may be effected with a boron trihalide, for
example boron tribromide, in a non-polar, aprotic solvent such as
DCM, at reduced temperatures for example at -5 to 0.degree. C.
##STR00027##
[0206] A further demonstration of the conversion of one
intermediate, into another compound of the same generic type is
provided by the functionalisation of the phenol examples of
Intermediate A described hereinabove. For example intermediates of
this composition can be conveniently alkylated on the phenolic
oxygen by reaction with an alkyl halide, for example with a simple
alkyl bromide. Alternatively, the phenol products may be reacted
with a functionalised alkyl halide, for example with a nitrogen
mustard, that is, with a salt of a 2-haloethylamine of formula
R.sup.f(CH.sub.2).sub.2LG.sub.4, wherein LG.sub.4 is a halogen such
as a chlorine and R.sup.f is selected such that
O(CH.sub.2).sub.2R.sup.f is allowable by the definition of Q in
compounds of formula (I)
##STR00028##
or is a suitably protected derivative thereof (Scheme 7). An
example of a salt of a 2-haloethylamine that could be used in
O-alkylations of this kind is 4-(2-chloroethyl)morpholine
hydrochloride. Reaction of this kind are usefully undertaken in
polar non protic solvents such as acetonitrile or DMF and in the
presence of a base such as potassium carbonate and with heating if
necessary.
[0207] In some instances it may be advantageous to effect the
O-alkylation under Mitsunobu conditions, by interaction of the
phenol with the corresponding alcohol R.sup.f(CH.sub.2).sub.2OH in
the presence of a triaryl phosphine such as triphenyphosphine,
together with a suitable diazodicarboxylate coupling reagent, for
example diisopropyl diazene-1,2-dicarboxylate. Such reactions are
typically carried out in non-polar, aprotic solvents such as THF at
reduced to ambient temperatures, for example at -50.degree. C. to
RT.
[0208] Other examples of Intermediate A may be prepared by
interconversion of substituents on the phenyl, pyridyl or thienyl
ring of group Q. For example, examples of Intermediate A bearing
the substituent --(CH.sub.2).sub.1-2P(O)R'R'' may be obtained by
coupling of equivalent compounds bearing the substituent
--(CH.sub.2).sub.1-2Hal, where Hal is a leaving group such as
chloro, bromo or iodo, with a compound of the formula H--P(O)R'R''.
The reaction may be performed, for example, by heating in a polar
aprotic solvent (e.g. DMF) in the presence of a
palladium-containing catalyst (e.g. a Pd(II) catalytic species,
such as Pd(II) acetate, optionally in the presence of a bidentate
phosphine ligand such as
4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos))
Alternatively, the coupling reaction may be with a compound of
formula (C.sub.1-4 alkyl)-O--PR'R'', using Arbuzov-type conditions
(WO 2010/141406; Bioorg. Med. Chem. Lett. 2009, 19, 2053-2058),
with compounds having the --(CH.sub.2).sub.1-2Hal substituent
mentioned above. (Compounds of formula (C.sub.1-4 alkyl)-O--PR'R''
are typically made in situ by reaction of the corresponding
chlorophosphine (Cl--PR'R'') with a C.sub.1-4 alkyl alcohol in the
presence or a base (e.g. diisopropylethylamine), or with an alkali
metal salt of a C.sub.1-4 alkyl alcohol.)
[0209] Compounds represented by Intermediate B may be obtained from
S.sub.NAr displacement reactions between electrophilic aryloxy
naphthylamines represented by Intermediate G, wherein LG.sub.2 is a
suitable leaving group such as a halogen atom, for example
chlorine, with an aniline component represented by Intermediate D
(Scheme 8). The coupling reaction may be undertaken on the free
naphthylamine (G.sub.1=H) or optionally, in order to control
chemoselectivity and thereby enhance efficiency, upon a protected
derivative thereof
##STR00029##
[0210] Intermediate G(P)
[0211] (G.sub.1=protective group). The reaction proceeds under
acidic conditions, for example in the presence of p-TSA and in a
polar aprotic solvent such as THF and typically at elevated
temperatures, for example at 70.degree. C. In those instances in
which a protective group has been employed the products represented
by Intermediate B are subsequently revealed by a suitable
deprotection step(s). For example a carbamate, such as a Boc group,
may be used to protect the naphthylamine nitrogen
(G.sub.1=tert-BuO.sub.2C) during the S.sub.NAr coupling reaction
and afterwards removed by treatment with a strong acid, for example
with TFA.
[0212] The synthetic processes cited hereinabove (Routes C.sub.1
and C.sub.2, Scheme 3) may likewise be exploited to access
compounds represented by Intermediate B (Scheme 9). Thus examples
of Intermediate B may be prepared by reaction of an activated
derivative of a carboxylic acid represented by Intermediate J
(R.sup.c=G.sub.1=H) or a protected derivative thereof Intermediate
J(P) (G.sub.1=protective group) with an amine R.sup.aR.sup.bNH,
whereby NR.sup.aR.sup.b comprises Y or a protected derivative
thereof. Alternatively the interconversion may be undertaken on an
ester Intermediate H (R.sup.c=alkyl, G.sub.1=H) or a protected
derivative thereof Intermediate H(P) (R.sup.c=alkyl,
G.sub.1=protective group) with an amine R.sup.aR.sup.bNH in the
presence of a trialkyl aluminium, as already described. A suitable
protective group for these transformations is a urethane
##STR00030##
derivative (G.sub.1=R.sup.hO.sub.2C) in which case the desired
anilines (G.sub.1=H) represented by Intermediate B are obtained
following an appropriate deprotection procedure. An example of a
urethane protective group which is suitable for this purpose is a
Boc group (G.sub.1=tert-BuO.sub.2C), which can be removed following
the amidation reaction by treatment with acid.
[0213] The ester and acid precursors represented by Intermediates E
and F are obtainable by use of the same or analogous procedures, to
those disclosed hereinabove (Scheme 1), that provide compound
examples of the present invention. In this manner Intermediates E
and F are conveniently obtained by the reaction of Intermediates H
and J respectively with the activated aminopyrazole derivatives
Intermediates A* (Scheme 10). It will be evident to those skilled
in the art that the esters: Intermediates H and E may be readily
transformed into the corresponding carboxylic acids: Intermediates
J and F by hydrolysis under suitable acidic or basic conditions.
For example this conversion can be effected by saponification,
using a base such as lithium hydroxide, in a protic solvent or
mixture of solvents, for example THF and water and at modestly
elevated temperatures, typically RT to 40.degree. C.
##STR00031##
[0214] The precursors represented by Intermediate G are
conveniently prepared by an S.sub.NAr displacement reaction between
4-aminonaphthalen-1-ol, either in the form of a salt or a suitable,
protected derivative and an electrophilic heteroaromatic (Scheme
11), for example a dihalo heteroaromatic wherein the leaving groups
LG.sub.2 and LG.sub.5 are both halogen atoms,
##STR00032##
such as chlorine. A suitable protective group for this
transformation is a Boc group (G.sub.1=tert-BuO.sub.2C) which may
be retained, in order to control chemoselectivity, during one or
more subsequent transformations, such as those described
hereinabove (Schemes 8 and 9). The displacement step is
conveniently carried out in a polar, aprotic solvent such as
acetonitrile and in the presence of a hindered base, typified by
DBU and at reduced temperature, for example at 0.degree. C.
[0215] Those compounds represented by Intermediates H and J were
assembled by analogous synthetic procedures to those already
described above (Scheme 8) for the preparation of Intermediates B
by substituting anilino acids or anilino esters represented by
Intermediate K in place of Intermediate D (Scheme 12). In a similar
manner the acid mediated S.sub.NAr coupling may be conducted on the
free naphthylamine Intermediate G (G.sub.1=H) or optionally, using
a protected derivative of the same, Intermediate G(P)
(G.sub.1=protective group), to maintain the desired
chemoselectivity in this and/or subsequent transformations. The
S.sub.NAr coupling is suitably carried out in a polar non protic
solvent, for example THF or IPA or DMF and in the presence of an
acid catalyst such as p-TSA or TFA and most usually at elevated
temperatures, typically at 60-70.degree. C. In alternative
procedures, a Buchwald-Hartwig amination may be performed, for
example at elevated temperature (e.g. 20 to 120.degree. C.) using a
palladium catalyst (e.g. a combination of Pd.sub.2dba.sub.3 and
BINAP) and base (e.g. Cs.sub.2CO.sub.3). In instances where the
phenyl group of the aniline bears a substituent that is sensitive
to palladium-catalysed reactions (e.g. an ethynyl group), then
Intermediate K may be replaced by Intermediate K*, in which the
sensitive (e.g. ethynyl) group is in protected form (e.g. for
ethynyl, in trialkylsilyl-protected form, such as in
triisopropylsilane-protected form). The protective group may then
be removed under conditions known to those skilled in the art. For
example, a triisopropylsilyl group can be removed with a source of
fluoride ion, e.g., tetrabutylammonium fluoride (TBAF) or caesium
fluoride.
##STR00033##
[0216] The known aniline components represented by Intermediate K
were either procured from commercial sources or prepared according
to published procedures. Novel examples of Intermediate D and
Intermediate K disclosed herein were synthesised from commercially
available starting materials using functional group
interconversions that are well established in the art (Scheme 13).
For example, the (leaving) group LG.sub.6 may be displaced with a
desired R.sup.1 group via an S.sub.NAr reaction or transition
metal-catalysed coupling. In some instances the desired anilines
are readily obtainable from appropriately substituted, amino
benzoic acids (R.sup.c=G.sub.2=H) and/or amino benzoic acid esters
(R.sup.c=alkyl G.sub.2=H) that may be optionally N-protected
(G.sub.2=PG) to ensure that subsequent reactions can be conducted
effectively. Transposition of the substituent R.sup.h into a group
R.sup.1 as defined for compounds of formula (I), provides compounds
represented by Intermediate K which may be hydrolysed and subjected
to an amide coupling reaction to furnish examples of Intermediate
D, after removal, where employed, of the nitrogen protective
group.
##STR00034##
[0217] Additional examples of Intermediate D are readily made from
commercially available (protected) amino or nitro benzoic acids
that are substituted with a suitable (leaving) group LG.sub.6, such
as a halogen, for example fluorine or, particularly, bromine.
Compounds of this composition may be converted into the examples of
the desired anilines by a series of reactions comprising of an
amide coupling, followed by an S.sub.NAr displacement reaction and
reduction of the nitro group into an amine. Alternatively, for
preparing examples of Intermediate D in which R.sup.1 represents
--C.ident.C--(C.sub.1-4 alkylene).sub.0-1-H, the (protected) amino
or nitro benzoic acids may undergo a Sonogashira coupling reaction
and (for protected amino or nitro compounds) either deprotection of
the amino group or reduction of the nitro group into an amine.
Alternatively, the Sonogashira coupling reaction may be performed
before the amide coupling (Scheme 14). In either alternative, when
the alkynyl moiety introduced by way of the Sonogashira coupling
reaction is ethynyl, it is introduced in protected form (e.g. in
trialkylsilyl-protected form, through use of an
ethynyltrialkylsilane, such as ethynyltriisopropylsilane). In such
instances, the protective (e.g. trialkylsilyl) group may be removed
under conditions known to those skilled in the art. For example, a
triisopropylsilyl group can be removed with a source of fluoride
ion, e.g., tetrabutylammonium fluoride (TBAF) or caesium fluoride.
For the Sonogashira coupling reaction, group LG.sub.6 is suitably a
halo group such as chloro, iodo or, particularly, bromo.
##STR00035##
[0218] Compounds of formula (I) may alternatively be obtained by
coupling of Intermediate B to an pyrazole-5-isocyanate compound,
Intermediate L. In this route, Intermediate L may, for example, be
conveniently prepared via a copper (II)-mediated Chan-Lam reaction
(see, for example: Tetrahedron Lett. 1998, 39, 2941-2944), wherein
an ester of a suitable pyrazole-5-carboxylic acid is coupled to an
aryl- or heteroaryl-boronic acids. The resulting N-aryl pyrazole
acid ester is saponified to yield the corresponding carboxylic acid
(Intermediate M), which acid is converted to an acyl azide (e.g.
using source of a leaving group and activated azide ion, such as
diphenyl phosphorazidate (DPPA); see, for example, Tetrahedron
1974, 30, 2151-2157)) before undergoing a Curtis rearrangement to
yield Intermediate L.
##STR00036##
[0219] As exemplified in Scheme 15 above, examples of Intermediate
M(P) may be prepared by metal-catalysed coupling of pyrazole acid
esters to suitable compounds containing aromatic group Q. However,
other examples of Intermediate M(P) may be prepared by further
elaboration of compounds so obtained. For example, when Q is
phenyl, a chloro, bromo or iodo substituent on the phenyl group in
a compound of Intermediate M(P) may be displaced by cross-coupling
with a variety of nucleophilic groups, such as a dialkylphosphine
oxide (Scheme 16). The cross-coupling typically employs a
palladium-containing catalyst (e.g. a Pd(II) catalytic species,
such as Pd(II) acetate, optionally in the presence of a bidentate
phosphine ligand such as
4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos); see,
for example, WO 2009/143389).
##STR00037##
[0220] It will be evident to those skilled in the art that in some
cases it is technically advantageous to use alternative protective
groups and/or to conduct the transformations described above in a
similar manner but in a different order, so as to improve the
overall efficiency of the synthetic processes.
[0221] Protective groups and the means for their removal are
described in "Protective Groups in Organic Synthesis", by Theodora
W. Greene and Peter G. M. Wuts, published by John Wiley & Sons
Inc; 4th Rev Ed., 2006, ISBN-10: 0471697540.
[0222] Novel intermediates as described herein form an aspect of
the invention. In this respect, further aspects of the invention
relate to:
(i) a compound of formula (III) as hereinbefore defined, wherein
Z.sup.2 represents a structural fragment of formula (V), as
hereinbefore defined, or a salt or protected derivative thereof;
and (ii) Intermediate D, as hereinbefore defined (i.e. a compound
of formula (VII), as hereinbefore defined) or a salt or protected
derivative thereof.
[0223] Protected derivatives of Intermediates B and D include
amides or, particularly, carbamates of those compounds. For
example, those protected derivatives include compounds in which a
H-atom of the NH.sub.2 group is replaced by: [0224] R'--C(O)--,
wherein R' is H, C.sub.1-8 alkyl, phenyl or benzyl, which latter
two groups are optionally substituted by one or more groups
selected from halo, hydroxy, methyl and methoxy; or [0225]
R''--O--C(O)--, wherein R'' is tert-butyl, phenyl, benzyl or
fluorenyl, which latter three groups are optionally substituted by
one or more groups selected from halo, hydroxy, methyl and
methoxy.
[0226] The compounds of formula (I) are p38 MAP kinase inhibitors
(especially of the alpha subtype) and in one aspect the compounds
are useful in the treatment of inflammatory diseases, for example
COPD and/or asthma.
[0227] Surprisingly, in at least some embodiments, the compounds of
formula (I) exhibit a long duration of action and/or persistence of
action.
[0228] In one embodiment the compounds of formula (I) do not
strongly inhibit, or bind to GSK 3.alpha., for example they have an
IC.sub.50 value against GSK 3.alpha. of 1500 nM or greater; such as
2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000 or 10,000 nM
or greater.
[0229] Persistence of action as used herein is related to the
dissociation rate or dissociation constant of the compound from the
target (such as a receptor). A low dissociation rate may lead to
persistence.
[0230] A low dissociation rate in combination with a high
association rate tends to provide potent therapeutic entities.
[0231] The compounds of formula (I) are expected to be potent in
vivo.
[0232] Typically, the prior art compounds developed to date have
been intended for oral administration. This strategy involves
optimizing the pharmacokinetic profile of drug substances in order
to achieve an adequate duration of action. In this manner a
sufficiently high drug concentration is established and maintained
between doses to provide sustained clinical benefit. The inevitable
consequence of this approach is that all bodily tissues, and
especially the liver and the gut, are likely to be exposed to
supra-therapeutically active concentrations of the drug, whether or
not they are adversely affected by the disease being treated.
[0233] An alternative strategy is to design treatment paradigms in
which the drug is dosed directly to the inflamed organ, that is, to
exploit topical administration. Whilst this approach is not
suitable for treating all chronic inflammatory diseases, it has
been exploited in lung disorders, such as asthma and COPD; in skin
diseases, for example against atopic dermatitis and psoriasis; for
nasal conditions, typified by allergic rhinitis; and in
gastrointestinal diseases, such as ulcerative colitis and Crohn's
disease and inflammatory diseases of the eye, such as uveitis.
[0234] In topical therapy, one way in which efficacy can be
achieved is by the use of a drug that has a sustained duration of
action and is retained in the relevant organ, thereby minimizing
the risk of systemic toxicity. Alternatively, in some cases, a
formulation can be developed that generates a "reservoir" of the
active drug which is available to sustain its desired effects. The
first approach is exemplified by the anticholinergic drug
tiotropium (Spiriva). This compound is administered topically to
the lung as a treatment for COPD, and has an exceptionally high
affinity for its target receptor resulting in a very slow off rate
and consequently displays a sustained duration of action.
[0235] In one aspect of the disclosure the compounds of formula (I)
is particularly suitable for topical delivery, such as topical
delivery to the lungs, in particular for the treatment of
respiratory disease, for example chronic respiratory diseases such
as COPD and/or asthma.
[0236] In one embodiment the compounds of formula (I) is suitable
for sensitizing patients to treatment with a corticosteroid who
have become refractory to such treatment regimens.
[0237] The compounds of formula (I) may have antiviral properties
(such as those described in WO 2011/070368 and/or WO 2011/070369),
for example the ability to prevent the infection of cells (such as
respiratory epithelial cells) with a picornavirus, in particular a
rhinovirus, influenza or respiratory syncytial virus.
[0238] Thus, in view of their kinase inhibition profiles, the
compounds are thought to be antiviral agents, in particular
suitable for the prevention, treatment or amelioration of
picornavirus infections, such as rhinovirus infection, influenza or
respiratory syncytial virus.
[0239] In one embodiment the compounds of formula (I) are able to
reduce inflammation induced by viral infection, such as rhinovirus
infection and in particular viral infections that result in the
release of cytokines such as IL-8, especially in vivo. This
activity may, for example, be tested in vitro employing a
rhinovirus induced IL-8 assay.
[0240] In one embodiment the compounds of formula (I) are able to
reduce ICAM1 expression induced by rhinovirus, especially in vivo.
ICAM1 is the receptor mechanism used by so-called major groove
rhinovirus serotypes to infect cells. This activity may be
measured, for example by a method described herein.
[0241] It is expected that the above properties render the
compounds of formula (I) particularly suitable for use in the
treatment (including prophylaxis) of exacerbations of inflammatory
diseases, in particular viral exacerbations, or in the treatment of
viral infections, in patients with one or more chronic conditions
such as congestive heart failure, COPD, asthma, diabetes, cancer
and/or in immunosuppressed patients, for example post-organ
transplant. Such use may be in combination with anti-viral agents
such as zanamivir, oseltamivir (for example oseltamivir phosphate)
peramivir or laninamivir.
[0242] In general, the compounds of formula (I) may be useful in
the treatment of one or more conditions having an inflammatory
component which, suitably, may be treated by topical or local
therapy.
[0243] In particular, the compounds of formula (I) may be useful in
the treatment of one or more respiratory disorders including COPD
(including chronic bronchitis and emphysema), asthma, pediatric
asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary
fibrosis, allergic rhinitis, rhinitis and sinusitis, especially
asthma, or COPD (including chronic bronchitis and emphysema).
[0244] The compounds of formula (I) may be useful in the treatment
of eye diseases or disorders including keratoconjunctivitis sicca
(dry eye), allergic conjunctivitis, conjunctivitis, diabetic
retinopathy, macular oedema (including wet macular oedema and dry
macular oedema), post-operative cataract inflammation or,
particularly, uveitis (including posterior, anterior and pan
uveitis) (e.g. eye diseases or disorders including allergic
conjunctivitis, conjunctivitis, diabetic retinopathy, macular
oedema (including wet macular oedema and dry macular oedema),
post-operative cataract inflammation or, particularly, uveitis
(including posterior, anterior and pan uveitis)).
[0245] The compounds of formula (I) may be useful in the treatment
of skin diseases or disorders including allergic dermatitis,
contact dermatitis, atopic dermatitis or psoriasis.
[0246] The compounds of formula (I) may be useful in the treatment
of gastrointestinal diseases or disorders including ulcerative
colitis or Crohn's disease.
[0247] The compounds of formula (I) may be useful in the treatment
of joint diseases or disorders including rheumatoid arthritis or
osteoarthritis and particularly inflamed joints secondary to such
conditions.
[0248] The compounds of formula (I) may be useful in the treatment
of cancers including cancer of the stomach and in the inhibition of
the growth and metastasis of tumours including non-small cell lung
carcinoma, gastric carcinoma, colorectal carcinomas and malignant
melanoma.
[0249] It is also expected that the compounds of formula (I) may be
useful in the treatment of certain other conditions including
periodontitis, gingivitis and pharyngitis.
[0250] Compounds of formula (I) may also re-sensitise the patient's
condition to treatment with a corticosteroid, when the patient's
condition has become refractory to the same.
[0251] Furthermore, the present invention provides a pharmaceutical
composition comprising a compound according to the disclosure
optionally in combination with one or more pharmaceutically
acceptable diluents or carriers.
[0252] Diluents and carriers may include those suitable for
parenteral, oral, topical, mucosal and rectal administration.
[0253] The present invention also provides a process for preparing
such a pharmaceutical composition (for example a pharmaceutical
composition for parenteral, oral, topical, mucosal or rectal
administration) which comprising mixing the ingredients.
[0254] As mentioned above, such compositions may be prepared e.g.
for parenteral, subcutaneous, intramuscular, intravenous,
intra-articular or peri-articular administration, particularly in
the form of liquid solutions or suspensions; for oral
administration, particularly in the form of tablets or capsules;
for topical e.g. pulmonary or intranasal administration,
particularly in the form of powders, nasal drops or aerosols and
transdermal administration; for mucosal administration e.g. to
buccal, sublingual or vaginal mucosa, and for rectal administration
e.g. in the form of a suppository.
[0255] The compositions may conveniently be administered in unit
dosage form and may be prepared by any of the methods well-known in
the pharmaceutical art, for example as described in Remington's
Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton,
Pa., (1985). Formulations for parenteral administration may contain
as excipients sterile water or saline, alkylene glycols such as
propylene glycol, polyalkylene glycols such as polyethylene glycol,
oils of vegetable origin, hydrogenated naphthalenes and the like.
Formulations for nasal administration may be solid and may contain
excipients, for example, lactose or dextran, or may be aqueous or
oily solutions for use in the form of nasal drops or metered
sprays. For buccal administration typical excipients include
sugars, calcium stearate, magnesium stearate, pregelatinated
starch, and the like.
[0256] Compositions suitable for oral administration may comprise
one or more physiologically compatible carriers and/or excipients
and may be in solid or liquid form. Tablets and capsules may be
prepared with binding agents, for example, syrup, acacia, gelatin,
sorbitol, tragacanth, or poly-vinylpyrollidone; fillers, such as
lactose, sucrose, corn starch, calcium phosphate, sorbitol, or
glycine; lubricants, such as magnesium stearate, talc, polyethylene
glycol, or silica; and surfactants, such as sodium lauryl sulfate.
Liquid compositions may contain conventional additives such as
suspending agents, for example sorbitol syrup, methyl cellulose,
sugar syrup, gelatin, carboxymethyl-cellulose, or edible fats;
emulsifying agents such as lecithin, or acacia; vegetable oils such
as almond oil, coconut oil, cod liver oil, or peanut oil;
preservatives such as butylated hydroxyanisole (BHA) and butylated
hydroxytoluene (BHT). Liquid compositions may be encapsulated in,
for example, gelatin to provide a unit dosage form.
[0257] Solid oral dosage forms include tablets, two-piece hard
shell capsules and soft elastic gelatin (SEG) capsules.
[0258] A dry shell formulation typically comprises of about 40% to
60% w/w concentration of gelatin, about a 20% to 30% concentration
of plasticizer (such as glycerin, sorbitol or propylene glycol) and
about a 30% to 40% concentration of water. Other materials such as
preservatives, dyes, opacifiers and flavours also may be present.
The liquid fill material comprises a solid drug that has been
dissolved, solubilized or dispersed (with suspending agents such as
beeswax, hydrogenated castor oil or polyethylene glycol 4000) or a
liquid drug in vehicles or combinations of vehicles such as mineral
oil, vegetable oils, triglycerides, glycols, polyols and
surface-active agents.
[0259] Suitably a compound of formula (I) is administered topically
to the lung, eye or bowel. Hence we provide according to the
invention a pharmaceutical composition comprising a compound of the
disclosure optionally in combination with one or more topically
acceptable diluents or carriers.
[0260] Topical administration to the lung may be achieved by use of
an aerosol formulation. Aerosol formulations typically comprise the
active ingredient suspended or dissolved in a suitable aerosol
propellant, such as a chlorofluorocarbon (CFC) or a
hydrofluorocarbon (HFC).
[0261] Suitable CFC propellants include trichloromonofluoromethane
(propellant 11), dichlorotetrafluoromethane (propellant 114), and
dichlorodifluoromethane (propellant 12). Suitable HFC propellants
include tetrafluoroethane (HFC-134a) and heptafluoropropane
(HFC-227). The propellant typically comprises 40% to 99.5% e.g. 40%
to 90% by weight of the total inhalation composition. The
formulation may comprise excipients including co-solvents (e.g.
ethanol) and surfactants (e.g. lecithin, sorbitan trioleate and the
like). Aerosol formulations are packaged in canisters and a
suitable dose is delivered by means of a metering valve (e.g. as
supplied by Bespak, Valois or 3M).
[0262] Topical administration to the lung may also be achieved by
use of a non-pressurised formulation such as an aqueous solution or
suspension. This may be administered by means of a nebuliser.
Topical administration to the lung may also be achieved by use of a
dry-powder formulation. A dry powder formulation will contain the
compound of the disclosure in finely divided form, typically with a
mass mean aerodynamic diameter (MMAD) of 1-10 .mu.m.
[0263] The formulation will typically contain a topically
acceptable diluent such as lactose, usually of large particle size
e.g. an MMAD of 100 .mu.m or more. Examples of dry powder delivery
systems include SPINHALER, DISKHALER, TURBOHALER, DISKUS and
CLICKHALER.
[0264] The compounds of the present invention (i.e. compounds of
formula (I), (Ia1), (Ia2), (Ib1), (Ib2), (Ic1), (Ic2), (Id1),
(Id2), (Ie1), (Ie2), (If1), (If2), (Ig1), (Ig2), (Ih1) or (Ih2), as
defined above, or pharmaceutically acceptable salts thereof) may
also be administered rectally, for example in the form of
suppositories or enemas, which include aqueous or oily solutions as
well as suspensions and emulsions. Such compositions are prepared
following standard procedures, well known by those skilled in the
art. For example, suppositories can be prepared by mixing the
active ingredient with a conventional suppository base such as
cocoa butter or other glycerides. In this case, the drug is mixed
with a suitable non-irritating excipient which is solid at ordinary
temperatures but liquid at the rectal temperature and will
therefore melt in the rectum to release the drug. Such materials
are cocoa butter and polyethylene glycols.
[0265] Generally, for compositions intended to be administered
topically to the eye in the form of eye drops or eye ointments, the
total amount of the inhibitor will be about 0.0001 to less than
4.0% (w/w).
[0266] Preferably, for topical ocular administration, the
compositions administered according to the present invention will
be formulated as solutions, suspensions, emulsions and other dosage
forms. Aqueous solutions are generally preferred, based on ease of
formulation, as well as a patient's ability to administer such
compositions easily by means of instilling one to two drops of the
solutions in the affected eyes. However, the compositions may also
be suspensions, viscous or semi-viscous gels, or other types of
solid or semi-solid compositions. Suspensions may be preferred for
compounds that are sparingly soluble in water.
[0267] An alternative for administration to the eye is intravitreal
injection of a solution or suspension of the compound of the
present invention. In addition, the compound of the present
invention may also be introduced by means of ocular implants or
inserts.
[0268] The compositions administered according to the present
invention may also include various other ingredients, including,
but not limited to, tonicity agents, buffers, surfactants,
stabilizing polymer, preservatives, co-solvents and viscosity
building agents. Preferred pharmaceutical compositions of the
present invention include the inhibitor with a tonicity agent and a
buffer. The pharmaceutical compositions of the present invention
may further optionally include a surfactant and/or a palliative
agent and/or a stabilizing polymer.
[0269] Various tonicity agents may be employed to adjust the
tonicity of the composition, preferably to that of natural tears
for ophthalmic compositions. For example, sodium chloride,
potassium chloride, magnesium chloride, calcium chloride, simple
sugars such as dextrose, fructose, galactose, and/or simply polyols
such as the sugar alcohols mannitol, sorbitol, xylitol, lactitol,
isomaltitol, maltitol, and hydrogenated starch hydrolysates may be
added to the composition to approximate physiological tonicity.
Such an amount of tonicity agent will vary, depending on the
particular agent to be added. In general, however, the compositions
will have a tonicity agent in an amount sufficient to cause the
final composition to have an ophthalmically acceptable osmolality
(generally about 150-450 mOsm, preferably 250-350 mOsm and most
preferably at approximately 290 mOsm). In general, the tonicity
agents of the invention will be present in the range of 2 to 4%
w/w. Preferred tonicity agents of the invention include the simple
sugars or the sugar alcohols, such as D-mannitol.
[0270] An appropriate buffer system (e.g., sodium phosphate, sodium
acetate, sodium citrate, sodium borate or boric acid) may be added
to the compositions to prevent pH drift under storage conditions.
The particular concentration will vary, depending on the agent
employed. Preferably however, the buffer will be chosen to maintain
a target pH within the range of pH 5 to 8, and more preferably to a
target pH of pH 5 to 7.
[0271] Surfactants may optionally be employed to deliver higher
concentrations of inhibitor. The surfactants function to solubilize
the inhibitor and stabilise colloid dispersion, such as micellar
solution, microemulsion, emulsion and suspension. Examples of
surfactants which may optionally be used include polysorbate,
poloxamer, polyosyl 40 stearate, polyoxyl castor oil, tyloxapol,
triton, and sorbitan monolaurate. Preferred surfactants to be
employed in the invention have a hydrophile/lipophile/balance "HLB"
in the range of 12.4 to 13.2 and are acceptable for ophthalmic use,
such as TritonX114 and tyloxapol.
[0272] Additional agents that may be added to the ophthalmic
compositions of the present invention are demulcents which function
as a stabilising polymer. The stabilizing polymer should be an
ionic/charged example with precedence for topical ocular use, more
specifically, a polymer that carries negative charge on its surface
that can exhibit a zeta-potential of (-)10-50 mV for physical
stability and capable of making a dispersion in water (i.e. water
soluble). A preferred stabilising polymer of the invention would be
polyelectrolyte, or polyelectrolytes if more than one, from the
family of cross-linked polyacrylates, such as carbomers and
Pemulen.RTM., specifically Carbomer 974p (polyacrylic acid), at
0.1-0.5% w/w.
[0273] Other compounds may also be added to the ophthalmic
compositions of the present invention to increase the viscosity of
the carrier. Examples of viscosity enhancing agents include, but
are not limited to: polysaccharides, such as hyaluronic acid and
its salts, chondroitin sulfate and its salts, dextrans, various
polymers of the cellulose family; vinyl polymers; and acrylic acid
polymers.
[0274] Topical ophthalmic products are typically packaged in
multidose form. Preservatives are thus required to prevent
microbial contamination during use. Suitable preservatives include:
benzalkonium chloride, chlorobutanol, benzododecinium bromide,
methyl paraben, propyl paraben, phenylethyl alcohol, edentate
disodium, sorbic acid, polyquaternium-1, or other agents known to
those skilled in the art. Such preservatives are typically employed
at a level of from 0.001 to 1.0% w/v. Unit dose compositions of the
present invention will be sterile, but typically unpreserved. Such
compositions, therefore, generally will not contain
preservatives.
[0275] The medical practitioner, or other skilled person, will be
able to determine a suitable dosage for the compounds of the
invention, and hence the amount of the compound of the invention
that should be included in any particular pharmaceutical
formulation (whether in unit dosage form or otherwise).
[0276] A compound of formula (I) has therapeutic activity. In a
further aspect, the present invention provides a compound of the
disclosure for use as a medicament. Thus, in a further aspect, the
present invention provides a compound as described herein for use
in the treatment of one or more of the above mentioned
conditions.
[0277] In one embodiment a dry powder formulation according the
present disclosure comprises magnesium or calcium stearate. Such
formulations may have superior chemical and/or physical stability
especially when such formulations also contain lactose.
[0278] In a further aspect, the present invention provides use of a
compound as described herein for the manufacture of a medicament
for the treatment of one or more of the above mentioned
conditions.
[0279] In a further aspect, the present invention provides a method
of treatment of one or more of the above mentioned conditions which
comprises administering to a subject an effective amount of a
compound of the disclosure or a pharmaceutical composition
comprising the compound.
[0280] The word "treatment" is intended to embrace prophylaxis as
well as therapeutic treatment. Treatment of conditions or disorders
also embraces treatment of exacerbations thereof.
[0281] A compound of the disclosure may also be administered in
combination with one or more other active ingredients e.g. active
ingredients suitable for treating the above mentioned
conditions.
[0282] For example, possible combinations for treatment of
respiratory disorders include combinations with steroids (e.g.
budesonide, beclomethasone dipropionate, fluticasone propionate,
mometasone furoate, fluticasone furoate), beta agonists (e.g.
terbutaline, salbutamol, salmeterol, formoterol), xanthines (e.g.
theophylline), anticholinergics (e.g. ipratropium or tiotropium,
for example as the bromide) and anti-viral agents (e.g. zanamivir,
oseltamivir, for example as the phosphate, peramivir and
laninamivir).
[0283] Further, for the treatment of gastrointestinal disorders
(such as Crohn's disease or ulcerative colitis), possible
combinations include combinations with, for example, one or more
agents selected from the list comprising: [0284] 5-aminosalicylic
acid, or a prodrug thereof (such as sulfasalazine, olsalazine or
bisalazide); [0285] corticosteroids (e.g. prednisolone,
methylprednisolone, or budesonide); [0286] immunosuppressants (e.g.
cyclosporin, tacrolimus, methotrexate, azathioprine or
6-mercaptopurine); [0287] anti-TNF.alpha. antibodies (e.g.,
infliximab, adalimumab, certolizumab pegol or golimumab); [0288]
anti-IL12/IL23 antibodies (e.g., ustekinumab) or small molecule
IL12/IL23 inhibitors (e.g., apilimod); [0289] Anti-.alpha.4.beta.7
antibodies (e.g., vedolizumab); [0290] MAdCAM-1 blockers (e.g.,
PF-00547659); [0291] antibodies against the cell adhesion molecule
.alpha.4-integrin (e.g., natalizumab); [0292] antibodies against
the IL2 receptor a subunit (e.g., daclizumab or basiliximab);
[0293] JAK3 inhibitors (e.g., tofacitinib or R348); [0294] Syk
inhibitors and prodrugs thereof (e.g., fostamatinib and R-406);
[0295] Phosphodiesterase-4 inhibitors (e.g., tetomilast); [0296]
HMPL-004; [0297] probiotics; [0298] Dersalazine; [0299]
semapimod/CPSI-2364; and [0300] protein kinase C inhibitors (e.g.
AEB-071).
[0301] For the treatment of eye disorders (such as
keratoconjunctivitis sicca or uveitis), possible combinations
include combinations with, for example, one or more agents selected
from the list comprising: [0302] corticosteroids (e.g.
dexamethasone, prednisolone, triamcinolone acetonide, difluprednate
or fluocinolone acetonide); [0303] immunosuppressants (e.g.
cyclosporin, voclosporin, azathioprine, methotrexate, mycophenolate
mofetil or tacrolimus); [0304] anti-TNF.alpha. antibodies (e.g.,
infliximab, adalimumab, certolizumab pegol, ESBA-105 or golimumab);
[0305] anti-IL-17A antibodies (e.g., secukinumab); [0306] mTOR
inhibitors (e.g., sirolimus); [0307] VGX-1027; [0308] JAK3
inhibitors (e.g., tofacitinib or R348); and [0309] protein kinase C
inhibitors (e.g. AEB-071).
[0310] Hence another aspect of the invention provides a compound of
formula (I) in combination with one or more further active
ingredients, for example one or more active ingredients described
above.
[0311] Similarly, another aspect of the invention provides a
combination product comprising: [0312] (A) a compound of the
present invention (i.e. a compound of formula (I), (Ia1), (Ia2),
(Ib1), (Ib2), (Ic1), (Ic2), (Id1), (Id2), (Ie1), (Ie2), (If1),
(If2), (Ig1), (Ig2), (Ih1) or (Ih2), as defined above, or a
pharmaceutically acceptable salt thereof); and [0313] (B) another
therapeutic agent, wherein each of components (A) and (B) is
formulated in admixture with a pharmaceutically-acceptable
adjuvant, diluent or carrier.
[0314] In this aspect of the invention, the combination product may
be either a single (combination) pharmaceutical formulation or a
kit-of-parts.
[0315] Thus, this aspect of the invention encompasses a
pharmaceutical formulation including a compound of the present
invention and another therapeutic agent, in admixture with a
pharmaceutically acceptable adjuvant, diluent or carrier (which
formulation is hereinafter referred to as a "combined
preparation").
[0316] It also encompasses a kit of parts comprising components:
[0317] (i) a pharmaceutical formulation including a compound of the
present invention in admixture with a pharmaceutically acceptable
adjuvant, diluent or carrier; and [0318] (ii) a pharmaceutical
formulation including another therapeutic agent, in admixture with
a pharmaceutically-acceptable adjuvant, diluent or carrier, which
components (i) and (ii) are each provided in a form that is
suitable for administration in conjunction with the other.
[0319] Component (i) of the kit of parts is thus component (A)
above in admixture with a pharmaceutically acceptable adjuvant,
diluent or carrier. Similarly, component (ii) is component (B)
above in admixture with a pharmaceutically acceptable adjuvant,
diluent or carrier.
[0320] The other therapeutic agent (i.e. component (B) above) may
be, for example, any of the agents mentioned above in connection
with the treatment of respiratory, gastrointestinal and eye
disorders.
[0321] The combination product (either a combined preparation or
kit-of-parts) of this aspect of the invention may be used in the
treatment or prevention of an inflammatory disease (e.g. the
inflammatory diseases mentioned above, such as: [0322] respiratory
disorders including COPD (including chronic bronchitis and
emphysema), asthma, pediatric asthma, cystic fibrosis, sarcoidosis,
idiopathic pulmonary fibrosis, allergic rhinitis, rhinitis and
sinusitis, especially asthma, or COPD (including chronic bronchitis
and emphysema); [0323] eye diseases or disorders including allergic
conjunctivitis, conjunctivitis, keratoconjunctivitis sicca (dry
eye), glaucoma, diabetic retinopathy, macular oedema (including
diabetic macular oedema), central retinal vein occlusion (CRVO),
dry and/or wet age related macular degeneration (AMD),
post-operative cataract inflammation or, particularly, uveitis
(including posterior, anterior and pan uveitis), corneal graft and
limbal cell transplant rejection; [0324] skin diseases or disorders
including allergic dermatitis, contact dermatitis, atopic
dermatitis or psoriasis; and [0325] gastrointestinal diseases or
disorders including gluten sensitive enteropathy (coeliac disease),
eosinophilic esophagitis, intestinal graft versus host disease or,
particularly, ulcerative colitis or Crohn's disease.
[0326] The aspects of the invention described herein (e.g. the
above-mentioned compound, combinations, methods and uses) may have
the advantage that, in the treatment of the conditions described
herein, they may be more convenient for the physician and/or
patient than, be more efficacious than, be less toxic than, be
longer acting than, have better selectivity over, have a broader
range of activity than, be more potent than, produce fewer side
effects than, have a better pharmacokinetic and/or pharmacodynamic
profile than, have more suitable solid state morphology than, have
better stability than, or may have other useful pharmacological
properties over, similar compounds, combinations, methods
(treatments) or uses known in the prior art for use in the
treatment of those conditions or otherwise.
[0327] Relative to compounds of the prior art, the compounds of
formula (I) may additionally (or alternatively): [0328] exhibit
properties that are particularly suited to topical/local
administration (e.g. following topical/local administration, the
generation of high target tissue concentrations but low plasma
concentrations of the compounds of formula (I) and/or rapid
clearance of the compounds of formula (I) from plasma); [0329] have
a reduced risk of extravascular exposure following intravenous
administration (e.g. due to a low volume of distribution for the
compounds of formula (I)); [0330] exhibit superior potency with
respect to selected kinases (e.g. Syk and/or a panel of kinases,
such as Syk, Src and p38 MAPK.alpha.); [0331] exhibit reduced
.beta.-catenin induction and/or inhibition of mitosis in cells;
[0332] exhibit no or less time-dependent inhibition of members of
the cytochrome P450 superfamily; and/or [0333] produce less
problematic (e.g. less toxic) metabolites, e.g. following
administration to a patient.
EXPERIMENTAL SECTION
[0334] Abbreviations used herein are defined below (Table 1). Any
abbreviations not defined are intended to convey their generally
accepted meaning.
TABLE-US-00001 TABLE 1 Abbreviations AcOH glacial acetic acid aq
aqueous ATP adenosine-5'-triphosphate BALF bronchoalveolar lavage
fluid br broad BSA bovine serum albumin CatCart .RTM. catalytic
cartridge CDI 1,1-carbonyl-diimidazole COPD chronic obstructive
pulmonary disease c-Src cellular sarc(oma) kinase d doublet DCM
dichloromethane DMEM Dulbecco's Modified Eagle Medium DMSO dimethyl
sulfoxide DSS dextran sodium sulphate d-U937 cells PMA
differentiated U-937 cells (ES.sup.+) electrospray ionization,
positive mode Et ethyl EtOAc ethyl acetate FCS foetal calf serum
FRET fluorescence resonance energy transfer GR glucocorticoid
receptor GSK3.alpha. glycogen synthase kinase 3.alpha. HBEC primary
human bronchial epithelial cells hr hour(s) HRP horseradish
peroxidise HRV human rhinovirus IBD inflammatory bowel disease
ICAM-1 inter-cellular adhesion molecule 1 IL-8 interleukin 8 JNK
c-Jun N-terminal kinase LPS lipopolysaccharide (M + H).sup.+
protonated molecular ion MAPK mitogen-activated protein kinase
MAPKAP-K2 mitogen-activated protein kinase-activated protein
kinase-2 Me methyl MeCN acetonitrile MeOH methanol MHz megahertz
MMAD mass median aerodynamic diameter MOI multiplicity of infection
min minute(s) MPO myeloperoxidase MTT
3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide m/z:
mass-to-charge ratio NMR nuclear magnetic resonance (spectroscopy)
NT Not tested PBMC peripheral blood mononuclear cell PBS phosphate
buffered saline PG protective group Ph phenyl PHA
phytohaemagglutinin PMA phorbol myristate acetate p-TSA
4-methylbenzenesulfonic acid q quartet RT room temperature RP HPLC
reverse phase high performance liquid chromatography RSV
respiratory syncytial virus s singlet sat saturated SCX solid
supported cation exchange (resin) SDS sodium dodecyl sulphate
S.sub.NAr nucleophilic aromatic substitution Syk spleen tyrosine
kinase t triplet T3P 1-propanephosphonic acid cyclic anhydride
TBDMS tert-butyldimethylsilyl TCID.sub.50 50% tissue culture
infectious dose THF tetrahydrofuran TMB
3,3',5,5'-tetramethylbenzidine TNBS 2,4,6-trinitrobenzenesuifonic
acid TNF.alpha. tumor necrosis factor alpha WB washing buffer
General Procedures
[0335] All starting materials and solvents were obtained either
from commercial sources or prepared according to the literature
citation. Unless otherwise stated all reactions were stirred.
Organic solutions were routinely dried over anhydrous magnesium
sulfate. Hydrogenations were performed on a Thales H-cube flow
reactor under the conditions stated.
[0336] Column chromatography was performed on pre-packed silica
(230-400 mesh, 40-63 .mu.m) cartridges using the amount indicated.
SCX was purchased from Supelco and treated with 1M hydrochloric
acid prior to use. Unless stated otherwise the reaction mixture to
be purified was first diluted with MeOH and made acidic with a few
drops of AcOH. This solution was loaded directly onto the SCX and
washed with MeOH. The desired material was then eluted by washing
with 0.7 M NH.sub.3 in MeOH.
[0337] Preparative Reverse Phase High Performance Liquid
Chromatography
[0338] Agilent Scalar column C18, 5 .mu.m (21.2.times.50 mm), flow
rate 28 mL min.sup.-1 eluting with a H.sub.2O-MeCN gradient
containing 0.1% v/v formic acid over 10 min using UV detection at
215 and 254 nm. Gradient information: 0.0-0.5 min; 95% H.sub.2O-5%
MeCN; 0.5-7.0 min; ramped from 95% H.sub.2O-5% MeCN to 5%
H.sub.2O-95% MeCN; 7.0-7.9 min; held at 5% H.sub.2O-95% MeCN;
7.9-8.0 min; returned to 95% H.sub.2O-5% MeCN; 8.0-10.0 min; held
at 95% H.sub.2O-5% MeCN.
[0339] Analytical Methods
[0340] Reverse Phase High Performance Liquid Chromatography
[0341] Method 1:
[0342] Agilent Scalar column C18, 5 .mu.m (4.6.times.50 mm) or
Waters XBridge C18, 5 .mu.m (4.6.times.50 mm) flow rate 2.5 mL
min.sup.-1 eluted with a H.sub.2O-MeCN gradient containing either
0.1% v/v formic acid (Method 1 acidic) or NH.sub.3 (Method 1 basic)
over 7 min employing UV detection at 215 and 254 nm. Gradient
information: 0.0-0.1 min, 95% H.sub.2O-5% MeCN; 0.1-5.0 min, ramped
from 95% H.sub.2O-5% MeCN to 5% H.sub.2O-95% MeCN; 5.0-5.5 min,
held at 5% H.sub.2O-95% MeCN; 5.5-5.6 min, held at 5% H.sub.2O-95%
MeCN, flow rate increased to 3.5 mL min.sup.-1; 5.6-6.6 min, held
at 5% H.sub.2O-95% MeCN, flow rate 3.5 mL min.sup.-1; 6.6-6.75 min,
returned to 95% H.sub.2O-5% MeCN, flow rate 3.5 mL min.sup.-1;
6.75-6.9 min, held at 95% H.sub.2O-5% MeCN, flow rate 3.5
mLmin.sup.-1; 6.9-7.0 min, held at 95% H.sub.2O-5% MeCN, flow rate
reduced to 2.5 mL min.sup.-1.
[0343] Method 2:
[0344] Agilent Extend C18 column, 1.8 .mu.m (4.6.times.30 mm) at
40.degree. C.; flow rate 2.5-4.5 mL min.sup.-1 eluted with a
H.sub.2O-MeCN gradient containing either 0.1% v/v formic acid
(Method 2 acidic) or NH.sub.3 (Method 2 basic) over 4 min employing
UV detection at 254 nm. Gradient information: 0-3.00 min, ramped
from 95% H.sub.2O-5% MeCN to 5% H.sub.2O-95% MeCN; 3.00-3.01 min,
held at 5% H.sub.2O-95% MeCN, flow rate increased to 4.5 mL
min.sup.-1; 3.01 3.50 min, held at 5% H.sub.2O-95% MeCN; 3.50-3.60
min, returned to 95% H.sub.2O-5% MeCN, flow rate reduced to 3.50 mL
min.sup.-1; 3.60-3.90 min, held at 95% H.sub.2O-5% MeCN; 3.90-4.00
min, held at 95% H.sub.2O-5% MeCN, flow rate reduced to 2.5 mL
min.sup.-1.
[0345] Method 3:
[0346] Waters Xselect CSH C18 3.5 .mu.m (4.6.times.50 mm) flow rate
2.5 mL min.sup.-1 eluted with a H.sub.2O-MeCN gradient containing
0.1% v/v formic acid over 7 min employing UV detection at 215 and
254 nm. Gradient information: 0.0-0.1 min, 95% H.sub.2O-5% MeCN;
0.1-5.0 min, ramped from 95% H.sub.2O-5% MeCN to 5% H.sub.2O-95%
MeCN; 5.0-5.5 min, held at 5% H.sub.2O-95% MeCN; 5.5-5.6 min, held
at 5% H.sub.2O-95% MeCN, flow rate increased to 3.5 mL min.sup.-1;
5.6-6.6 min, held at 5% H.sub.2O-95% MeCN, flow rate 3.5 mL
min.sup.-1; 6.6-6.75 min, returned to 95% H.sub.2O-5% MeCN, flow
rate 3.5 mL min.sup.-1; 6.75-6.9 min, held at 95% H.sub.2O-5% MeCN,
flow rate 3.5 mLmin.sup.-1; 6.9-7.0 min, held at 95% H.sub.2O-5%
MeCN, flow rate reduced to 2.5 mL min.sup.-1.
[0347] Method 4:
[0348] Waters Xselect CSH C18 3.5 .mu.m (4.6.times.50 mm); flow
rate 2.5-4.5 mL min.sup.-1 eluted with a H.sub.2O-MeCN gradient
containing 0.1% v/v formic acid over 4 min employing UV detection
at 254 nm. Gradient information: 0-3.00 min, ramped from 95%
H.sub.2O-5% MeCN to 5% H.sub.2O-95% MeCN; 3.00-3.01 min, held at 5%
H.sub.2O-95% MeCN, flow rate increased to 4.5 mL min.sup.-1; 3.01
3.50 min, held at 5% H.sub.2O-95% MeCN; 3.50-3.60 min, returned to
95% H.sub.2O-5% MeCN, flow rate reduced to 3.50 mL min.sup.-1;
3.60-3.90 min, held at 95% H.sub.2O-5% MeCN; 3.90-4.00 min, held at
95% H.sub.2O-5% MeCN, flow rate reduced to 2.5 mL min.sup.-1.
[0349] .sup.1H NMR Spectroscopy
[0350] .sup.1H NMR spectra were acquired on a Bruker Avance III
spectrometer at 400 MHz using residual undeuterated solvent as
reference and unless specified otherwise were run in
DMSO-d.sub.6.
[0351] Those intermediates, used to prepare compound examples of
the invention, that have been previously disclosed were obtained
using the procedures contained in the references cited below (Table
2). Additional intermediates were prepared by the representative
synthetic processes described herein.
TABLE-US-00002 TABLE 2 Compound Intermediates Name, LCMS Data No.
Structure and Reference A1 ##STR00038## 3-tert-butyl-1-
p-tolyl-pyrazol- 5-amine. R.sup.t 2.46 min (Method 1 basic); m/z
230 (M + H).sup.+, (ES.sup.+). Cirillo, P. F. et al., WO
2000/43384, 27 Jul. 2000. A1* ##STR00039## phenyl (3- (tert-butyl)-
1-(p-tolyl)-1H- pyrazol-5-yl) carbamate LCMS m/z 350 (M + H).sup.+
(ES.sup.+); 348 (M - H).sup.- (ES.sup.-) Kapadia, S. R. et al.,
U.S. Pat. No. 6,492,529, 10 Dec. 2002. A2 ##STR00040##
3-isopropyl-1-(p- tolyl)-1H-pyrazol-5- amine. R.sup.t 3.14 min
(Method 1, acidic, X-Select); m/z 216 (M + H).sup.+, (ES.sup.+).
Ito, K. et al., WO 2010/067130, 17 Jun. 2010 A3 ##STR00041##
3-tert-butyl-1-(4- methoxyphenyl)- 1H-pyrazol- 5-amine. R.sup.t
1.32 min (Method 2, acidic); m/z 246 (M + H).sup.+, (ES.sup.+).
Mathias, J. P. et al., US 2006/0035922, 10 Aug. 2005. A3*
##STR00042## phenyl (3-(tert- butyl)-1-(4- methoxyphenyl)-
1H-pyrazol-5-yl) carbamate LCMS m/z 366 (M + H).sup.+ (ES.sup.+);
364 (M - H).sup.- (ES.sup.-) Abraham, S. et al., WO 2009/117080, 24
Sep. 2009. A4 ##STR00043## 3-tert-butyl-1-(2,3, 5,6-tetradeutero-
4-(trideuteromethyl) phenyl)-1H- pyrazole-5-amine m/z 237 (M +
H).sup.+, (ES.sup.+). Ito, K. et al., WO 2010/067130, 17 Jun. 2010
G1 ##STR00044## 4-((2-chloropyridin- 4-yl)oxy)naphthalen- 1-amine.
R.sup.t 3.13 min (Method 3); m/z 271/273 (M + H).sup.+, (ES.sup.+).
Ito, K. et al., WO 2010/112936, 07 Oct. 2010 G2 ##STR00045##
4-((2-chloro- pyrimidin- 4-yl)oxy) naphthalen-1- amine. R.sup.t
1.80 min (Method 2, acidic); m/z 272/ 274 (M + H).sup.+,
(ES.sup.+). Cirillo, P. F. et al., WO 2002/92576, 21 Nov. 2000.
G2(P) ##STR00046## tert-butyl (4-((2- chloropyrimidin- 4-yl)oxy)
naphthalen-1- yl)carbamate. R.sup.t 2.43 min (Method 2, acidic);
m/z 372/ 374 (M + H).sup.+, (ES.sup.+). Ito, K. et al., WO
2010/067130, 17 Jun. 2010
Intermediate A4*
Phenyl(3-(tert-butyl)-1-(2,3,5,6-tetradeutero-4-(trideuteromethyl)-phenyl)-
-1H-pyrazol-5-yl)carbamate
##STR00047##
[0353] Phenyl chloroformate (580 .mu.L, 4.62 mmol) was added to a
stirred mixture of Intermediate A4 (1 g, 4.23 mmol) and NaHCO.sub.3
(0.711 g, 8.46 mmol) in DCM (20 mL) and THF (10 mL). The mixture
was stirred for 3 h then partitioned between DCM (200 mL) and water
(100 mL). The organic layer was separated, washed with brine, dried
(MgSO.sub.4), filtered and evaporated under reduced pressure. The
residue was triturated with ether/isohexane, filtered and dried to
afford the sub-title compound (1.335 g) LCMS m/z 357 (M+H).sup.+
(ES.sup.+); 355 (M-H).sup.- (ES.sup.-)
Intermediate A5
3-(tert-Butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-amine
##STR00048##
[0355] DPPA (0.550 mL, 2.55 mmol) was added to a stirred solution
of Intermediate M1 (500 mg, 1.740 mmol) and Et.sub.3N (0.4 mL, 2.87
mmol) in tert-butanol (10 ml) under N.sub.2 then heated to reflux
for 18 h. The mixture was cooled, water (75 mL) added and extracted
with ethyl acetate (3.times.50 mL). The combined organic phases
were washed with saturated brine (50 mL), dried (MgSO.sub.4) and
concentrated under reduced pressure. The crude product was purified
by chromatography on the Companion (40 g column, 25-100%
DCM:iso-hexane) to afford
tert-butyl(3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)car-
bamate (459 mg) as a pale orange oil.
[0356] LCMS m/z 359 (M+H).sup.+ (ES.sup.+); 357 (M-H).sup.-
(ES.sup.-)
[0357] TFA (1 mL, 12.98 mmol) was added to a stirred solution of
(3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)carbamate
obtained immediately above (459 mg, 1.280 mmol) in DCM (5 mL) at rt
for 3 h. The mixture was concentrated under reduced pressure and
the residue was redissolved in ethyl acetate (25 mL). The organic
solution was washed with saturated NaHCO.sub.3 solution (2.times.25
mL), saturated brine (25 mL), dried (MgSO.sub.4) and concentrated
under reduced pressure to yield Intermediate A5 (335 mg).
[0358] LCMS m/z 259 (M+H).sup.+ (ES.sup.+)
Intermediate A5*
Phenyl(3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)carbamat-
e
##STR00049##
[0360] Phenyl chloroformate (175 .mu.L, 1.395 mmol) was added to a
suspension of Intermediate A5 (335 mg, 1.297 mmol) and NaHCO.sub.3
(220 mg, 2.62 mmol) in THF (4 mL) and DCM (4 mL). The mixture was
stirred at rt for 2 h. The mixture was diluted with DCM (20 mL) and
washed with water (25 mL). The organic phase was washed with
saturated brine (20 mL), dried (MgSO.sub.4) and concentrated under
reduced pressure. The residue was recrystallised in cyclohexane to
afford the sub-title compound (345 mg) as a white solid. .sup.1H
NMR (CDCl.sub.3) 400 MHz, .delta.: 7.44-7.31 (m, 4H), 7.29-7.22 (m,
1H), 7.21-7.11 (m, 2H), 7.03-6.90 (m, 1H), 6.90-6.76 (m, 2H),
6.56-6.36 (m, 1H), 3.04 (s, 6H), 1.37 (s, 9H).
[0361] LCMS m/z 379 (M+H).sup.+ (ES.sup.+)
Intermediate B1
3-((4-((4-Aminonaphthalen-1-yl)oxy)pyridin-2-yl)amino)-5-methoxy-N-(2-(2-(-
2-methoxyethoxy)ethoxy)ethyl)benzamide
##STR00050##
[0363] Pd.sub.2dba.sub.3 (22 mg, 0.024 mmol) and BINAP (30 mg,
0.048 mmol) were stirred in 1,4-dioxane (1 mL) for 10 minutes under
N.sub.2. In a separate vessel, purged with N.sub.2, caesium
carbonate (455 mg, 1.396 mmol), Intermediate D3 (291 mg, 0.930
mmol) and Intermediate G1(P) (345 mg, 0.930 mmol) were stirred in
1,4-dioxane (5 mL). The catalyst solution was added to the main
reaction mixture and the whole was heated to 90.degree. C. for 18
h. Upon cooling, the mixture was diluted with water (40 mL) and
extracted with ethyl acetate (3.times.25 mL). The combined organic
phases were washed with saturated brine (15 mL), dried (MgSO.sub.4)
and concentrated under reduced pressure. The crude product was
purified by chromatography on the Companion (40 g column, 0-50%
acetone/ethyl acetate) to afford
tert-butyl(4-((2-((3-methoxy-5-((2-(2-(2-methoxyethoxy)ethoxy)ethyl)carba-
moyl)phenyl)amino)pyridin-4-yl)oxy)-naphthalen-1-yl)carbamate
(Intermediate B1(P), 320 mg) as a sticky orange oil.
[0364] .sup.1H NMR (DMSO-d6) 400 MHz, .delta.: 9.37 (s, 1H), 9.09
(s, 1H), 8.35 (t, 1H), 8.17-8.05 (m, 2H), 7.83 (d, 1H), 7.67-7.46
(m, 5H), 7.35 (d, 1H), 6.88 (s, 1H), 6.57 (dd, 1H), 6.09 (d, 1H),
3.74 (s, 3H), 3.58-3.44 (m, 8H), 3.44-3.34 (m, 4H), 3.20 (s, 3H),
1.52 (s, 9H).
[0365] LCMS m/z 647 (M+H).sup.+ (ES.sup.+); 645 (M-H).sup.-
(ES.sup.-)
[0366] A solution of Intermediate B1(P) (320 mg, 0.495 mmol) in DCM
(1 mL) was treated with TFA (1000 .mu.L, 12.98 mmol) and stirred at
rt for 3 h. The mixture was diluted with water (10 mL) and DCM (10
mL). The mixture was neutralised with saturated NaHCO.sub.3 and
passed through a phase separation cartridge. The organic phase was
dried (MgSO.sub.4) and concentrated to give Intermediate B1 (270
mg) as a brown gum.
[0367] .sup.1H NMR (DMSO-d6) 400 MHz, .delta.: 9.00 (s, 1H), 8.34
(dd, 1H), 8.20-8.10 (m, 1H), 8.05 (d, 1H), 7.67-7.60 (m, 1H),
7.59-7.55 (m, 1H), 7.52-7.47 (m, 1H), 7.47-7.41 (m, 2H), 7.10 (d,
1H), 6.89-6.84 (m, 1H), 6.71 (d, 1H), 6.51 (dd, 1H), 6.05 (d, 1H),
5.83 (s, 2H), 3.73 (S, 3H), 3.58-3.45 (m, 8H), 3.45-3.35 (m, 4H),
3.21 (s, 3H).
[0368] LCMS m/z 547 (M+H).sup.+ (ES.sup.+)
Intermediate B2
3-((4-((4-Aminonaphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-
-(2-methoxyethoxy)ethoxy)ethyl)benzamide
##STR00051##
[0370] Method 1
[0371] T3P, 50% w/w in EtOAc (54.0 ml, 91 mmol) was added to a
solution Intermediate J1(P) (30 g, 60.4 mmol),
2-(2-(2-methoxyethoxy)ethoxy)ethanamine (11.83 g, 72.5 mmol), and
TEA (20 mL, 143 mmol) in DMF (400 mL). The mixture was stirred at
rt for 18 h. The mixture was diluted with water (700 mL) and
saturated sodium hydrogen carbonate solution (500 mL) and the
mixture was extracted with ethyl acetate (3.times.400 mL). The
combined organic phases were washed with 20% brine (3.times.500
mL), saturated brine (3.times.500 mL), dried (MgSO.sub.4), filtered
and concentrated in vacuo. The crude product was purified in two
batches by chromatography on the companion (330 g column, 1-5% MeOH
in DCM) to afford
tert-butyl(4-((2-((3-ethynyl-5-((2-(2-(2-methoxyethoxy)ethoxy)ethyl)carba-
moyl)phenyl)amino)-pyrimidin-4-yl)oxy)naphthalen-1-yl)carbamate
(Intermediate B2(P), 24.4 g) as a pale yellow foam.
[0372] .sup.1H NMR (400 MHz, DMSO-d6) .delta.: 9.74 (s, 1H), 9.31
(s, 1H), 8.44-8.47 (m, 2H), 8.11 (s, 1H), 8.10 (d, 1H), 7.91 (s,
1H), 7.82 (d, 1H), 7.54-7.63 (m, 3H), 7.46 (s, 1H), 7.42 (d, 1H),
6.58 (d, 1H), 4.15 (s, 1H), 3.49-3.53 (m, 8H), 3.36-3.41 (m, 4H),
3.21 (s, 3H), 1.52 (s, 9H).
[0373] LCMS m/z 642 (M+H).sup.+ (ES.sup.+); 640 (M-H).sup.-
(ES.sup.-)
[0374] Trifluoroacetic acid (30 ml, 389 mmol) was added dropwise to
a stirred solution of Intermediate B2(P) (12.0 g, 18.70 mmol) in
DCM (200 mL). The reaction was stirred at rt for 3 h. The reaction
was concentrated in vacuo and the residue partitioned between DCM
(300 mL) and saturated NaHCO.sub.3 solution (400 mL). The aqueous
phase was separated and extracted with DCM (200 mL). The combined
organics were dried (MgSO.sub.4), filtered and concentrated in
vacuo to give a beige foam. The crude product was purified by
chromatography on the Companion (220 g column, 1-5% MeOH in DCM) to
afford Intermediate B2 (9.0 g) as a pale pink foam.
[0375] .sup.1H NMR (400 MHz, DMSO-d6) .delta.: 9.74 (s, 1H), 8.46
(t, 1H), 8.36 (d, 1H), 8.12-8.14 (m, 1H), 8.07 (s, 1H), 7.94 (s,
1H), 7.62-7.64 (m, 1H), 7.41-7.46 (m, 3H), 7.15 (d, 1H), 6.70 (d,
1H), 6.38 (d, 1H), 5.76 (s, 2H), 4.18 (s, 1H), 3.49-3.53 (m, 8H),
3.36-3.41 (m, 4H), 3.21 (s, 3H). LCMS m/z 542 (M+H).sup.+
(ES.sup.+); 540 (M-H).sup.- (ES.sup.-)
[0376] Method 2
[0377] A mixture of Intermediate D2 (155.76 g of approx. 90%
purity, 458 mmol), Intermediate G2(P) (166.6 g, 448 mmol) and
para-toluenesulfonic acid (14.7 g, 85 mmol) in THF (2.5 L) was
heated at reflux for 6 h. The reaction mixture was then allowed to
cool overnight to provide a dark brown mixture having a "jelly"
consistency. Solvent was evaporated to provide a viscous, tacky
material. This was dissolved in mixture of ethyl acetate and sodium
bicarbonate (aqueous). The aqueous and organic layers were
separated and the aqueous layer was re-extracted with ethyl
acetate. The combined ethyl acetate layers were washed with brine
(.times.2) before being dried (MgSO.sub.4), filtered through a
silica plug, reduced (by solvent evaporation) to approx 10% volume
and then poured onto a large excess of n-hexane. The resulting
mixture was stirred for 6-8 h to provide a solid that was isolated
by filtration, washed with n-hexane and then dried to afford a pale
brown solid (Intermediate B2(P), 223 g, 77.5%).
[0378] Washing of the silica plug with acetone yielded a further 42
g (14.6%) of mixture of Intermediate B2(P) and Intermediate B2, as
determined by TLC.
[0379] The two solid materials comprising or containing
Intermediate B2(P) were combined and then used in the next stage
without any further purification.
[0380] A mixture of Intermediate B2(P) (265 g, 413 mmol),
trifluoroacetic acid (575.62 g, 5.048 mol) and dichloromethane (2
L) was stirred together for 3 h. Analysis by TLC (ethyl acetate)
showed complete consumption of starting material. The solvent was
reduced by evaporation and the resulting residue dissolved in ethyl
acetate. The organic solution was cautiously washed with sodium
bicarbonate (saturated, aq.) before being dried (MgSO.sub.4),
filtered and then concentrated in vacuo to afford Intermediate B2
as a black gum/foam (200 g, 89.4%) that had .sup.1H NMR and LCMS
data essentially identical to those of the material obtained via
Method 1 above, and which gum/foam was used in the next step
without further purification.
Intermediate B3
3-((4-((4-Aminonaphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2,5,-
8,11-tetraoxatridecan-13-yl)benzamide
##STR00052##
[0382] T3P (50% w/w in EtOAc, 1.80 ml, 3.02 mmol) was added to a
solution of Intermediate J1(P) (1 g, 2.014 mmol),
2,5,8,11-tetraoxatridecan-13-amine (0.501 g, 2.417 mmol), and
Et.sub.3N (0.70 mL, 5.02 mmol) in DMF (15 mL). The reaction was
stirred at rt for 18 h. The mixture was diluted with water (200 mL)
and saturated aqueous NaHCO.sub.3 solution (100 mL) and the aqueous
phase extracted with EtOAc (3.times.100 mL). The combined organic
phases were washed with 20% brine (3.times.100 mL), saturated brine
(3.times.100 mL), then dried (MgSO.sub.4), filtered and
concentrated in vacuo affording a brown foam. The crude product was
purified by chromatography on silica gel (40 g column, 1-5% MeOH in
DCM) to afford the sub-title compound
tert-butyl(4-((2-((3-((2,5,8,11-tetraoxatridecan-13-yl)carbamoyl)-5-ethyn-
ylphenyl)-amino)pyrimidin-4-yl)oxy)naphthalen-1-yl)carbamate
(Intermediate B3(P), 940 mg) as an off-white foam.
[0383] LCMS m/z 686 (M+H).sup.+ (ES.sup.+); 684 (M-H).sup.-
(ES.sup.-)
[0384] Trifluoroacetic acid (2000 .mu.L, 26.0 mmol) was added
dropwise to a stirred solution of Intermediate B3(P) (940 mg, 1.371
mmol) in DCM (20 ml). The reaction was stirred at rt overnight. The
reaction was concentrated in vacuo and the residue partitioned
between DCM (30 mL) and saturated aqueous NaHCO.sub.3 solution (100
mL). The aqueous phase was extracted with DCM (20 mL). The combined
organics were dried (MgSO.sub.4), filtered and concentrated in
vacuo onto silica gel. The crude product was purified by
chromatography (40 g column, 3-5% MeOH in DCM) to afford the
sub-title compound (670 mg) as a pale yellow oil which became
foam-like on drying at 40.degree. C. under vacuum for 2 h.
[0385] .sup.1H NMR (400 MHz, DMSO-d6) .delta.: 9.74 (s, 1H), 8.46
(t, 1H), 8.36 (d, 1H), 8.12-8.14 (m, 1H), 8.07 (s, 1H), 7.94 (s,
1H), 7.62-7.64 (m, 1H), 7.41-7.46 (m, 3H), 7.14 (d, 1H), 6.70 (d,
1H), 6.37 (d, 1H), 5.76 (s, 2H), 4.17 (s, 1H), 3.47-3.53 (m, 12H),
3.36-3.41 (m, 4H), 3.22 (s, 3H).
[0386] LCMS m/z 586 (M+H).sup.+ (ES.sup.+); 584 (M-H).sup.-
(ES.sup.-)
Intermediate B4
3-((4-((4-Aminonaphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-
-methoxyethoxy)ethyl)benzamide
##STR00053##
[0388] HATU (842 mg, 2.215 mmol) was added to a stirred solution of
Intermediate J1(P) (1000 mg, 2.014 mmol),
2-(2-methoxyethoxy)ethanamine (360 mg, 3.02 mmol) and Hunig's Base
(1000 .mu.L, 5.73 mmol) in DMF (10 mL) at rt. The mixture was
stirred for 3 h then added to a vigorously stirred solution of 0.1
M hydrogen chloride (200 mL). The resulting precipitate was
collected by filtration and washed with water (20 mL) to yield the
crude product as a tan solid. The solid was purified by
chromatography on silica gel (40 g column, 0-20% Acetone/EtOAc) to
afford
tert-butyl(4-((2-((3-ethynyl-5-((2-(2-methoxyethoxy)ethyl)-carbamoyl)phen-
yl)amino)pyrimidin-4-yl)oxy)naphthalen-1-yl)carbamate (Intermediate
B4(P), 895 mg) as a yellow foam.
[0389] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.75 (s, 1H), 9.31
(s, 1H), 8.53-8.40 (m, 1H), 8.45 (d, 1H), 8.17-8.06 (m, 2H),
7.95-7.87 (m, 1H), 7.87-7.77 (m, 1H), 7.65-7.52 (m, 3H), 7.46 (d,
1H), 7.42 (d, 1H), 6.57 (d, 1H), 4.15 (s, 1H), 3.58-3.47 (m, 4H),
3.47-3.35 (m, 4H), 3.23 (s, 3H), 1.52 (s, 9H).
[0390] LCMS m/z 598 (M+H).sup.+ (ES.sup.+); 596 (M-H).sup.-
(ES.sup.-)
[0391] Trifluoroacetic acid (1.000 mL, 12.98 mmol) was added
dropwise to a stirred solution of Intermediate B4(P) (0.895 g,
1.498 mmol) in DCM (8 mL). The reaction was stirred at rt for 18 h.
The solvents were evaporated and the residue partitioned between
EtOAc (50 mL) and sat. NaHCO.sub.3 soln. (50 ml), the organic phase
was washed with saturated brine (50 ml). The organics were bulked,
dried, filtered and evaporated to give a pale brown foam. The foam
was purified by chromatography on silica gel (12 g column, EtOAc)
to afford Intermediate B4 (700 mg) as a light beige foam.
[0392] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.74 (s, 1H), 8.45
(dd, 1H), 8.36 (d, 1H), 8.17-8.10 (m, 1H), 8.10-8.03 (m, 1H),
7.97-7.90 (m, 1H), 7.67-7.59 (m, 1H), 7.48-7.38 (m, 3H), 7.15 (d,
1H), 6.70 (d, 1H), 6.37 (d, 1H), 5.81-5.71 (m, 2H), 4.18 (s, 1H),
3.57-3.47 (m, 4H), 3.47-3.34 (m, 4H), 3.23 (s, 3H).
[0393] LCMS m/z 498 (M+H).sup.+ (ES.sup.+); 496 (M-H).sup.-
(ES.sup.-)
Intermediate B5
3-((4-((4-Aminonaphthalen-1-yl)oxy)pyridin-2-yl)amino)-5-ethynyl-N-(2-(2-(-
2-methoxyethoxy)ethoxy)ethyl)benzamide
##STR00054##
[0395] HATU (500 mg, 1.315 mmol) was added to a stirred solution of
Intermediate J2(P) (500 mg, 1.009 mmol),
2-(2-(2-methoxyethoxy)ethoxy)ethanamine (277 mg, 1.695 mmol) and
Et.sub.3N (250 .mu.L, 1.796 mmol) in DMF (10 mL). The mixture was
stirred at rt for 18 h. The mixture was diluted with ethyl acetate
(50 mL) and washed with water (50 mL), 20% brine (3.times.50 mL)
and saturated brine (50 mL). The organic phase was dried
(MgSO.sub.4), filtered and concentrated under reduced pressure. The
crude product was purified by chromatography on the Companion (40 g
column, EtOAc) to afford
tert-butyl(4-((2-((3-ethynyl-5-((2-(2-(2-methoxyethoxy)ethoxy)ethyl)carba-
moyl)phenyl)amino)pyridin-4-yl)oxy)naphthalen-1-yl)carbamate
(Intermediate B5(P), 580 mg) as a tan foam.
[0396] LCMS m/z 641 (M+H).sup.+ (ES.sup.+); 639 (M-H).sup.-
(ES.sup.-)
[0397] TFA (1 mL, 12.98 mmol) was added to a solution of
Intermediate B5(P) (580 mg, 0.905 mmol) in DCM (5 mL) at rt and
stirred overnight. The volatiles were removed under reduced
pressure and the residue was redissolved in DCM (20 mL). The
organic phase was washed with saturated NaHCO.sub.3 solution (20
mL), dried (MgSO.sub.4) and concentrated under reduced pressure to
yield Intermediate B5 (475 mg).
[0398] LCMS m/z 541 (M+H).sup.+ (ES.sup.+); 539 (M-H).sup.-
(ES.sup.-)
Intermediate B6
3-((4-((4-Aminonaphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-methoxy-N-(2-(2-
-(2-methoxyethoxy)ethoxy)ethyl)benzamide
##STR00055##
[0400] HATU (425 mg, 1.118 mmol) was added to a stirred solution of
Intermediate J3(P) (500 mg, 0.995 mmol),
2-(2-(2-methoxyethoxy)ethoxy)ethanamine (250 mg, 1.532 mmol) and
Hunig's Base (500 .mu.l, 2.86 mmol) in DMF (10 ml) at rt. The
mixture was stirred for 1 h then partitioned between 10% aq brine
(100 ml) and EtOAc (100 ml). The organic layer was washed with sat
aq NaHCO.sub.3 soln (50 ml), 0.5M HCl (50 ml), 10% aq brine (50
ml), dried (MgSO.sub.4), filtered and evaporated under reduced
pressure to afford
tert-butyl(4-((2-((3-methoxy-5-((2-(2-(2-methoxyethoxy)ethoxy)ethyl)carba-
moyl)phenyl)amino)pyrimidin-4-yl)oxy)naphthalen-1-yl)carbamate
(Intermediate B6(P), 532 mg) as a white foam.
[0401] LCMS m/z 648 (M+H).sup.+ (ES.sup.+); 646 (M-H).sup.-
(ES.sup.-)
[0402] TFA (1.5 mL, 19.47 mmol) was added to a solution of
Intermediate B6(P) (530 mg, 0.818 mmol) in DCM (5 mL) and the
mixture was stirred at rt for 35 minutes. The mixture was diluted
with toluene (100 mL) and concentrated under reduced pressure. The
residue was redissolved in DCM (20 mL) and washed with saturated
NaHCO.sub.3 solution (20 mL) followed by saturated brine (20 mL).
The organic phase was dried (MgSO.sub.4) and concentrated under
reduced pressure to yield Intermediate B6 (440 mg) as a brown
foam.
[0403] LCMS m/z 548 (M+H).sup.+ (ES.sup.+); 546 (M-H).sup.-
(ES.sup.-)
Intermediate C1
1-(4-(2-Chloropyrimidin-4-yloxy)naphthalen-1-yl)-3-(3-isopropyl-1-p-tolyl--
1H-pyrazol-5-yl)urea
##STR00056##
[0405] To a solution of Intermediate G2 (5.00 g, 18.4 mmol) in a
mixture of isopropyl acetate (50 mL) and anhydrous THF (50 mL) was
added portion-wise
phenyl(3-isopropyl-1-(p-tolyl)-1H-pyrazol-5-yl)carbamate
Intermediate A2* (7.72 g, 23.0 mmol) followed by triethylamine
(0.64 mL, 4.6 mmol) and the reaction mixture maintained at RT for
18 hr. During this interval a thick purple precipitate formed which
was collected by filtration and then washed with a mixture of
isopropyl acetate and THF (1:1 v/v, 3.times.40 mL). The solid was
purified by flash column chromatography (SiO.sub.2, 330 g, 0-5%
MeOH in DCM, gradient elution) to afford the title compound,
Intermediate C1 as a pale purple solid (5.72 g, 47%); R.sup.t 2.48
min (Method 4); m/z 513 (M+H).sup.+ (ES.sup.+).
Intermediate C2
1-(3-(tert-Butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-chloropyrimidin-4--
yl)oxy)naphthalen-1-yl)urea
##STR00057##
[0407] A stirred suspension of Intermediate A1* (3 g, 8.59 mmol)
and Intermediate G2 (2.333 g, 8.59 mmol) in isopropyl acetate (100
mL) was treated with triethylamine (0.3 mL, 2.152 mmol) and stirred
at 60.degree. C. (bath) for 1 h. The solution was diluted with
ethyl acetate (300 mL), washed with water (2.times.100 mL) followed
by brine (100 mL), was dried (Na.sub.2SO.sub.4) and evaporated. The
residue was purified on a 220 g redisep silica cartridge using 5%,
for 17 column volumes, and then 40% of acetone in toluene as eluent
and then on another 220 g redisep silica cartridge using 0 to 3%
MeOH/DCM as eluent to give Intermediate C2 (3.703 g) as a buff
foam.
[0408] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.14 (s, 1H), 8.79
(s, 1H), 8.65 (d, 1H), 8.09 (d, 1H), 7.96 (d, 1H), 7.79 (d, 1H),
7.67-7.64 (m, 1H), 7.60-7.56 (m, 1H), 7.47-7.37 (m, 5H), 7.26 (d,
1H), 6.41 (s, 1H), 2.40 (s, 3H), 1.28 (s, 9H).
[0409] LCMS m/z 527/529 (M+H).sup.+ (ES.sup.+)
Intermediate C3
1-(3-(tert-Butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)-3-(4-((2-chloropyri-
midin-4-yl)oxy)naphthalen-1-yl)urea
##STR00058##
[0411] In a 100 mL flask, a solution of Intermediate A3* (1917 mg,
5.24 mmol) and Intermediate G2 (1500 mg, 5.24 mmol) in isopropyl
acetate (58 mL) was treated with triethylamine (113 .mu.L, 0.813
mmol). The resultant brown solution was heated at 70.degree. C. for
2 h then the solvent removed in vacuo to afford a thick brown oil.
The crude product was purified by chromatography on silica gel (120
g column, EtOAc 0-15% in DCM) to afford Intermediate C3 (2.169 g)
as a white crystalline solid.
[0412] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.14 (s, 1H), 8.75
(s, 1H), 8.66 (d, 1H), 8.09 (d, 1H), 7.97 (d, 1H), 7.82-7.77 (m,
1H), 7.69-7.62 (m, 1H), 7.58 (ddd, 1H), 7.51-7.46 (m, 2H), 7.43 (d,
1H), 7.27 (d, 1H), 7.15-7.10 (m, 2H), 6.40 (s, 1H), 3.84 (s, 3H),
1.29 (s, 9H).
[0413] LCMS m/z 544 (M+H).sup.+ (ES.sup.+)
Intermediate C4(H)
1-(3-(tert-Butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-chloropyrimidin-4--
yl)oxy)-5,6,7,8-tetrahydronaphthalen-1-yl)urea
##STR00059##
[0415] A mixture of Intermediate A1* (760 mg, 2.176 mmol),
Intermediate G3 (500 mg, 1.813 mmol) and Et.sub.3N (80 .mu.L, 0.574
mmol) in iPrOAc (15 mL) was heated at 60.degree. C. for 1.5 h. The
mixture was cooled, evaporated under reduced pressure and the
residue purified by chromatography on silica gel (80 g column,
0-50% EtOAc/isohexane) to afford Intermediate C4(H) (807 mg) as a
light brown foam.
[0416] .sup.1H NMR (CDCl.sub.3) 400 MHz, .delta.: 8.42 (d, 1H),
7.43 (d, 1H), 7.32 (d, 2H), 7.22 (d, 2H), 6.88 (d, 1H), 6.74 (d,
1H), 6.50 (s, 1H), 6.44 (s, 1H), 6.37 (s, 1H), 2.48 (t, 2H), 2.41
(t, 2H), 2.36 (s, 3H), 1.73-1.62 (m, 4H), 1.35 (s, 9H).
[0417] LCMS m/z 531/3 (M+H).sup.+ (ES.sup.+)
Intermediate D1
3-Amino-5-bromo-N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)benzamide
##STR00060##
[0419] Method 1
[0420] T3P (1-propanephosphonic acid cyclic anhydride 50 wt % in
EtOAc, 4.13 ml, 6.94 mmol) was added carefully to a solution of
3-amino-5-bromobenzoic acid (1 g, 4.63 mmol),
2-(2-(2-methoxyethoxy)ethoxy)ethanamine (1.022 ml, 6.13 mmol) and
TEA (1.936 ml, 13.89 mmol) in DCM (20 mL). Ice bath used
sporadically to prevent temperature rising above 35.degree. C.
Stirred at rt for 1 h then partitioned with sat. NaHCO.sub.3 soln.
(20 mL). Aqueous layer was separated and partitioned with fresh DCM
(20 mL), organics separated, bulked and partitioned with 20% w/w
NaCl soln. (20 mL). Organic layer was separated, dried
(MgSO.sub.4), filtered and the solvent evaporated. The crude
product was purified by chromatography on the Companion 40 g
column, 2% MeOH:DCM to 5%) to afford Intermediate D1 (1.5 g) as a
thick, colourless oil.
[0421] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 8.37 (t, 1H), 7.08
(t, 1H), 7.00 (dd, 1H), 6.85 (t, 1H), 5.58 (s, 2H), 3.57-3.46 (m,
8H), 3.45-3.39 (m, 2H), 3.39-3.34 (m, 2H), 3.23 (s, 3H).
[0422] LCMS m/z 361/363 (M+H).sup.+ (ES.sup.+)
[0423] Method 2
[0424] 3-Bromo-5-nitrobenzoic acid (725 g, 2.947 mol) was refluxed
in thionyl chloride (2.365 kg, 19.88 mol) until a clear (brown)
solution obtained (takes about 3-4 h). [NOTE: HCl is evolved, and
so a large NaOH(aq) scrubber is required, with ice/water cooling].
The solution was concentrated in vacuo to provide the (brown) acid
chloride (3-bromo-5-nitrobenzoyl chloride). The acid chloride was
dissolved in ethyl acetate (500 mL) and added as a small,
controlled stream to 2-(2-(2-methoxyethoxy)ethoxy)ethanamine (481
g, 2.947 mol) dissolved in ethyl acetate (4 L) and triethylamine
(447.31 g, 4.42 mol)) at 15.degree. C. over a period of about 1 h.
The resulting heavy suspension was stirred overnight at rt, after
which brine (5 L) was added to the reaction mixture and the aqueous
phase was separated. The aqueous washings were re-extracted with
ethyl acetate and then the combined organics were washed with water
(1.times.5 L), dried (MgSO4), and passed through a silica plug
(washed with 1.times.500 mL fresh ethyl acetate). The solvent was
evaporated to provide a deep brown oil, to which was added diethyl
ether (2 L). The resulting mixture was cooled in an ice bath and
stirred for 1 h, after which the solid thereby obtained was washed
twice with diethyl ether and then dried. The product
(3-nitro-5-bromo-N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)-benzamide,
Intermediate Dr) was obtained as 850 g (73.3%) of a pale brown,
amorphous, free flowing solid that was used in the next step
without any further purification.
[0425] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.04 (t, 1H), 8.66
(dd, 1H), 8.55 (t, 1H), 8.47 (t, 1H), 3.60-3.43 (m, 10H), 3.42-3.37
(m, 2H), 3.21 (s, 3H).
[0426] LCMS m/z 391/393 (M+H).sup.+ (ES.sup.+); 389/391 (M-H).sup.-
(ES.sup.-)
Intermediate D1*
[0427] (250 g, 0.639 mol) was placed in a 4 L autoclave with Pt/C
(5%) and IMS (2 L). The mixture was then heated to 80.degree. C.
under H.sub.2 (40 atm) for 48 h. The resulting mixture was then
cooled and filtered and the residue was washed with fresh IMS. The
solvent was evaporated from the combined organics to provide an
orange/red oil. This oil was triturated with diethyl ether to
provide a suspension of a solid that was filtered, washed with
further diethyl ether and then dried. This afforded Intermediate D1
(207.8 g, 90%) as an off-white, amorphous solid that had .sup.1H
NMR and LCMS data essentially identical to those of the material
obtained via Method 1 above.
Intermediate D2
3-Amino-5-ethynyl-N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)benzamide
##STR00061##
[0429] Method 1
[0430] Pd(PPh.sub.3).sub.4 (0.240 g, 0.208 mmol) was added to a
degassed suspension of Intermediate D1 (1.5 g, 4.15 mmol), CuI
(0.040 g, 0.208 mmol), and ethynyltriisopropylsilane (1.397 ml,
6.23 mmol) in TEA (2 mL) and DMF (10 mL). Heated at 80.degree. C.
(block temp.) for 4 h then cooled and filtered (Whatman glass fibre
pad GF/A). Solvents were evaporated and the residue partitioned
between EtOAc (200 mL) and 20% w/w NaCl soln. (250 mL) Organic
layer separated, dried (MgSO.sub.4), filtered and solvent
evaporated to a thick brown oil found to be an impure mixture of
starting material and product. This mixture was subjected to the
same reaction conditions and work up as before for 1 h. The crude
product was purified by chromatography on the Companion 40 g
column, MeOH:EtOAc to 0% to 5%) to afford
3-amino-N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)-5-((triisopropylsilyl)ethy-
nyl)benzamide (1.5 g) as a thick, yellow oil.
[0431] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 8.41 (t, 1H),
7.10-7.01 (m, 2H), 6.79 (dd, 1H), 5.45 (s, 2H), 3.55-3.47 (m, 8H),
3.44-3.35 (m, 4H), 3.22 (s, 3H), 1.10 (s, 21H).
[0432] LCMS m/z 463 (M+H).sup.+ (ES.sup.+)
[0433] The (triisopropylsilyl)ethynyl-substituted benzamide
obtained immediately above (1.5 g, 3.24 mmol) was dissolved in
EtOAc (15 mL) and TBAF, 1M in THF (3.24 ml, 3.24 mmol) added.
Stirred for 1 h then partitioned between water (10 mL) and ethyl
acetate (10 mL). The organic layer separated and washed with 20%
w/w NaCl soln. (20 mL), dried (MgSO.sub.4), filtered and
evaporated. The crude product was purified by chromatography on
silica gel (40 g column, 1% MeOH:DCM to 6%) to afford Intermediate
D2 (750 mg) as a clear, yellow oil.
[0434] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 8.36 (t, 1H),
7.12-7.02 (m, 2H), 6.76 (dd, 1H), 5.45 (s, 2H), 4.07 (s, 1H),
3.58-3.46 (m, 8H), 3.45-3.36 (m, 4H), 3.23 (s, 3H).
[0435] LCMS m/z 307 (M+H).sup.+ (ES.sup.+)
[0436] Method 2
[0437] Pd(PPh.sub.3).sub.4 (90 g, 78 mmol) was added to a degassed
(N.sub.2 purging for 30 mins) solution of Intermediate D1 (500 g,
1.384 mol), CuI (13.7 g, 72 mmol), ethynyltriisopropylsilane
(227.68 g, 1.523 mol) and TEA (667.92 g, 6.601 mol) in DMF (4 L).
The mixture was heated to 85.degree. C. under N.sub.2 for 7 h
before being allowed to cool overnight. As much DMF solvent as
possible was removed in vacuo to provide a residue that was then
taken up in ethyl acetate. The resulting solution was passed
through large silica plug to remove inorganic impurities. The
silica plug was washed twice with ethyl acetate. The combined
organics were stirred with 1 L of conc. HCl/water (50%) for 10
mins. The aqueous layer was separated and the ethyl acetate layer
was discarded (after checking by TLC for any remaining product).
The acidic aqueous layer was back washed with diethyl ether
(.times.2), and the organic washings were discarded. The aqueous
layer was then basified cautiously with NaOH until the pH reached
approximately 9 to 10. The aqueous layer was then extracted twice
with ethyl acetate. The combined organics were washed with water,
dried (MgSO.sub.4) and passed through a silica plug before the
solvent was evaporated to provide
3-amino-N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)-5-((triisopropylsilyl)-eth-
ynyl)benzamide (489.4 g, 76.4%) as a viscous orange/red oil that
had .sup.1H NMR and LCMS data essentially identical to those of the
material obtained via Method 1 above, and which oil was used in the
next step without further purification.
[0438] The (triisopropylsilyl)ethynyl-substituted benzamide
obtained immediately above (290 g, 627 mmol, 1 eq.) was dissolved
in EtOAc (2.5 L) and TBAF, 1 M in THF (690.7 mL, 689 mmol, 1.1 eq.)
was added in one portion. The resulting mixture was stirred
overnight at rt before the solvent was evaporated. The residue was
dissolved in fresh ethyl acetate before being washed with a
solution of sodium hexafluorophosphate (210 g, 2 eq.) in water (750
mL). The aqueous and organic layers were then separated. The
organic layer was dried (MgSO.sub.4) and passed through a silica
plug. The solvent was then evaporated to provide a solid that was
found to contain some TBAF. The solid was then slurried in a small
quantity of ethyl acetate and passed through a further silica plug
that was washed sparingly with ethyl acetate. Solvent removed from
the filtrate in vacuo to provide Intermediate D2 (155.76 g, 81.1%)
as a viscous, orange/red oil of about 90% purity that had .sup.1H
NMR and LCMS data essentially identical to those of the material
obtained via Method 1 above, and which oil was used without further
purification.
Intermediate D3
3-Amino-5-methoxy-N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)-benzamide
##STR00062##
[0440] 3-Amino-5-methoxybenzoic acid (1.0 g, 5.98 mmol) was added
to an ice cold suspension of
2-(2-(2-methoxyethoxy)ethoxy)ethanamine (1.2 g, 7.35 mmol), 50% T3P
in ethyl acetate (4.50 ml, 7.56 mmol) and TEA (2.5 ml, 17.94 mmol)
in ethyl acetate (15 mL). The mixture was allowed to warm to rt and
stir overnight. Saturated NaHCO.sub.3 (20 mL) was added and the
mixture was extracted with ethyl acetate (3.times.10 mL). The
combined organic phases were washed with saturated brine (20 mL),
dried (MgSO.sub.4) and concentrated under reduced pressure to yield
a yellow oil. The oil was purified by chromatography on the
Companion (40 g column, 0-100% acetone/toluene) to afford a pale
yellow oil. The oil was purified by chromatography on the Companion
(40 g column, 0-100% THF/DCM) to afford the subtitle compound (843
mg) as a pale yellow oil.
[0441] LCMS m/z 313 (M+H).sup.+ (ES.sup.+)
Intermediate D4
3-Amino-5-bromo-N-(2-(2-methoxyethoxy)ethyl)benzamide
##STR00063##
[0443] A stirred mixture of 3-amino-5-bromobenzoic acid (800 mg,
3.59 mmol), 2-(2-methoxy-ethoxy)ethanamine (856 mg, 7.18 mmol) and
triethylamine (1.5 mL, 10.76 mmol) in DCM (13 mL) was cooled in an
ice bath. 50 wt % T3P in EtOAc (3.2 mL, 5.38 mmol) was added
dropwise, the ice bath was removed and the reaction mixture allowed
to warm to rt. DMF (2 mL) was added to aid solubility and the
reaction stirred at rt overnight. The reaction mixture was
partitioned between sat. aq. NaHCO.sub.3 (50 mL) and DCM (50 mL).
The aqueous phase was back extracted with fresh DCM (50 mL). The
combined organic extracts were washed with water (100 mL), brine
(100 mL), dried (MgSO.sub.4), filtered and concentrated in vacuo to
afford an orange oil. The crude product was purified by
chromatography on silica gel (40 g column, 0-5% MeOH) to afford
Intermediate D4 (880 mg) as an orange oil.
[0444] .sup.1H NMR (DMSO-d6) 400 MHz, .delta.: 8.36 (t, 1H), 7.07
(t, 1H), 7.00-6.99 (m, 1H), 6.84 (t, 1H), 5.57 (s, 2H), 3.53-3.48
(m, 4H), 3.44-3.42 (m, 2H), 3.35 (q, 2H), 3.23 (s, 3H).
[0445] LCMS m/z 317/319 (M+H).sup.+ (ES.sup.+)
Intermediate D5
3-Amino-5-ethynyl-N-(2-(2-methoxyethoxy)ethyl)benzamide
##STR00064##
[0447] To a degassed solution of Intermediate D4 (830 mg, 2.59
mmol), ethynyltriisopropylsilane (880 .mu.L, 3.92 mmol), copper(I)
iodide (24.67 mg, 0.130 mmol) and TEA (1.55 mL, 11.12 mmol) in DMF
(8 mL) was added Pd(PPh.sub.3).sub.4 (150 mg, 0.130 mmol). The
reaction was heated at 85.degree. C. for 3 h. The reaction was
cooled to rt then partitioned between EtOAc (50 mL) and brine (50
mL). The aqueous phase was back extracted with EtOAc (50 mL). The
combined organic extracts were washed with brine (100 mL), dried
(MgSO.sub.4), filtered and concentrated in vacuo to afford a brown
semi-solid (1.65 g). The crude product was purified by
chromatography on silica gel (80 g column, 0-3% MeOH in DCM) to
afford
3-amino-N-(2-(2-methoxyethoxy)ethyl)-5-((triisopropylsilyl)ethy-
nyl)benzamide (796 mg) as a beige solid.
[0448] .sup.1H NMR (DMSO-d6) 400 MHz, .delta.: 8.39 (t, 1H),
7.05-7.04 (m, 1H), 7.03 (t, 1H), 6.79-6.78 (m, 1H), 5.44 (br s,
2H), 3.53-3.48 (m, 4H), 3.44-3.42 (m, 2H), 3.35 (q, 2H), 3.23 (s,
3H), 1.10 (s, 21H).
[0449] LCMS m/z 419 (M+H).sup.+ (ES.sup.+)
[0450] To a stirred solution of the
(triisopropylsilyl)ethynyl-substituted benzamide obtained
immediately above (717 mg, 1.473 mmol) in EtOAc (9 mL) was added 1M
TBAF in THF (1473 .mu.L, 1.473 mmol). The reaction was stirred at
rt for 1 h. The reaction mixture was partitioned between water (30
mL) and EtOAc (20 mL). The organic layer was washed with brine (20
mL), dried (MgSO.sub.4), filtered and concentrated to afford a
brown oil. The crude product was dissolved in the minimum quantity
of MeOH and loaded onto SCX. The column was eluted with MeOH
followed by 1% NH.sub.3 in MeOH. The filtrate was concentrated in
vacuo to afford a brown oil at .about.70% purity. The crude product
was purified by chromatography on silica gel (40 g column, 0-5%
MeOH in DCM) to afford Intermediate D5 (377 mg) as an orange
oil.
[0451] .sup.1H NMR (DMSO-d6) 400 MHz, .delta.: 8.36 (t, 1H),
7.06-7.04 (m, 2H), 6.75-6.74 (m, 1H), 5.45 (s, 2H), 4.07 (s, 1H),
3.53-3.47 (m, 4H), 3.44-3.42 (m, 2H), 3.37-3.33 (m, 2H), 3.23 (s,
3H).
[0452] LCMS m/z 263 (M+H).sup.+ (ES.sup.+)
Intermediate G1(P)
tert-Butyl(4((2-chloropyridin-4-yl)oxy)naphthalen-1-yl)carbamate
##STR00065##
[0454] A mixture of Intermediate G1 (1000 mg, 3.69 mmol)
di-tert-butyl dicarbonate (750 mg, 3.44 mmol) in t-BuOH (10 mL) was
stirred at reflux for 18 h. The mixture was diluted with water (15
mL) and collected by filtration. The solid was triturated in
diethyl ether to yield Intermediate G1(P)(1002 mg) as a pale grey
solid.
[0455] .sup.1H NMR (DMSO-d6) 400 MHz, .delta.: 9.37 (s, 1H), 8.28
(d, 1H), 8.16 (d, 1H), 8.82 (dd, 1H), 7.66 (d, 1H), 7.66-7.54 (m,
2H), 7.40 (d, 1H), 7.03 (d, 1H), 6.91 (dd, 1H), 1.52 (s, 9H). LCMS
m/z 371 (M+H).sup.+ (ES.sup.+); 369 (M-H).sup.- (ES.sup.-)
Intermediate G3
4-((2-Chloropyrimidin-4-yl)oxy)-5,6,7,8-tetrahydronaphthalen-1-amine
##STR00066##
[0457] 2,4-Dichloropyrimidine (0.958 g, 6.43 mmol) was added to a
stirred mixture of 4-amino-5,6,7,8-tetrahydronaphthalen-1-ol (1 g,
6.13 mmol) and DBU (1.1 mL, 7.30 mmol) at 0-5.degree. C. The
mixture was stirred for 3 h then more DBU (0.6 mL) and
2,4-dichloropyrimidine (300 mg) added and stirred for a further 2
h. The mixture was partitioned between EtOAc (100 mL) and water (50
mL), the organic layer was washed with water (50 mL), dried
(MgSO.sub.4), filtered and evaporated under reduced pressure. The
crude product was purified by chromatography on silica gel (80 g
column, 0-50% EtOAc/isohexane) to afford Intermediate G3 (510 mg)
as brown solid.
[0458] .sup.1H NMR (CDCl.sub.3) 400 MHz, .delta.: 8.36 (d, 1H),
6.74 (d, 1H), 6.62 (d, 1H), 6.56 (d, 1H), 3.60 (s, 2H), 2.49-2.46
(m, 4H), 1.87-1.81 (m, 2H), 1.74-1.68 (m, 2H).
[0459] LCMS m/z 276/8 (M+H).sup.+ (ES.sup.+)
Intermediate J1(P)
3-((4-((4-((tert-Butoxycarbonyl)amino)naphthalen-1-yl)oxy)pyrimidin-2-yl)a-
mino)-5-ethynylbenzoic acid
##STR00067##
[0461] A suspension of Intermediate G2(P) (42.6 g, 115 mmol),
Intermediate K1* (40.00 g, 126 mmol), BINAP (6.42 g, 10.31 mmol)
and caesium carbonate (74.6 g, 229 mmol) in 1,4-dioxane (500 mL)
was degassed with nitrogen for 10 minutes. Pd.sub.2(dba).sub.3
(4.20 g, 4.58 mmol) was added and the mixture was heated to
90.degree. C. for 2.5 h. The mixture was diluted with diethyl ether
(600 mL) then washed with water (600 mL), followed by 0.5 M HCl
solution (500 mL) and saturated brine (500 mL). The organic phase
was dried (MgSO.sub.4), filtered and concentrated in vacuo
affording
3-((4-((4-((tert-butoxycarbonyl)amino)naphthalen-1-yl)oxy)pyrim-
idin-2-yl)amino)-5-((triisopropylsilyl)ethynyl)benzoic acid
(Intermediate J1(P)*, 96 g) as a red foam which was used without
further purification.
[0462] Intermediate J1(P)* (96 g) was dissolved in THF (60 mL) and
diluted with MeCN (400 mL). 1.0 M TBAF in THF (235 mL, 235 mmol)
was added and the reaction stirred at rt overnight. The reaction
was diluted with MeCN (300 mL) and water (600 mL), then 1M HCl
solution (100 mL, 1 eq.) was added and stirring continued resulting
in the precipitation of a pink solid which was collected by
filtration. The pink solid was triturated in MeCN at 80.degree. C.,
collected by filtration and dried at 40.degree. C. under vacuum for
2 h. The solid was re-suspended in (9:1) EtOAc/THF (400 ml) and
heated to 60.degree. C. for 90 mins then cooled to room temperature
and stirred overnight. The suspended solid was collected by
filtration, washing with EtOAc affording Intermediate J1(P) (47 g)
as a pale yellow/beige solid.
[0463] .sup.1H NMR (400 MHz, DMSO-d6) .delta.: 13.12 (bs, 1H), 9.83
(s, 1H), 9.32 (s, 1H), 8.46 (d, 1H), 8.28 (s, 1H), 8.10 (d, 1H),
8.01 (s, 1H), 7.82 (d, 1H), 7.54-7.63 (m, 3H), 7.49 (s, 1H), 7.42
(d, 1H), 6.61 (d, 1H), 4.17 (s, 1H), 1.52 (s, 9H).
[0464] LCMS m/z 497 (M+H).sup.+ (ES.sup.+); 495 (M-H).sup.-
(ES.sup.-)
Intermediate J2(P)
3-((4-((4-((tert-Butoxycarbonyl)amino)naphthalen-1-yl)oxy)pyridin-2-yl)ami-
no)-5-ethynylbenzoic acid
##STR00068##
[0466] N.sub.2 was bubbled through a mixture of Intermediate G1(P)
(0.5 g, 1.348 mmol), 3-amino-5-((triisopropylsilyl)ethynyl)benzoic
acid (0.490 g, 1.544 mmol), Cs.sub.2CO.sub.3 (0.966 g, 2.97 mmol),
BINAP (0.078 g, 0.125 mmol) and Pd.sub.2dba.sub.3 (0.056 g, 0.061
mmol) in dioxane (15 mL) for 10 min then heated at 90C for 4 h. The
mixture was partitioned between ether (100 mL) and 1M HCl (50 mL),
the organic layer separated, washed with water, dried (MgSO.sub.4),
filtered and evaporated under reduced pressure. The residue was
triturated with ether/isohexane, filtered and dried to afford
3-((4-((4-((tert-butoxycarbonyl)amino)naphthalen-1-yl)oxy)pyridin-2-yl)am-
ino)-5-((triisopropylsilyl)ethynyl)benzoic acid (760 mg) which was
used crude in the next step.
[0467] 1.0 M TBAF in THF (2.5 ml, 2.500 mmol) was added to a
stirred solution of
3-((4-((4-((tert-butoxycarbonyl)amino)naphthalen-1-yl)oxy)pyridin-2-yl)am-
ino)-5-((triisopropylsilyl)ethynyl)-benzoic acid obtained
immediately above (760 mg) in THF (15 mL). The mixture was stirred
for 2 h then water (10 mL) added and acidified to pH-4 with 1M HCl.
The mixture was partitioned between EtOAc (70 mL) and water (40
mL), the organic phase washed with sat brine (50 mL), dried
(MgSO.sub.4), filtered and evaporated under reduced pressure. The
crude product was purified by chromatography on silica gel (40 g
column, 0-100% EtOAc/isohexane) to afford Intermediate J2(P) (344
mg) as a foam.
[0468] .sup.1H NMR (DMSO-d6) 400 MHz, .delta.: 13.07 (s, 1H), 9.39
(s, 1H), 9.29 (s, 1H), 8.18-8.13 (m, 4H), 7.84 (d, 1H), 7.66-7.56
(m, 3H), 7.44 (s, 1H), 7.38 (d, 1H), 6.66 (dd, 1H), 6.07 (d, 1H),
4.22 (s, 1H), 1.53 (s, 9H).
[0469] LCMS m/z 496 (M+H).sup.+ (ES.sup.+)
Intermediate J3(P)
3-((4-((4-((tert-Butoxycarbonyl)amino)naphthalen-1-yl)oxy)pyrimidin-2-yl)a-
mino)-methoxybenzoic acid
##STR00069##
[0471] N.sub.2 was bubbled through a stirred mixture of
Intermediate G2(P) (10 g, 26.9 mmol), 3-amino-5-methoxybenzoic acid
(8.99 g, 53.8 mmol) and p-TSA monohydrate (1.02 g, 5.36 mmol) in
THF (150 mL) for 10 min. The mixture was heated under reflux for 20
h, cooled and filtered. The filtrate was evaporated, MeOH (300 mL)
added and the solid filtered, washed with MeOH then ether to afford
the sub-title compound (10.063 g).
[0472] .sup.1H NMR (400 MHz; DMSO-d6) .delta. 12.83 (brs, 1H), 9.68
(s, 1H), 9.32 (s, 1H), 8.44 (d, 1H), 8.11 (d, 1H), 8.13-8.10 (m,
2H), 7.61-7.51 (m, 4H), 7.41 (d, 1H), 6.98 (s, 1H), 6.58 (d, 1H),
3.60 (s, 3H), 1.52 (s, 9H).
[0473] LCMS m/z 503 (M+H).sup.+ (ES.sup.+)
Intermediate K1*
3-Amino-5-((triisopropylsilyl)ethynyl)benzoic acid
##STR00070##
[0475] Pd(PPh.sub.3).sub.4 (9.36 g, 8.10 mmol) was added to a
degassed suspension of 3-amino-5-bromobenzoic acid (50 g, 231
mmol), CuI (1.499 g, 7.87 mmol), and ethynyltriisopropylsilane (80
mL, 356 mmol) in Et.sub.3N (300 mL) and DMF (300 mL). The mixture
was heated to 90.degree. C. for 2 h. The mixture was cooled and
carefully poured into ice-cold HCl (2.0 M aq.; 1100 mL, 2200 mmol)
and diluted with diethyl ether (500 mL). The biphasic mixture was
filtered to remove palladium residues. The layers of the filtrate
were separated and the aqueous phase was extracted with a further
portion of diethyl ether (300 mL). The organic phases were combined
and washed with 20% brine (2.times.300 mL), 40% brine (300 mL),
dried (MgSO.sub.4), filtered and concentrated in vacuo affording a
pale orange solid. The solid was recrystallised in acetonitrile
(250 mL) and collected by filtration, washing with fresh
acetonitrile (2.times.30 mL) affording the product as a yellow
solid. The solid was slurried in hexane (250 mL) for 5 h then
filtered, washing with more hexane to afford Intermediate K1* (45.5
g) as a pale yellow solid.
[0476] .sup.1H NMR (400 MHz, DMSO-d6) .delta.: 12.87 (bs, 1H), 7.18
(t, 1H), 7.10 (t, 1H), 6.86 (t, 1H), 5.54 (bs, 2H), 1.10 (s,
21H).
[0477] LCMS m/z 318 (M+H).sup.+ (ES.sup.+); 316 (M-H).sup.-
(ES.sup.-)
Intermediate M1
3-(tert-Butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazole-5-carboxylic
acid
##STR00071##
[0479] Pyridine (350 .mu.L, 4.33 mmol) followed by activated 4A
molecular sieves (0.5 g) were added to a stirred mixture of
(4-(dimethylamino)phenyl)boronic acid (575 mg, 3.48 mmol), ethyl
3-(tert-butyl)-1H-pyrazole-5-carboxylate (425 mg, 2.166 mmol) and
copper (II) acetate (590 mg, 3.25 mmol) in DCM (15 mL) at rt. open
to the air. The mixture was stirred for 4 h. A mixture of
ether/isohexane (3:1, 300 mL) was added and the solid was filtered
off. The filtrate was evaporated under reduced pressure and the
residue was purified by chromatography on the Companion (80 g
column, 0-60% ether/isohexane) to afford ethyl
3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazole-5-carboxylate
(Intermediate M(P)1; 464 mg) as a colourless oil.
[0480] LCMS m/z 316 (M+H).sup.+ (ES.sup.+)
[0481] 1 M sodium hydroxide solution (1.5 ml, 1.500 mmol) was added
to a stirred solution of Intermediate M(P)1 (0.46 g, 1.458 mmol) in
THF (3 mL) at rt. The mixture was stirred for 3 h at rt then
methanol (1 mL) was added and the mixture was stirred for a further
1 h. The mixture was then heated to 40.degree. C. for 1 h, diluted
with water (10 mL) and washed with diethyl ether (2.times.10 mL).
The aqueous phase was treated with 1 M HCl (1.5 mL) and extracted
with ethyl acetate (3.times.10 mL). The combined organic phases
were washed with saturated brine (10 mL), dried (MgSO.sub.4) and
concentrated to yield Intermediate M1 (395 mg) as an off-white
solid.
[0482] .sup.1H NMR (400 MHz; CDCl.sub.3) .delta.: 7.28-7.22 (m,
2H), 6.91 (s, 1H), 6.74-6.67 (m, 2H), 2.98 (s, 6H), 1.35 (s,
9H).
[0483] LCMS m/z 288 (M+H).sup.+ (ES.sup.+); 286 (M-H).sup.-
(ES.sup.-)
Intermediate M2
3-(tert-Butyl)-1-(2,4-dimethoxyphenyl)-1H-pyrazole-5-carboxylic
acid
##STR00072##
[0485] Pyridine (2.3 mL, 28.4 mmol) followed by activated 4A
molecular sieves (2 g) were added to a stirred mixture of
(2,4-dimethoxyphenyl)boronic acid (3.88 g, 21.31 mmol), ethyl
3-(tert-butyl)-1H-pyrazole-5-carboxylate (2.79 g, 14.20 mmol) and
copper (II) acetate (3.87 g, 21.31 mmol) in DCM (50 mL) at rt. open
to the air. The mixture was stirred for 3 days then a mixture of
ether/isohexane (3:1, 300 mL) was added and the solid was filtered
off. The filtrate was evaporated under reduced pressure and the
residue was purified by chromatography on silica gel (120 g column,
0-20% EtOAc/isohexane) to afford ethyl
3-(tert-butyl)-1-(2,4-dimethoxyphenyl)-1H-pyrazole-5-carboxylate
(Intermediate M(P)2; 377 mg) as an oil.
[0486] .sup.1H NMR (CDCl.sub.3) 400 MHz, .delta.: 7.31 (d, 1H),
6.84 (s, 1H), 6.56 (dd, 1H), 6.54 (d, 1H), 4.21 (q, 2H), 3.86 (s,
3H), 3.73 (s, 3H), 1.38 (s, 9H), 1.24 (t, 3H).
[0487] LCMS m/z 333 (M+H).sup.+ (ES.sup.+)
[0488] A mixture of Intermediate M(P)2 (365 mg, 0.933 mmol), LiOH
(70 mg, 2.92 mmol) in THF (5 mL) and water (2 mL) was stirred at rt
for 4 h. EtOH (5 mL) was added and the mixture stirred at rt for 18
h. The solvent was evaporated and the residue partitioned between
EtOAc (30 mL) and aq 1M HCl (30 mL). The organic layer was washed
with water (10 mL), dried (MgSO.sub.4), filtered and evaporated
under reduced pressure to give a gum that was triturated with
ether/isohexane to afford Intermediate M2 (220 mg) as a white
solid.
[0489] .sup.1H NMR (CDCl.sub.3) 400 MHz, .delta.: 7.32 (d, 1H),
6.91 (s, 1H), 6.56 (dd, 1H), 6.52 (d, 1H), 3.86 (s, 3H), 3.72 (s,
3H), 1.38 (s, 9H).
[0490] LCMS m/z 305 (M+H).sup.+ (ES.sup.+); 303 (M-H).sup.-
(ES.sup.-)
Intermediate M(P)3
Ethyl
3-(tert-butyl)-1-(3-(hydroxymethyl)phenyl)-1H-pyrazole-5-carboxylate
##STR00073##
[0492] To a stirred mixture of ethyl
3-(tert-butyl)-1H-pyrazole-5-carboxylate (4.39 g, 22.37 mmol),
(3-(hydroxymethyl)phenyl)boronic acid (5.1 g, 33.6 mmol) and copper
(II) acetate (6.10 g, 33.6 mmol) in DCM (130 mL) was added pyridine
(3.62 mL, 44.7 mmol) followed by 4A molecular sieves. The resulting
mixture was stirred at rt open to the air for 48 h. The reaction
mixture was filtered and the filtrate concentrated in vacuo.
Et.sub.2O (200 mL) was added, the resulting mixture filtered and
the filtrated concentrated in vacuo to afford a green oil. The
crude product was purified by chromatography on silica gel (120 g
column, 0-40% EtOAc in isohexane) to afford Intermediate M(P)3 (6.2
g) as an oil.
[0493] .sup.1H NMR (DMSO-d6) 400 MHz, .delta.: 7.42-7.35 (m, 3H),
7.27-7.24 (m, 1H), 6.97 (s, 1H), 5.31 (t, 1H), 4.56 (d, 2H), 4.17
(q, 2H), 1.30 (s, 9H), 1.16 (t, 3H).
[0494] LCMS m/z 303 (M+H).sup.+ (ES.sup.+)
Intermediate M(P)4
Ethyl
3-(tert-butyl)-1-(3-(chloromethyl)phenyl)-1H-pyrazole-5-carboxylate
##STR00074##
[0496] To a stirred solution of Intermediate M(P)3 (6.2 g, 20.50
mmol) in DCM (10 mL) was added SOCl.sub.2 (1 M in DCM, 41.0 mL,
41.0 mmol). The resulting solution was stirred at rt for 2 h. The
solvent was removed in vacuo and the crude product was purified by
chromatography on silica gel (220 g column, 0-100% EtOAc in
isohexane) to afford Intermediate M(P)4 (5.64 g) as an oil.
[0497] .sup.1H NMR (DMSO-d6) 400 MHz, .delta.: 7.52-7.45 (m, 3H)
7.41-7.38 (m, 1H) 7.00 (s, 1H) 4.83 (s, 2H) 4.17 (q, 2H) 1.30 (s,
9H) 1.16 (t, 3H).
[0498] LCMS m/z 321 (M+H).sup.+ (ES.sup.+)
Intermediate M5
3-(tert-Butyl)-1-(3-((dimethylphosphoryl)methyl)phenyl)-1H-pyrazole-5-carb-
oxylic acid
##STR00075##
[0500] A suspension of Intermediate M(P)4 (3.65 g, 10.81 mmol),
xantphos (0.375 g, 0.649 mmol), palladium(II) acetate (0.121 g,
0.540 mmol), potassium phosphate, tribasic (2.52 g, 11.89 mmol) and
dimethylphosphine oxide (0.928 g, 11.89 mmol) in DMF (30 mL) was
purged with N.sub.2 for 20 mins. The reaction mixture was heated at
110.degree. C. for 1 h, cooled to rt then partitioned between DCM
(300 mL) and water (200 mL). The organic layer was washed with
water (2.times.200 mL), brine (300 mL), dried (MgSO.sub.4),
filtered and concentrated in vacuo. The crude product was purified
by chromatography on silica gel (120 g column, 0-10% MeOH/DCM) to
afford ethyl
3-(tert-butyl)-1-(3-((dimethylphosphoryl)methyl)phenyl)-1H-pyrazole-5-car-
boxylate (Intermediate M(P)5, 2.29 g) as an oil which solidified on
standing.
[0501] .sup.1H NMR (CDCl.sub.3) 400 MHz, .delta.: 7.43-7.27 (m,
4H), 6.87 (s, 1H), 4.22 (q, 2H), 3.23 (d, 2H), 1.48 (d, 6H), 1.36
(s, 9H), 1.28 (t, 3H).
[0502] LCMS m/z 363 (M+H).sup.+ (ES.sup.+)
[0503] Sodium hydroxide (1 M aq.) (12.0 mL, 12.00 mmol) was added
to a stirred solution of Intermediate M(P)5 (2.2 g, 6.07 mmol) in
EtOH (40 mL). The resulting mixture was stirred at rt for 3 h. The
solvent was removed in vacuo and the resulting residue partitioned
between 1M HCl (90 mL) and EtOAc (300 mL). The organic layer was
washed with brine (150 mL), dried (MgSO.sub.4), filtered and
concentrated in vacuo to afford Intermediate M5 (1.61 g) as a cream
solid.
[0504] .sup.1H NMR (DMSO-d6) 400 MHz, .delta.: 13.18 (bs, 1H),
7.39-7.43 (m, 1H), 7.29-7.31 (m, 3H), 6.93 (s, 1H), 3.23 (d, 2H),
1.36 (d, 6H), 1.30 (s, 9H).
[0505] LCMS m/z 335 (M+H).sup.+ (ES.sup.+); 333 (M-H).sup.-
(ES.sup.-)
Compound Examples of the Invention
Example 1
3-Ethynyl-5-((4-((4-(3-(3-isopropyl-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)-na-
phthalen-1-yl)oxy)pyrimidin-2-yl)amino)-N-(2-(2-(2-methoxyethoxy)ethoxy)et-
hyl)-benzamide
##STR00076##
[0507] Intermediate C1 (146 mg, 0.285 mmol) was dissolved in DMF (3
mL) and added to Intermediate D2 (87 mg, 0.285 mmol) and p-TSA
monohydrate (27.1 mg, 0.142 mmol). Stirred at 70.degree. C. (block
temperature) for 7 h then poured into sat. NaHCO.sub.3 solution (20
mL) and the product extracted with EtOAc (2.times.20 mL). Organics
bulked and washed with 20% w/w brine solution (20 mL), dried
(MgSO.sub.4), filtered and evaporated to a yellow solid.
[0508] The crude product was preabsorbed onto silica (4 g) and
purified by chromatography on silica gel (40 g column, 1% MeOH:DCM
to 6%) to afford a pale brown solid. Triturated 4 times with MeCN
(2 mL) to afford the title compound (60 mg) .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 9.76 (s, 1H), 9.09 (s, 1H), 8.78 (s, 1H),
8.51-8.40 (m, 2H), 8.13-8.01 (m, 2H), 7.94 (d, 1H), 7.87 (s, 1H),
7.82 (d, 1H), 7.68-7.54 (m, 2H), 7.53-7.32 (m, 6H), 6.56 (d, 1H),
6.38 (s, 1H), 4.11 (s, 1H), 3.58-3.46 (m, 8H), 3.43-3.35 (m, 4H),
3.21 (s, 3H), 2.90 (hept, 1H), 2.41 (s, 3H), 1.25 (d, 6H).
[0509] LCMS m/z 783 (M+H).sup.+ (ES.sup.+)
Example 2
3-((4-((4-(3-(3-(tert-Butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthalen-
-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-methoxyethoxy)ethoxy)-
ethyl)-benzamide
##STR00077##
[0511] Method 1
[0512] A suspension of Intermediate C2 (165 mg, 0.282 mmol),
Intermediate D2 (173 mg, 0.564 mmol) and p-TSA monohydrate (11.0
mg, 0.058 mmol) in THF/DMF (6 mL, 1:2) was heated at 60.degree. C.
overnight. The reaction was cooled to rt and partitioned between
EtOAc (40 mL) and sat. aq. NaHCO.sub.3 (30 mL). The aqueous layer
was extracted with EtOAc (2.times.40 mL). The combined organic
extracts were washed with water (2.times.50 mL), brine (2.times.50
mL), dried (MgSO.sub.4), filtered and concentrated in vacuo. The
crude product was purified by chromatography on silica gel (40 g
column, 0-10% MeOH) to afford a pale yellow solid. The solid was
triturated with EtOAc affording the title compound (68 mg) as a
white solid.
[0513] .sup.1H NMR (DMSO-d6) 400 MHz, .delta.: 9.75 (s, 1H), 9.08
(s, 1H), 8.76 (s, 1H), 8.43-8.46 (m, 2H), 8.06-8.08 (m, 2H), 7.94
(d, 1H), 7.87 (s, 1H), 7.83 (d, 1H), 7.56-7.65 (m, 6H), 6.56 (d,
1H), 6.42 (s, 1H), 4.10 (s, 1H), 3.48-3.53 (m, 8H), 3.36-3.41 (m,
4H), 3.21 (s, 3H), 2.41 (s, 3H), 1.30 (s, 9H).
[0514] LCMS m/z 399 (M+2H).sup.2+ (ES.sup.+)
[0515] Method 2
[0516] TEA (13.38 g, 132 mmol) was added to solution of
Intermediate A1* (219 g, 627 mmol) and Intermediate B2 (503.11 g,
929 mmol) in isopropyl acetate (4 L) in a 10 L jacketed vessel. The
resulting mixture was heated to 50-60.degree. C. under stirring.
After about 5 minutes, a heavy precipitate started to form.
Stirring was continued for a further 2 h. Analysis by TLC (ethyl
acetate) indicated consumption of the starting materials. Heating
was ceased and the suspension allowed to cool slowly overnight. The
reaction mixture was then filtered through a cloth on a large
diameter (40 cm), large pore clay filter. The solid product was
washed with ethyl acetate and then n-hexane to provide the title
compound (256 g, 51.2%) as a colourless, amorphous solid that had
.sup.1H NMR and LCMS data essentially identical to those of the
material obtained via Method 1 above.
Example 3
3-((4-((4-(3-(3-(tert-Butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)ureido)-n-
aphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-methoxyethox-
y)-ethoxy)ethyl)benzamide
##STR00078##
[0518] To a stirred solution of Intermediate C3 (175 mg, 0.316
mmol) and Intermediate D2 (153 mg, 0.474 mmol) in DMF (4 mL) was
added p-TSA monohydrate (30 mg, 0.158 mmol). The resulting solution
was heated at 60.degree. C. overnight. The reaction was cooled to
rt and partitioned between EtOAc (30 mL) and sat aq. NaHCO.sub.3
(30 mL). The aqueous phase was back extracted with EtOAc (30 mL).
The combined organic extracts were washed with water (2.times.50
mL), brine (50 mL), dried (MgSO.sub.4), filtered and concentrated
in vacuo to afford an orange oil (276 mg) at 85% purity. The crude
product was purified by chromatography on silica gel (40 g column,
0-10% MeOH in DCM) to afford a pink solid (188 mg), which was
triturated with MeCN to afford the title compound (98 mg) as an
off-white solid.
[0519] .sup.1H NMR (DMSO-d6) 400 MHz, .delta.: 9.75 (s, 1H), 9.08
(s, 1H), 8.72 (s, 1H), 8.46 (t, 1H), 8.43 (d, 1H), 8.06-8.04 (m,
2H), 7.93 (d, 1H), 7.86 (br s, 1H), 7.82-7.80 (m, 1H), 7.64-7.54
(m, 2H), 7.50-7.46 (m, 2H), 7.45-7.42 (m, 2H), 7.14-7.10 (m, 2H),
6.55 (d, 1H), 6.39 (s, 1H), 4.11 (s, 1H), 3.84 (s, 3H), 3.53-3.46
(m, 8H), 3.40-3.35 (m, 4H), 3.20 (s, 3H), 1.28 (s, 9H).
[0520] LCMS m/z 813 (M+H).sup.+ (ES.sup.+)
Example 4
3-((4-((4-(3-(3-(tert-Butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthalen-
-1-yl)oxy)pyridin-2-yl)amino)-5-methoxy-N-(2-(2-(2-methoxyethoxy)ethoxy)et-
hyl)-benzamide
##STR00079##
[0522] Triethylamine (6 .mu.L, 0.043 mmol) was added to a mixture
of Intermediate A1* (75 mg, 0.215 mmol) and Intermediate B1 (128
mg, 0.234 mmol) in isopropyl acetate (2 mL) and the mixture heated
at 50.degree. C. for 2 h. The reaction mixture was concentrated
under reduced pressure then purified by chromatography on the
Companion (80 g column, 0-50% acetone/EtOAc) to afford a colourless
gum. The gum was purified by chromatography on the Companion (40 g
column, 5% MeOH/DCM) to afford a tan foam. The crude product was
purified by preparative HPLC (Waters, Acidic (0.1% Formic acid),
Waters X-Select Prep-C18, 5 .mu.m, 19.times.50 mm column, 25-70%
MeCN in Water) to afford the title compound (55 mg) as a white
solid.
[0523] .sup.1H NMR (DMSO-d6) 400 MHz, .delta.: 9.19 (s, 1H), 9.06
(s, 1H), 8.84 (s, 1H), 8.34 (dd, 1H), 8.13-8.07 (m, 2H), 7.97 (d,
1H), 7.85 (dd, 1H), 7.69-7.62 (m, 1H), 7.62-7.55 (m, 2H), 7.52-7.44
(m, 3H), 7.41-7.33 (m, 3H), 6.91-6.86 (m, 1H), 6.55 (dd, 1H), 6.42
(s, 1H), 6.13 (d, 1H), 3.75 (s, 3H), 3.56-3.46 (m, 8H), 3.43-3.34
(m, 4H), 3.21 (s, 3H), 2.41 (s, 3H), 1.30 (s, 9H).
[0524] LCMS m/z 802 (M+H).sup.+ (ES.sup.+); 800 (M-H).sup.-
(ES.sup.-)
Example 5
3-((4-((4-(3-(3-(tert-Butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)ureido)-n-
aphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-methoxyethoxy)e-
thyl)-benzamide
##STR00080##
[0526] To a stirred solution of Intermediate C3 (152 mg, 0.274
mmol) and Intermediate D5 (124 mg, 0.411 mmol) in DMF (4 mL) was
added p-TSA monohydrate (26 mg, 0.137 mmol). The resulting solution
was heated at 60.degree. C. overnight. The reaction was cooled to
rt and partitioned between EtOAc (30 mL) and sat aq. NaHCO.sub.3
(30 mL). The aqueous phase was back extracted with EtOAc (30 mL).
The combined organic extracts were washed with water (2.times.50
mL), brine (50 mL), dried (MgSO.sub.4), filtered and concentrated
in vacuo to afford a dark orange glass. The crude product was
purified by chromatography on silica gel (40 g column, 0-10% MeOH
in DCM) to afford a pale pink solid, which was triturated with
Et.sub.2O to afford a pale, pink solid (25 mg). The crude product
was purified by preparative HPLC (Waters, Acidic (0.1% Formic
acid), Waters X-Select Prep-C18, 5 .mu.m, 19.times.50 mm column,
45-65% MeCN in Water) to afford the title compound (13 mg) as an
off-white solid.
[0527] .sup.1H NMR (DMSO-d6) 400 MHz, .delta.: 9.77 (s, 1H), 9.14
(s, 1H), 8.79 (s, 1H), 8.48 (t, 1H), 8.44 (d, 1H), 8.07-8.04 (m,
2H), 7.93 (d, 1H), 7.86 (br s, 1H), 7.81 (d, 1H), 7.64-7.54 (m,
2H), 7.50-7.41 (m, 4H), 7.12 (d, 2H), 6.56 (d, 1H), 6.39 (s, 1H),
4.12 (s, 1H), 3.83 (s, 3H), 3.53-3.48 (m, 4H), 3.43-3.41 (m, 2H),
2H under water peak at 3.35 ppm, 3.22 (s, 3H), 1.28 (s, 9H).
[0528] LCMS m/z 385 (M+2H).sup.2+ (ES.sup.+)
Example 6
3-((4-((4-(3-(3-(tert-Butyl)-1-(2,3,5,6-tetradeutero-4-(trideuteromethyl)--
phenyl)-1H-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-
-ethynyl-N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)benzamide
##STR00081##
[0530] A mixture of Intermediate A4* (0.5 g, 1.403 mmol),
Intermediate B2 (0.760 g, 1.403 mmol) and Et.sub.3N (40 .mu.L,
0.287 mmol) in iPrOAc (20 mL) were stirred at 50.degree. C. for 3
h. The mixture was cooled, filtered and the solid washed with
iPrOAc (15 mL), EtOAc (15 mL) then MeCN (15 mL). The solid was
dried at 50.degree. C. under vacuum to afford the title compound
(745 mg) as a white solid.
[0531] .sup.1H NMR (DMSO-d6) 400 MHz, .delta.: 9.75 (s, 1H), 9.09
(s, 1H), 8.76 (s, 1H), 8.47-8.43 (m, 2H), 8.08-8.06 (m, 2H), 7.94
(d, 1H), 7.87 (s, 1H), 7.83 (d, 1H), 7.65-7.56 (m, 2H), 7.45 (s,
1H), 7.43 (d, 1H), 6.56 (d, 1H), 6.42 (s, 1H), 4.10 (s, 1H),
3.54-3.48 (m, 8H), 3.41-3.36 (m, 4H), 3.21 (s, 3H), 1.30 (s,
9H)
[0532] LCMS m/z 804 (M+H).sup.+ (ES.sup.+)
Example 7
3-((4-((4-(3-(3-(tert-Butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthalen-
-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2,5,8,11-tetraoxatridecan-13--
yl)benzamide
##STR00082##
[0534] Et.sub.3N (35 .mu.L, 0.251 mmol) was added to a stirred
solution of Intermediate A1* (400 mg, 1.144 mmol) and Intermediate
B3 (670 mg, 1.144 mmol) in isopropyl acetate (30 mL). The mixture
was heated at 50.degree. C. for 8 h then cooled to rt and stirred
overnight during which time a precipitate was formed. The solid was
filtered off and washed with isopropyl acetate (15 mL) then dried
to constant weight. The product was recrystallised in MeCN (40 mL)
and the resulting white solid isolated by filtration washing with
further MeCN. The crude product was purified by chromatography on
silica gel (12 g column, 1-5% MeOH in DCM) to afford the title
compound (316 mg) as a white solid.
[0535] .sup.1H NMR (400 MHz, DMSO-d6) .delta.: 9.75 (s, 1H), 9.08
(s, 1H), 8.76 (s, 1H), 8.43-8.47 (m, 2H), 8.06-8.08 (m, 2H), 7.94
(d, 1H), 7.87 (s, 1H), 7.83 (d, 1H), 7.63 (t, 1H), 7.57 (t, 1H),
7.37-7.48 (m, 6H), 6.56 (d, 1H), 6.42 (s, 1H), 4.10 (s, 1H),
3.46-3.53 (m, 12H), 3.36-3.42 (m, 4H), 3.21 (s, 3H), 2.41 (s, 3H),
1.30 (s, 9H).
[0536] LCMS m/z 841 (M+H).sup.+ (ES.sup.+); 421 (M+2H).sup.2+
(ES.sup.+)
Example 8
3-((4-((4-(3-(3-(tert-Butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthalen-
-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-methoxyethoxy)ethyl)benz-
amide
##STR00083##
[0538] TEA (40.0 .mu.l, 0.287 mmol) was added to a stirred solution
of Intermediate A1* (525 mg, 1.502 mmol) and Intermediate B4 (700
mg, 1.407 mmol) in isopropyl acetate (20 mL). The mixture was
heated at 50.degree. C. for 18 h. The resulting precipitate was
collected by filtration and washed with ethyl acetate (2.times.25
mL). The solid was recrystallised in acetonitrile to yield the
title compound (571 mg) as a white solid.
[0539] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.75 (s, 1H), 9.08
(s, 1H), 8.76 (s, 1H), 8.50-8.40 (m, 2H), 8.12-8.04 (m, 2H), 7.94
(d, 1H), 7.90-7.78 (m, 2H), 7.67-7.60 (m, 1H), 7.60-7.54 (m, 1H),
7.52-7.32 (m, 6H), 6.55 (d, 1H), 6.42 (s, 1H), 4.10 (s, 1H),
3.57-3.47 (m, 4H), 3.47-3.35 (m, 4H), 3.23 (s, 3H), 2.41 (s, 3H),
1.30 (s, 9H).
[0540] LCMS m/z 753 (M+H).sup.+ (ES.sup.+); 751 (M-H).sup.-
(ES.sup.-)
Example 9
3-((4-((4-(3-(3-(tert-Butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)u-
reido)-naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-meth-
oxyethoxy)-ethoxy)ethyl)benzamide
##STR00084##
[0542] Intermediate A5* (80 mg, 0.211 mmol), Intermediate B2 (114
mg, 0.211 mmol) and Et.sub.3N (10.00 .mu.L, 0.072 mmol) were heated
to 60.degree. C. (block temp) in iPrOAc (3 mL) for 2 h. The
resulting precipitate was collected by filtration then
recrystallised in acetonitrile to yield the title compound (63 mg)
as a white solid.
[0543] .sup.1H NMR (DMSO-d6) 400 MHz, .delta.: 9.75 (s, 1H), 9.11
(s, 1H), 8.66 (s, 1H), 8.45 (dd, 1H), 8.44 (d, 1H), 8.11-8.04 (m,
2H), 7.96 (d, 1H), 7.87 (br s, 1H), 7.82 (dd, 1H), 7.63 (ddd, 1H),
7.57 (ddd, 1H), 7.45 (dd, 1H), 7.43 (d, 1H), 7.37-7.31 (m, 2H),
6.91-6.83 (m, 2H), 6.55 (d, 1H), 6.38 (s, 1H), 4.10 (s, 1H),
3.56-3.46 (m, 8H), 3.42-3.35 (m, 4H), 3.21 (s, 3H), 2.99 (s, 6H),
1.29 (s, 9H).
[0544] LCMS m/z 826 (M+H).sup.+ (ES.sup.+)
Example 10
3-((4-((4-(3-(3-(tert-Butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)u-
reido)-naphthalen-1-yl)oxy)pyridin-2-yl)amino)-5-methoxy-N-(2-(2-(2-methox-
yethoxy)-ethoxy)ethyl)benzamide
##STR00085##
[0546] Intermediate A5* (80 mg, 0.211 mmol), Intermediate B1 (116
mg, 0.211 mmol) and Et.sub.3N (10.00 .mu.L, 0.072 mmol) were heated
to 60.degree. C. (block temp) in iPrOAc (3 mL) for 2 h. The mixture
was concentrated under reduced pressure and the residue was
purified by chromatography on the Companion (40 g column, 0-5%
MeOH/DCM) to afford a gum. The gum was purified by preparative HPLC
(Gilson, Acidic (0.1% Formic acid), Acidic, Waters X-Select
Prep-C18, 5 .mu.m, 19.times.50 mm column, 25-75% MeCN in Water).
Fractions containing product were combined, concentrated under
reduced pressure then redissolved in ethyl acetate (50 mL). The
organic solution was washed with saturated NaHCO.sub.3 solution (50
mL), saturated brine (50 mL), dried (MgSO.sub.4) and concentrated
under reduced pressure. The resulting foam was slurried in diethyl
ether (5 mL) overnight then collected by filtration to afford the
title compound (75 mg) as a white solid.
[0547] .sup.1H NMR (DMSO-d6) 400 MHz, .delta.: 9.16 (s, 1H), 9.06
(s, 1H), 8.67 (s, 1H), 8.38-8.30 (m, 1H), 8.14-8.05 (m, 2H), 8.00
(d, 1H), 7.85 (d, 1H), 7.69-7.62 (ddd, 1H), 7.62-7.55 (m, 2H),
7.52-7.48 (m, 1H), 7.39-7.31 (m, 3H), 6.91-6.84 (m, 3H), 6.59-6.53
(dd, 1H), 6.38 (s, 1H), 6.13 (d, 1H), 3.75 (s, 3H), 3.56-3.47 (m,
8H), 3.43-3.35 (m, 4H), 3.21 (s, 3H), 2.99 (s, 6H), 1.28 (s,
9H).
[0548] LCMS m/z 831 (M+H).sup.+ (ES.sup.+); 829 (M-H).sup.-
(ES.sup.-)
Example 11
3-((4-((4-(3-(3-(tert-Butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)u-
reido)-naphthalen-1-yl)oxy)pyridin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-methox-
yethoxy)ethoxy)-ethyl)benzamide
##STR00086##
[0550] Intermediate A5* (80 mg, 0.211 mmol), Intermediate B5 (114
mg, 0.211 mmol) and Et.sub.3N (10.00 .mu.L, 0.072 mmol) were heated
to 60.degree. C. (block temp) in iPrOAc (3 mL) for 2 h. The mixture
was concentrated under reduced pressure and the residue was
purified by chromatography on the Companion (40 g column, 0-5%
MeOH/DCM) to afford a gum. The gum was purified by preparative HPLC
(Gilson, Acidic (0.1% Formic acid), Acidic, Waters X-Select
Prep-C18, 5 .mu.m, 19.times.50 mm column, 25-75% MeCN in Water).
Fractions containing product were combined, concentrated under
reduced pressure then redissolved in ethyl acetate (50 mL). The
organic solution was washed with saturated NaHCO.sub.3 carbonate
solution (50 mL), saturated brine (50 mL), dried (MgSO.sub.4) and
concentrated under reduced pressure. The resulting foam was
slurried in diethyl ether (5 mL) overnight then collected by
filtration to afford the title compound (93 mg) as a white
solid.
[0551] .sup.1H NMR (DMSO-d6) 400 MHz, .delta.: 9.21 (s, 1H), 9.17
(s, 1H), 8.67 (s, 1H), 8.47 (dd, 1H), 8.14 (d, 1H), 8.13-8.07 (m,
2H), 8.00 (d, 1H), 7.93 (dd, 1H), 7.85 (d, 1H), 7.66 (ddd, 1H),
7.59 (ddd, 1H), 7.42 (dd, 1H), 7.38 (d, 1H), 7.36-7.31 (ddd, 2H),
6.91-6.84 (ddd, 2H), 6.61 (dd, 1H), 6.38 (s, 1H), 6.12 (d, 1H),
4.19 (s, 1H), 3.58-3.46 (m, 8H), 3.43-3.35 (m, 4H), 3.21 (s, 3H),
2.99 (s, 6H), 1.29 (s, 9H).
[0552] LCMS m/z 825 (M+H).sup.+ (ES.sup.+); 823 (M-H).sup.-
(ES.sup.-)
Example 12
3-((4-((4-(3-(3-(tert-Butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)-5,6,7,8-t-
etrahydronaphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-me-
thoxyethoxy)-ethoxy)ethyl)benzamide
##STR00087##
[0554] A mixture of Intermediate C4(H) (250 mg, 0.471 mmol),
Intermediate D2 (288 mg, 0.942 mmol) and pTSA monohydrate (20 mg,
0.105 mmol) in THF (8 mL) was heated at 60.degree. C. for 6 h. The
mixture was partitioned between EtOAc (60 mL) and aq 1M HCl (40
mL), the organic layer washed with brine (20 mL), dried
(MgSO.sub.4), filtered and evaporated under reduced pressure. The
crude product was purified by chromatography on silica gel (40 g
column, 0-5% MeOH/DCM) to give a solid that was triturated with
MeCN to afford the title compound (136 mg) as a white solid.
[0555] .sup.1H NMR (DMSO-d6) 400 MHz, .delta.: 9.79 (s, 1H), 8.68
(s, 1H), 8.47 (t, 1H), 8.38 (d, 1H), 8.14 (s, 1H), 8.09 (s, 1H),
7.95 (s, 1H), 7.59 (d, 1H), 7.47 (s, 1H), 7.42 (d, 2H), 7.35 (d,
2H), 6.97 (d, 1H), 6.40 (d, 1H), 6.35 (s, 1H), 4.11 (s, 1H),
3.55-3.48 (m, 8H), 3.43-3.37 (m, 4H), 3.22 (s, 3H), 2.39 (s, 3H),
1.75-1.60 (m, 4H), 1.28 (s, 9H). (4H under DMSO)
[0556] LCMS m/z 801 (M+H).sup.+ (ES.sup.+)
Example 13
3-((4-((4-(3-(3-(tert-Butyl)-1-(2,4-dimethoxyphenyl)-1H-pyrazol-5-yl)ureid-
o)naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-methoxyet-
hoxy)ethoxy)ethyl)-benzamide
##STR00088##
[0558] DPPA (160 .mu.L, 0.742 mmol) was added to a stirred solution
of Intermediate M2 (210 mg, 0.690 mmol) and triethylamine (240
.mu.L, 1.725 mmol) in DMF (3 mL). The reaction was stirred at rt
for 1 h before addition of Intermediate B2 (350 mg, 0.646 mmol) and
heating to 100.degree. C. for 2 h. The reaction mixture was cooled
and partitioned between EtOAc (20 mL) and 20% w/w NaCl soln. (40
mL). The organics were separated, dried (MgSO.sub.4), filtered and
evaporated to a brown gum. The crude product was purified by
chromatography on silica gel (40 g column, 2% MeOH:DCM to 8%) to
afford a yellow gum which was stirred in MeCN overnight. The
resulting precipitate was filtered off and washed with MeCN (2 mL)
to afford the title compound (240 mg) as a beige solid.
[0559] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.75 (s, 1H), 9.13
(s, 1H), 8.58-8.36 (m, 3H), 8.10-8.01 (m, 2H), 7.98 (d, 1H),
7.90-7.85 (m, 1H), 7.83 (d, 1H), 7.69-7.60 (m, 1H), 7.60-7.52 (m,
1H), 7.48-7.40 (m, 2H), 7.32 (d, 1H), 6.84 (d, 1H), 6.71 (dd, 1H),
6.55 (d, 1H), 6.37 (s, 1H), 4.08 (s, 1H), 3.88 (s, 3H), 3.84 (s,
3H), 3.55-3.46 (m, 8H), 3.39 (m, 4H), 3.21 (s, 3H), 1.27 (s,
9H).
[0560] LCMS m/z 843 (M+H).sup.+ (ES.sup.+)
Example 14
3-((4-((4-(3-(3-(tert-Butyl)-1-(3-((dimethylphosphoryl)methyl)phenyl)-1H-p-
yrazol-5-yl)-ureido)naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N--
(2-(2-(2-methoxyethoxy)-ethoxy)ethyl)benzamide
##STR00089##
[0562] DPPA (80 .mu.L, 0.371 mmol) was added to a solution of
Intermediate M5 (110 mg, 0.329 mmol) and triethylamine (120 .mu.L,
0.861 mmol) in DMF (2 mL). The reaction was stirred at rt for 1 h
before addition of Intermediate B2 (170 mg, 0.314 mmol) and heating
at 100.degree. C. (block temperature) for 2 h. The reaction mixture
was cooled and partitioned between EtOAc (20 mL) and 20% w/w NaCl
soln. (40 mL). The organics were separated, dried (MgSO.sub.4),
filtered and evaporated to a brown gum. The crude product was
purified by chromatography on silica gel (40 g column, 2% MeOH:DCM
to 8%) to afford a beige solid which was recrystallised from MeCN
(3 mL) to afford the title compound (80 mg) as a colourless
solid.
[0563] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.75 (s, 1H), 9.42
(s, 1H), 8.95 (s, 1H), 8.52-8.36 (m, 2H), 8.21 (d, 1H), 8.07 (s,
1H), 8.00 (d, 1H), 7.92-7.77 (m, 2H), 7.70-7.51 (m, 4H), 7.52-7.38
(m, 3H), 7.32 (d, 1H), 6.56 (d, 1H), 6.51 (s, 1H), 4.10 (s, 1H),
3.56-3.45 (m, 8H), 3.44-3.35 (m, 6H), 3.21 (s, 3H), 1.47 (d, 6H),
1.31 (s, 9H).
[0564] LCMS m/z 873 (M+H).sup.+ (ES.sup.+)
Example 15
3-((4-((4-(3-(3-(tert-Butyl)-1-(3-((dimethylphosphoryl)methyl)phenyl)-1H-p-
yrazol-5-yl)-ureido)naphthalen-1-yl)oxy)pyridin-2-yl)amino)-5-methoxy-N-(2-
-(2-(2-methoxyethoxy)-ethoxy)ethyl)benzamide
##STR00090##
[0566] DPPA (80 .mu.L, 0.371 mmol) was added to a solution of
Intermediate M5 (112 mg, 0.335 mmol) and triethylamine (120 .mu.L,
0.861 mmol) in DMF (2 mL). The reaction was stirred at rt for 1 h
before addition of Intermediate B1 (170 mg, 0.311 mmol) and heating
at 100.degree. C. (block temperature) for 2 h. The reaction mixture
was cooled and partitioned between EtOAc (20 mL) and 20% w/w NaCl
soln. (40 mL). The organics were separated, dried (MgSO.sub.4),
filtered and evaporated to a brown gum. The crude product was
purified by chromatography on silica gel (40 g column, 2% MeOH:DCM
to 8%) to afford a beige solid which was recrystallised from MeCN
(3 ml) to afford the title compound (70 mg) as a tan solid.
[0567] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.48 (s, 1H), 9.07
(s, 1H), 8.96 (s, 1H), 8.34 (t, 1H), 8.24 (d, 1H), 8.11 (d, 1H),
8.03 (d, 1H), 7.86 (d, 1H), 7.71-7.63 (m, 1H), 7.63-7.44 (m, 6H),
7.36 (d, 1H), 7.35-7.29 (m, 1H), 6.89 (dd, 1H), 6.57 (dd, 1H), 6.51
(s, 1H), 6.12 (d, 1H), 3.74 (s, 3H), 3.57-3.46 (m, 8H), 3.43-3.35
(m, 6H), 3.21 (s, 3H), 1.47 (d, 6H), 1.31 (s, 9H).
[0568] LCMS m/z 878 (M+H).sup.+ (ES.sup.+)
Example 16
3-((4-((4-(3-(3-(tert-Butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)u-
reido)-naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-methoxy-N-(2-(2-(2-meth-
oxyethoxy)-ethoxy)ethyl)benzamide
##STR00091##
[0570] Intermediate A5* (70 mg, 0.185 mmol), Intermediate B6 (101
mg, 0.185 mmol) and Et.sub.3N (10 .mu.L, 0.072 mmol) were heated to
60.degree. C. (block temperature) in isopropyl acetate (6 mL) and
stirred for 2 h. The cooled, gelatinous mixture was diluted with
acetonitrile (6 mL) and the resulting solid was collected by
filtration to yield a white solid. The solid was purified by
preparative HPLC (Gilson, Acidic (0.1% Formic acid), Acidic, Waters
X-Select Prep-C18, 5 .mu.m, 19.times.50 mm column, 5-95% MeCN in
Water). Colourless needles formed in the fractions over 72 h, which
were collected by filtration to afford the title compound (63 mg)
as a colourless crystalline solid.
[0571] .sup.1H NMR (400 MHz, DMSO-d6) .delta.: 9.61 (s, 1H), 9.15
(br s, 1H), 8.71 (br s, 1H), 8.41 (d, 1H), 8.32 (dd, 1H), 8.08 (d,
1H), 7.98 (d, 1H), 7.82 (d, 1H), 7.62 (ddd, 1H), 7.59-7.53 (m, 2H),
7.41 (d, 1H), 7.38-7.30 (m, 3H), 6.91-6.83 (m, 3H), 6.53 (d, 1H),
6.38 (s, 1H), 3.59-3.55 (m, 2H), 3.54-3.46 (m, 8H), 3.41-3.37 (m,
2H), 3.20 (s, 3H), 2.98 (s, 6H), 2.08 (s, 3H), 1.28 (s, 9H).
[0572] LCMS m/z 832 (M+H).sup.+ (ES.sup.+); 830 (M-H).sup.-
(ES.sup.-)
Example 17
3-((4-((4-(3-(3-(tert-Butyl)-1-(4-methoxy-2-methylphenyl)-1H-pyrazol-5-yl)-
ureido)-naphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-met-
hoxyethoxy)-ethoxy)ethyl)benzamide
##STR00092##
[0574] The title compound was prepared by methods analogous to
those described above.
[0575] .sup.1H NMR (DMSO-d6) 400 MHz, .delta.: 9.74 (s, 1H), 9.09
(s, 1H), 8.58 (s, 1H), 8.43-8.46 (m, 2H), 8.07 (s, 1H), 8.02 (d,
1H), 7.95 (d, 1H), 7.87 (s, 1H), 7.81 (d, 1H), 7.53-7.63 (m, 2H),
7.44 (s, 1H), 7.42 (d, 1H), 7.34 (d, 1H), 7.04 (d, 1H), 6.96 (dd,
1H), 6.55 (d, 1H), 6.38 (s, 1H), 4.09 (s, 1H), 3.85 (s, 3H),
3.48-3.51 (m, 8H), 3.37-3.41 (m, 4H), 3.21 (s, 3H), 2.02 (s, 3H),
1.29 (s, 9H).
[0576] LCMS m/z 827 (M+H).sup.+ (ES.sup.+)
Biological Testing
Experimental Methods
Enzyme Binding Assays (Kinomescan)
[0577] Kinase enzyme binding activities of compounds disclosed
herein may be determined using a proprietary assay which measures
active site-directed competition binding to an immobilized ligand
(Fabian, M. A. et al., Nature Biotechnol., 2005, 23:329-336). These
assays may be conducted by DiscoverX (formerly Ambit; San Diego,
Calif.). The percentage inhibition produced by incubation with a
test compound may be calculated relative to the non-inhibited
control.
[0578] Enzyme Inhibition Assays
[0579] The enzyme inhibitory activities of compounds disclosed
herein are determined by FRET using synthetic peptides labelled
with both donor and acceptor fluorophores (Z-LYTE, Invitrogen Ltd.,
Paisley, UK).
[0580] p38 MAPK.alpha. Enzyme Inhibition
[0581] The following two assay variants are used for determination
of p38 MAPK.alpha. inhibition.
[0582] Method 1
[0583] The inhibitory activities of test compounds against the p38
MAPK.alpha. isoform (MAPK14: Invitrogen), are evaluated indirectly
by determining the level of activation/phosphorylation of the
down-stream molecule, MAPKAP-K2. The p38 MAPK.alpha. protein (80
ng/mL, 2.5 .mu.L) is mixed with the test compound (2.5 .mu.L of
either 4 .mu.g/mL, 0.4 .mu.g/mL, 0.04 .mu.g/mL or 0.004 .mu.g/mL)
for 2 hr at RT. The mix solution (2.5 .mu.L) of the p38.alpha.
inactive target MAPKAP-K2 (Invitrogen, 600 ng/mL) and FRET peptide
(8 .mu.M; a phosphorylation target for MAPKAP-K2) is then added and
the kinase reaction is initiated by adding ATP (40 .mu.M, 2.5
.mu.L). The mixture is incubated for 1 hr at RT. Development
reagent (protease, 5 .mu.L) is added for 1 hr prior to detection in
a fluorescence microplate reader (Varioskan.RTM. Flash,
ThermoFisher Scientific).
[0584] Method 2
[0585] This method follows the same steps as Method 1 above, but
utilises a higher concentration of the p38 MAPK.alpha. protein (2.5
.mu.L of 200 ng/mL protein instead of 2.5 .mu.L of 80 ng/mL
protein) for mixing with the test compound.
[0586] p38 MAPK.gamma. Enzyme Inhibition
[0587] The inhibitory activities of compounds of the invention
against p38MAPK.gamma. (MAPK12: Invitrogen), are evaluated in a
similar fashion to that described hereinabove. The enzyme (800
ng/mL, 2.5 .mu.L) is incubated with the test compound (2.5 .mu.L at
either 4 .mu.g/mL, 0.4 .mu.g/mL, 0.04 .mu.g/mL, or 0.004 .mu.g/mL)
for 2 hr at RT. The FRET peptides (8 .mu.M, 2.5 .mu.L), and
appropriate ATP solution (2.5 .mu.L, 400 .mu.M) is then added to
the enzymes/compound mixtures and incubated for 1 hr. Development
reagent (protease, 5 .mu.L) is added for 1 hr prior to detection in
a fluorescence microplate reader (Varioskan.RTM. Flash, Thermo
Scientific).
[0588] c-Src and Syk Enzyme Inhibition
[0589] The inhibitory activities of compounds of the invention
against c-Src and Syk enzymes (Invitrogen), are evaluated in a
similar fashion to that described hereinabove. The relevant enzyme
(3000 ng/mL or 2000 ng/mL respectively, 2.5 .mu.L) is incubated
with the test compound (either 4 .mu.g/mL, 0.4 .mu.g/mL, 0.04
.mu.g/mL, or 0.004 .mu.g/mL, 2.5 .mu.L each) for 2 hr at RT. The
FRET peptides (8 .mu.M, 2.5 .mu.L), and appropriate ATP solutions
(2.5 .mu.L, 800 .mu.M for c-Src, and 60 .mu.M ATP for Syk) are then
added to the enzymes/compound mixtures and incubated for 1 hr.
Development reagent (protease, 5 .mu.L) is added for 1 hr prior to
detection in a fluorescence microplate reader (Varioskan.RTM.
Flash, ThermoFisher Scientific).
[0590] GSK 3.alpha. Enzyme Inhibition
[0591] The following two assay variants are used for determination
of GSK 3.alpha. inhibition.
[0592] Method 1
[0593] The inhibitory activities of compounds of the invention
against the GSK 3.alpha. enzyme isoform (Invitrogen), are evaluated
by determining the level of activation/phosphorylation of the
target peptide. The GSK3-.alpha. protein (500 ng/mL, 2.5 .mu.L) is
mixed with the test compound (2.5 .mu.L at either 4 .mu.g/mL, 0.4
.mu.g/mL, 0.04 .mu.g/mL, or 0.004 .mu.g/mL) for 2 hr at RT. The
FRET peptide (8 .mu.M, 2.5 .mu.L), which is a phosphorylation
target for GSK3.alpha., and ATP (40 .mu.M, 2.5 .mu.L) are then
added to the enzyme/compound mixture and the resulting mixture
incubated for 1 hr. Development reagent (protease, 5 .mu.L) is
added for 1 hr prior to detection in a fluorescence microplate
reader (Varioskan.RTM. Flash, ThermoFisher Scientific).
[0594] In all cases, the site-specific protease cleaves
non-phosphorylated peptide only and eliminates the FRET signal.
Phosphorylation levels of each reaction are calculated using the
ratio of coumarin emission (donor) over fluorescein emission
(acceptor), for which high ratios indicate high phosphorylation and
low ratios indicate low phosphorylation levels. The percentage
inhibition of each reaction is calculated relative to non-inhibited
control and the 50% inhibitory concentration (IC.sub.50 value) is
then calculated from the concentration-response curve.
[0595] Method 2
[0596] This method follows the same steps as Method 1 above, but
utilises a shorter period of mixing of the test compound (105
minutes instead of 2 hours) with the GSK3-.alpha. protein.
[0597] Cellular Assays
[0598] (a) LPS-induced TNF.alpha./IL-8 Release in d-U937 Cells
[0599] U937 cells, a human monocytic cell line, are differentiated
into macrophage-type cells by incubation with PMA (100 ng/mL) for
48 to 72 hr. Cells are pre-incubated with final concentrations of
test compound for 2 hr and are then stimulated with LPS (0.1
.mu.g/mL; from E. Coli: O111:B4, Sigma) for 4 hr. The supernatant
is collected for determination of TNF.alpha. and IL-8
concentrations by sandwich ELISA (Duo-set, R&D systems). The
inhibition of TNF.alpha. production is calculated as a percentage
of that achieved by 10 .mu.g/mL of BIRB796 at each concentration of
test compound by comparison against vehicle control. The relative
50% effective concentration (REC.sub.50) is determined from the
resultant concentration-response curve. The inhibition of IL-8
production is calculated at each concentration of test compound by
comparison with vehicle control. The 50% inhibitory concentration
(IC.sub.50) is determined from the resultant concentration-response
curve.
[0600] (b) LPS-Induced TNF.alpha./IL-8 Release in PBMC Cells
[0601] Peripheral blood mononuclear cells (PBMCs) from healthy
subjects are separated from whole blood using a density gradient
(Lymphoprep, Axis-Shield Healthcare). The PBMCs are seeded in 96
well plates and treated with compounds at the desired concentration
for 2 hours before addition of 1 ng/ml LPS (Escherichia Coli
0111:B4 from Sigma Aldrich) for 24 hours under normal tissue
culture conditions (37.degree. C., 5% CO.sub.2). The supernatant is
harvested for determination of IL-8 and TNF.alpha. concentrations
by sandwich ELISA (Duo-set, R&D systems) and read on the
fluorescence microplate reader (Varioskan.RTM. Flash, ThermoFisher
Scientific). The concentration at 50% inhibition (IC.sub.50) of
IL-8 and TNF.alpha. production is calculated from the dose response
curve.
[0602] (c) IL-2 and IFN Gamma Release in CD3/CD28 Stimulated PBMC
Cells
[0603] PBMCs from healthy subjects are separated from whole blood
using a density gradient (Lymphoprep, Axis-Shield Healthcare).
Cells are added to a 96 well plate pre-coated with a mixture of
CD3/CD28 monoclonal antibodies (0.3 ug/ml eBioscience and 3 ug/ml
BD Pharmingen respectively). Compound at the desired concentration
is then added to the wells and the plate left for 3 days under
normal tissue culture conditions. Supernatants are harvested and
IL-2 and IFN gamma release determined by Sandwich ELISA (Duo-set,
R&D System). The IC.sub.50 is determined from the dose response
curve.
[0604] (d) IL-1.beta.-Induced IL-8 Release in HT29 Cells
[0605] HT29 cells, a human colon adenocarcinoma cell line, are
plated in a 96 well plate (24 hrs) and pre-treated with compounds
at the desired concentration for 2 hours before addition of 5 ng/ml
of IL-1.beta. (Abcam) for 24 hours. Supernatants are harvested for
IL-8 quantification by Sandwich ELISA (Duo-set, R&D System).
The IC.sub.50 is determined from the dose response curve.
[0606] (e) LPS-Induced IL-8 and TNF.alpha. Release in Primary
Macrophages
[0607] PBMCs from healthy subjects are separated from whole blood
using a density gradient (Lymphoprep, Axis-Shield Healthcare).
Cells are incubated for 2 hrs and non-adherent cells removed by
washing. To differentiate the cells to macrophages the cells are
incubated with 5 ng/ml of GM-CSF (Peprotech) for 7 days under
normal tissue culture conditions. Compounds are then added to the
cells at the desired concentration for a 2 hour pre-treatment
before stimulation with 10 ng/ml LPS for 24 hours. Supernatants are
harvested and IL-8 and TNF.alpha. release determined by Sandwich
ELISA (Duo-set, R&D System). The IC.sub.50 is determined from
the dose response curve.
[0608] (f) Poly I:C-Induced ICAM-1 Expression in BEAS2B Cells
[0609] Poly I:C is used in these studies as a simple, RNA virus
mimic. Poly I:C-Oligofectamine mixture (1 .mu.g/mL Poly I:C, .+-.2%
Oligofectamine, 25 .mu.L; Invivogen Ltd., San Diego, Calif., and
Invitrogen, Carlsbad, Calif., respectively) is transfected into
BEAS2B cells (human bronchial epithelial cells, ATCC). Cells are
pre-incubated with final concentrations of test compounds for 2 hr
and the level of ICAM1 expression on the cell surface is determined
by cell-based ELISA. At a time point 18 hr after poly I:C
transfection, cells are fixed with 4% formaldehyde in PBS (100
.mu.L) and then endogenous peroxidase is quenched by the addition
of washing buffer (100 .mu.L, 0.05% Tween in PBS: PBS-Tween)
containing 0.1% sodium azide and 1% hydrogen peroxide. Cells are
washed with wash-buffer (3.times.200 .mu.L). and after blocking the
wells with 5% milk in PBS-Tween (100 .mu.L) for 1 hr, the cells are
incubated with anti-human ICAM-1 antibody (50 .mu.L; Cell
Signalling Technology, Danvers, Mass.) in 1% BSA PBS overnight at
4.degree. C.
[0610] The cells are washed with PBS-Tween (3.times.200 .mu.L) and
incubated with the secondary antibody (100 .mu.L; HRP-conjugated
anti-rabbit IgG, Dako Ltd., Glostrup, Denmark). The cells are then
incubated with of substrate (50 .mu.L) for 2-20 min, followed by
the addition of stop solution (50 .mu.L, 1N H.sub.2SO.sub.4). The
ICAM-1 signal is detected by reading the absorbance at 450 nm
against a reference wavelength of 655 nm using a spectrophotometer.
The cells are then washed with PBS-Tween (3.times.200 .mu.L) and
total cell numbers in each well are determined by reading
absorbance at 595 nm after Crystal Violet staining (50 .mu.L of a
2% solution in PBS) and elution by 1% SDS solution (100 .mu.L) in
distilled water. The measured OD 450-655 readings are corrected for
cell number by dividing with the OD595 reading in each well. The
inhibition of ICAM-1 expression is calculated at each concentration
of test compound by comparison with vehicle control. The 50%
inhibitory concentration (IC.sub.50) is determined from the
resultant concentration-response curve.
[0611] (g) T Cell Proliferation
[0612] PBMCs from healthy subjects are separated from whole blood
using a density gradient (Lymphoprep, Axis-Shield Healthcare). The
lymphocyte fraction is first enriched for CD4+ T cells by negative
magnetic cell sorting as per the manufacturer's instructions
(Miltenyi Biotec 130-091-155). Naive CD4+ T cells are then
separated using positive magnetic selection of CD45RA+ cells using
microbeads as per the manufacturer's instructions (130-045-901).
Cells are plated at 2.times.10.sup.5 cells per well in 100 .mu.L
RPMI/10% FBS on 96 well flat bottomed plate (Corning Costar). 25
.mu.L of test compound are diluted to the appropriate concentration
(8.times. final conc.) in normal medium and added to duplicate
wells on the plate to achieve a dose response range of 0.03
ng/mL-250 ng/mL. DMSO is added as a negative control. Plates are
allowed to pre-incubate for 2 hours before stimulation with 1
.mu.g/mL anti-CD3 (OKT3; eBioscience). After 72 h, the medium in
each well is replaced with 150 .mu.L of fresh medium containing 10
.mu.M BrdU (Roche). After 16 h, the supernatant is removed, the
plate is dried and the cells fixed by adding 100 .mu.L of
fix/denature solution to each well for 20 min as per the
manufacturer's instructions (Roche). Plates are washed once with
PBS before addition of the anti-BrdU detection antibody and
incubated for 90 mins at room temperature. Plates are then washed
gently 3.times. with the wash buffer supplied and developed by
addition of 100 .mu.L of substrate solution. The reaction is
stopped by addition of 50 .mu.L of 1 M H.sub.2SO.sub.4, and read
for absorbance at 450 nm on a plate reader (Varioskan.RTM. Flash,
ThermoFisher Scientific). The IC.sub.50 is determined from the dose
response curve.
[0613] (h) Human Biopsy Assay
[0614] Intestinal mucosa biopsies are obtained from the inflamed
regions of the colon of IBD patients. The biopsy material is cut
into small pieces (2-3 mm) and placed on steel grids in an organ
culture chamber at 37.degree. C. in a 5% CO.sub.2/95% C.sub.2
atmosphere in serum-free media. DMSO control or test compounds at
the desired concentration are added to the tissue and incubated for
24 hr in the organ culture chamber. The supernatant is harvested
for determination of IL-6, IL-8, IL-1.beta. and TNF.alpha. levels
by R&D ELISA. Percentage inhibition of cytokine release by the
test compounds is calculated relative to the cytokine release
determined for the DMSO control (100%).
[0615] (i) Cell Mitosis Assay
[0616] PBMCs from healthy subjects are separated from whole blood
(Quintiles, London, UK) using a density gradient
(Histopaque.RTM.-1077, Sigma-Aldrich, Poole, UK). The PBMCs (3
million cells per sample) are subsequently treated with 2% PHA
(Sigma-Aldrich, Poole, UK) for 48 hr, followed by a 20 hr exposure
to varying concentrations of test compounds. At 2 hr before
collection, PBMCs are treated with demecolcine (0.1 .mu.g/mL;
Invitrogen, Paisley, UK) to arrest cells in metaphase. To observe
mitotic cells, PBMCs are permeabilized and fixed by adding
Intraprep (50 .mu.L; Beckman Coulter, France), and stained with
anti-phospho-histone 3 (0.26 ng/L; #9701; Cell Signalling, Danvers,
Mass.) and propidium iodide (1 mg/mL; Sigma-Aldrich, Poole, UK) as
previously described (Muehlbauer P. A. and Schuler M. J., Mutation
Research, 2003, 537:117-130). Fluorescence is observed using an
ATTUNE flow cytometer (Invitrogen, Paisley, UK), gating for
lymphocytes. The percentage inhibition of mitosis is calculated for
each treatment relative to vehicle (0.5% DMSO) treatment.
[0617] (j) Assessment of HRV16 induced CPE in MRC5 cells
[0618] MRC-5 cells are infected with HRV16 at an MOI of 1 in DMEM
containing 5% FCS and 1.5 mM magnesium chloride, followed by
incubation for 1 hr at 33.degree. C. to promote adsorption. The
supernatants are aspirated, and then fresh media added followed by
incubation for 4 days. Where appropriate, cells are pre-incubated
with compound or DMSO for 2 hr, and the compounds and DMSO added
again after washout of the virus.
[0619] Supernatants are aspirated and incubated with methylene blue
solution (100 .mu.L, 2% formaldehyde, 10% methanol and 0.175%
Methylene Blue) for 2 hr at RT. After washing, 1% SDS in distilled
water (100 .mu.L) is added to each well, and the plates are shaken
lightly for 1-2 hr prior to reading the absorbance at 660 nm. The
percentage inhibition for each well is calculated. The IC.sub.50
value is calculated from the concentration-response curve generated
by the serial dilutions of the test compounds.
[0620] (k) In vitro RSV virus load in primary bronchial epithelial
cells
[0621] Normal human bronchial epithelial cells (NHBEC) grown in 96
well plates are infected with RSV A2 (Strain A2, HPA, Salisbury,
UK) at an MOI of 0.001 in the LHC8 Media:RPMI-1640 (50:50)
containing 15 mM magnesium chloride and incubated for 1 hr at
37.degree. C. for adsorption. The cells are then washed with PBS
(3.times.200 .mu.L), fresh media (200 .mu.L) is added and
incubation continued for 4 days. Where appropriate, cells are
pre-incubated with the compound or DMSO for 2 hr, and then added
again after washout of the virus.
[0622] The cells are fixed with 4% formaldehyde in PBS solution (50
.mu.L) for 20 min, washed with WB (3.times.200 .mu.L), (washing
buffer, PBS including 0.5% BSA and 0.05% Tween-20) and incubated
with blocking solution (5% condensed milk in PBS) for 1 hr. Cells
are then washed with WB (3.times.200 .mu.L) and incubated for 1 hr
at RT with anti-RSV (2F7) F-fusion protein antibody (40 .mu.L;
mouse monoclonal, lot 798760, Cat. No. ab43812, Abcam) in 5% BSA in
PBS-tween. After washing, cells are incubated with an
HRP-conjugated secondary antibody solution (50 .mu.L) in 5% BSA in
PBS-Tween (lot 00053170, Cat. No. P0447, Dako) and then TMB
substrate added (50 .mu.L; substrate reagent pack, lot 269472, Cat.
No. DY999, R&D Systems, Inc.). This reaction is stopped by the
addition of 2N H.sub.2SO.sub.4 (50 .mu.L) and the resultant signal
is determined colourimetrically (OD: 450 nm with a reference
wavelength of 655 nm) in a microplate reader (Varioskan.RTM. Flash,
ThermoFisher Scientific). Cells are then washed and a 2.5% crystal
violet solution (50 .mu.L; lot 8656, Cat. No. PL7000, Pro-Lab
Diagnostics) is applied for 30 min. After washing with WB, 1% SDS
in distilled water (100 .mu.L) is added to each well, and plates
are shaken lightly on the shaker for 1 hr prior to reading the
absorbance at 595 nm. The measured OD.sub.450-655 readings are
corrected to the cell number by dividing the OD.sub.450-655 by the
OD.sub.505 readings. The percentage inhibition for each well is
calculated and the IC.sub.50 value is calculated from the
concentration-response curve generated from the serial dilutions of
compound.
[0623] (l) The Effect of Test Compounds on Cell Viability: MTT
Assay
[0624] Differentiated U937 cells are pre-incubated with each test
compound (final concentration 1 .mu.g/mL or 10 .mu.g/mL in 200
.mu.L media indicated below) under two protocols: the first for 4
hr in 5% FCS RPMI1640 media and the second in 10% FCS RPMI1640
media for 24 h. The supernatant is replaced with new media (200
.mu.L) and MTT stock solution (10 .mu.L, 5 mg/mL) is added to each
well. After incubation for 1 hr the media are removed, DMSO (200
.mu.L) is added to each well and the plates are shaken lightly for
1 hr prior to reading the absorbance at 550 nm. The percentage loss
of cell viability is calculated for each well relative to vehicle
(0.5% DMSO) treatment. Consequently an apparent increase in cell
viability for drug treatment relative to vehicle is tabulated as a
negative percentage.
[0625] (m) Accumulation of).beta. catenin in d-U937 Cells
[0626] U937 cells, a human monocytic cell line, are differentiated
into macrophage-type cells by incubation with PMA; (100 ng/mL) for
between 48 to 72 hr. The cells are then incubated with either final
concentrations of test compound or vehicle for 18 hr. The induction
of .beta.-catenin by the test compounds is stopped by replacing the
media with 4% formaldehyde solution. Endogenous peroxide activity
is neutralised by incubating with quenching buffer (100 .mu.L, 0.1%
sodium azide, 1% H.sub.2O.sub.2 in PBS with 0.05% Tween-20) for 20
min. The cells are washed with washing buffer (200 .mu.L; PBS
containing 0.05% Tween-20) and incubated with blocking solution
(200 .mu.L; 5% milk in PBS) for 1 hr, re-washed with washing buffer
(200 .mu.L) and then incubated overnight with anti-.beta.-catenin
antibody solution (50 .mu.L) in 1% BSA/PBS (BD, Oxford, UK).
[0627] After washing with washing buffer (3.times.200 .mu.L; PBS
containing 0.05% Tween-20), cells are incubated with an
HRP-conjugated secondary antibody solution (100 .mu.L) in 1%
BSA/PBS (Dako, Cambridge, UK) and the resultant signal is
determined colourimetrically (OD: 450 nm with a reference
wavelength of 655 nm) using TMB substrate (50 .mu.L; R&D
Systems, Abingdon, UK). This reaction is stopped by addition of 1N
H.sub.2SO.sub.4 solution (50 .mu.L). Cells are then washed with
washing buffer and 2% crystal violet solution (50 .mu.L) is applied
for 30 min. After washing with washing buffer (3.times.200 .mu.L),
1% SDS (100 .mu.L) is added to each well and the plates are shaken
lightly for 1 hr prior to measuring the absorbance at 595 nm
(Varioskan.RTM. Flash, Thermo-Fisher Scientific).
[0628] The measured OD.sub.450-655 readings are corrected for cell
number by dividing the OD.sub.450-655 by the OD.sub.595 readings.
The percentage induction for each well is calculated relative to
vehicle, and the ratio of induction normalized in comparison with
the induction produced by a standard control comprising of the
Reference Compound
(N-(4-(4-(3-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)ureido)naphthalen-1-y-
loxy)pyridin-2-yl)-2-methoxyacetamide) (1 .mu.g/m L) which is
defined as 100%.
[0629] (n) IL-2 and IFN.gamma. Release in CD3/CD28 Stimulated LPMC
Cells from IBD Patients
[0630] Lamina propria mononuclear cells (LPMCs) are isolated and
purified from inflamed IBD mucosa of surgical specimens or from
normal mucosa of surgical specimens as follows: The mucosa is
removed from the deeper layers of the surgical specimens with a
scalpel and cut in fragments 3-4 mm size. The epithelium is removed
by washing the tissue fragments three times with 1 mM EDTA
(Sigma-Aldrich, Poole, UK) in HBSS (Sigma-Aldrich) with agitation
using a magnetic stirrer, discarding the supernatant after each
wash. The sample is subsequently treated with type 1A collagenase
(1 mg/mL; Sigma-Aldrich) for 1 h with stirring at 37.degree. C. The
resulting cell suspension is then filtered using a 100 .mu.m cell
strainer, washed twice, resuspended in RPMI-1640 medium
(Sigma-Aldrich) containing 10% fetal calf serum, 100 U/mL
penicillin and 100 .mu.g/mL streptomycin, and used for cell
culture.
[0631] Freshly isolated LPMCs (2.times.10.sup.5 cells/well) are
stimulated with 1 .mu.g/mL .alpha.-CD3/.alpha.-CD28 for 48 h in the
presence of either DMSO control or appropriate concentrations of
compound. After 48 h, the supernatant is removed and assayed for
the presence of TNF.alpha. and IFN.gamma. by R&D ELISA.
Percentage inhibition of cytokine release by the test compounds is
calculated relative to the cytokine release determined for the DMSO
control (100%).
[0632] (o) Inhibition of Cytokine Release from Myofibroblasts
Isolated from IBD Patients
[0633] Myofibroblasts from inflamed IBD mucosa are isolated as
follows: The mucosa is dissected and discarded and 1 mm-sized
mucosal samples are cultured at 37.degree. C. in a humidified
CO.sub.2 incubator in Dulbecco's modified Eagle's medium (DMEM,
Sigma-Aldrich) supplemented with 20% FBS, 1% non-essential amino
acids (Invitrogen, Paisley, UK), 100 U/mL penicillin, 100 .mu.g/mL
streptomycin, 50 .mu.g/mL gentamycin, and 1 .mu.g/mL amphotericin
(Sigma-Aldrich). Established colonies of myofibroblasts are seeded
into 25-cm.sup.2 culture flasks and cultured in DMEM supplemented
with 20% FBS and antibiotics to at least passage 4 to provide a
sufficient quantity for use in stimulation experiments.
[0634] Subconfluent monolayers of myofibroblasts are then seeded in
12-well plates at 3.times.10.sup.5 cells per well are starved in
serum-free medium for 24 h at 37.degree. C., 5% CO.sub.2 before
being cultured for 24 h in the presence of either DMSO control or
appropriate concentrations of compound. After 24 h the supernatant
is removed and assayed for the presence of IL-8 and IL-6 by R&D
ELISA. Percentage inhibition of cytokine release by the test
compounds is calculated relative to the cytokine release determined
for the DMSO control (100%).
[0635] (p) Human Neutrophil Degranulation
[0636] Neutrophils are isolated from human peripheral blood as
follows:
[0637] Blood is collected by venepuncture and anti-coagulated by
addition of 1:1 EDTA: sterile phosphate buffered saline (PBS, no
Ca+/Mg+). Dextran (3% w/v) is added (1 part dextran solution to 4
parts blood) and the blood allowed to stand for approximately 20
minutes at rt. The supernatant is carefully layered on a density
gradient (Lymphoprep, Axis-Shield Healthcare) and centrifuged (15
mins, 2000 rpm, no brake). The supernatant is aspirated off and the
cell pellet is re-suspended in sterile saline (0.2%) for no longer
than 60 seconds (to lyse contaminating red blood cells). 10 times
volume of PBS is then added and the cells centrifuged (5 mins, 1200
rpm). Cells are re-suspended in HBSS+ (Hanks buffered salt solution
(without phenol red) containing cytochalasin B (5 .mu.g/mL) and 1
mM CaCl.sub.2) to achieve 5.times.10.sup.6 cells/mL.
[0638] 5.times.10.sup.4 cells are added to each well of a V-bottom
96 well plate and incubated (30 mins, 37.degree. C.) with the
appropriate concentration of test compound (0.3-1000 ng/mL) or
vehicle (DMSO, 0.5% final conc). Degranulation is stimulated by
addition of fMLP (final conc 1 .mu.M) which after a further
incubation (30 mins, 37.degree. C.) the cells are removed by
centrifugation (5 mins, 1500 rpm) and the supernatants transferred
to a flat bottom 96 well plate. An equal volume of
tetramethylbenzidine (TMB) is added and after 10 mins the reaction
terminated by addition of an equal volume of sulphuric acid (0.5 M)
and absorbance read at 450 nm (background at 655 nm subtracted).
The 50% inhibitory concentration (IC.sub.50) is determined from the
resultant concentration-response curve.
[0639] (q) Cell Cytotoxicity Assay
[0640] 5.times.10.sup.4 TK6 cells (lymphoblastic T cell line) are
added to the appropriate number of wells of a 96 well plate in 195
.mu.L of media (RPMI supplemented with 10% foetal bovine serum). 5
.mu.L of DMSO control (final concentration 0.5% v/v) or test
compound (final concentration either 5 or 1 .mu.g/mL) is added to
the wells and incubated at 37.degree. C., 5% CO.sub.2. After 24
hours, the plate is centrifuged at 1300 rpm for 3 minutes and the
supernatant discarded. Cells are then resuspended in 7.5 .mu.g/mL
propidium iodide (PI) in PBS. After 15 minutes, cells are analysed
by flow cytometry (BD accuri). The % viability is calculated as the
% of cells that are PI negative in the test wells normalized to the
DMSO control.
[0641] In Vivo Screening: Pharmacodynamics and Anti-Inflammatory
Activity
[0642] (A) LPS-Induced Neutrophil Accumulation in Mice
[0643] Non-fasted Balb/c mice are dosed by the intra tracheal route
with either vehicle, or the test substance at the indicated times
(within the range 2-8 hr) before stimulation of the inflammatory
response by application of an LPS challenge. At T=0, mice are
placed into an exposure chamber and exposed to LPS (7.0 mL, 0.5
mg/mL solution in PBS) for 30 min. After a further 8 hr the animals
are anesthetized, their tracheas cannulated and BALF extracted by
infusing and then withdrawing from their lungs 1.0 mL of PBS via
the tracheal catheter. Total and differential white cell counts in
the BALF samples are measured using a Neubaur haemocytometer.
Cytospin smears of the BALF samples are prepared by centrifugation
at 200 rpm for 5 min at RT and stained using a DiffQuik stain
system (Dade Behring). Cells are counted using oil immersion
microscopy. Data for neutrophil numbers in BAL are shown as
mean.+-.S.E.M. (standard error of the mean). The percentage
inhibition of neutrophil accumulation is calculated for each
treatment relative to vehicle treatment.
[0644] (B) DSS-induced colitis in mice
[0645] Non-fasted, 10-12 week old, male BDF1 mice are dosed by oral
gavage twice daily with either vehicle, reference item (5-ASA) or
test compound one day before (Day -1) stimulation of the
inflammatory response by treatment with dextran sodium sulphate
(DSS). On Day 0 of the study DSS (5% w/v) is administered in the
drinking water followed by BID dosing of the vehicle (5 mL/kg),
reference (100 mg/kg) or test compound (5 mg/kg) for 7 days. The
drinking water with DSS is replenished every 3 days. During the
study animals are weighed every day and stool observations are made
and recorded as a score, based on stool consistency. At the time of
sacrifice on Day +6 the large intestine is removed and the length
and weight are recorded. Sections of the colon are taken for either
MPO analysis to determine neutrophil infiltration or for
histopathology scoring to determine disease severity.
[0646] (C) TNBS-Induced Colitis in Mice
[0647] Non-fasted, 10-12 week old, male BDF1 mice are dosed by oral
gavage twice daily with either vehicle (5 mL/kg), reference item
(Budesonide 2.5 mg/kg) or test compound (1 or 5 mg/kg) one day
before (Day -1) stimulation of the inflammatory response by
treatment with 2,4,6-trinitrobenzenesulphonic acid (TNBS) (15 mg/mL
in 50% ethanol/50% saline). On Day 0 of the study TNBS (200 .mu.L)
is administered intra-colonically via a plastic catheter with BID
dosing of the vehicle, reference or test compound continuing for 2
or 4 days. During the study animals are weighed every day and stool
observations are made and recorded as a score, based on stool
consistency. At the time of sacrifice on Day 2 (or Day 4) the large
intestine is removed and the length and weight recorded. Sections
of the colon are taken for histopathology scoring to determine
disease severity.
[0648] (D) Adoptive transfer in mice
[0649] On Study day 0, female Balb/C mice are terminated and
spleens obtained for CD45RB.sup.high cell isolation (Using SCID IBD
cell Separation protocol). Approximately 4.times.10.sup.5 cells/mL
CD45RB.sup.high cells are then injected IP (100 .mu.L/mouse) into
female SCID animals. On study day 14, mice are weighed and
randomized into treatment groups based on body weight. On Day 14
compounds are administered BID, via oral gavage, in a peanut oil
vehicle at the dose levels outlined below and a dose volume of 5
mL/kg. Treatment continues until study day 42, at which point the
animals are necropsied 4 hours after am administration. The colon
length and weight is recorded and used as a secondary endpoint in
the study as a measurement of colon oedema. The colon is then
divided into six cross-sections, four of which are used for
histopathology scoring (primary endpoint) and two are homogenised
for cytokine analysis.
[0650] Data shown is the % inhibition of the induction window
between naive animals and vehicle animals, where higher inhibition
implies closer to the non-diseased, naive, phenotype.
[0651] (E) Cigarette smoke model
[0652] A/J mice (males, 5 weeks old) are exposed to cigarette smoke
(4% cigarette smoke, diluted with air) for 30 min/day for 11 days
using a Tobacco Smoke Inhalation Experiment System for small
animals (Model SIS-CS; Sibata Scientific Technology, Tokyo, Japan).
Test substances are administered intra-nasally (35 .mu.L of
solution in 50% DMSO/PBS) once daily for 3 days after the final
cigarette smoke exposure. At 12 hr after the last dosing, each of
the animals is anesthetized, the trachea cannulated and
bronchoalveolar lavage fluid (BALF) is collected. The numbers of
alveolar macrophages and neutrophils are determined by FACS
analysis (EPICS.RTM. ALTRA II, Beckman Coulter, Inc., Fullerton,
Calif., USA) using anti-mouse MOMA2 antibody (macrophage) or
anti-mouse 7/4 antibody (neutrophil).
[0653] (F) Endotoxin-induced uveitis in rats
[0654] Male, Lewis rats (6-8 weeks old, Charles River UK Limited)
are housed in cages of 3 at 19-21.degree. C. with a 12 h light/dark
cycle (07:00/19:00) and fed a standard diet of rodent chow and
water ad libitum. Non-fasted rats are weighed, individually
identified on the tail with a permanent marker and receive a single
intravitreal administration into the right vitreous humor (5 .mu.L
dose volume) of 100 ng/animal, i.v.t. of LPS (Escherichia coli
0111:B4 prepared in PBS, Sigma Aldrich, UK) using a 32-gauge
needle. Untreated rats are injected with PBS. Test compound,
dexamethasone (Dex) or vehicle (20%
hydroxypropyl-.beta.-cyclodextrin, 0.1% HPMC, 0.01% Benzalconium
chloride, 0.05% EDTA, 0.7% NaCl in deionised water) are
administered by the topical route onto the right eye (10 .mu.L) of
animals 30 minutes prior to LPS, at the time of LPS administration,
and 1, 2 and 4 hours post LPS administration. Before
administration, the solution or suspension to be administered is
agitated for 5 minutes to ensure a uniform suspension. 6 hours
after LPS dosing, animals are euthanized by overdose with
pentobarbitone (i.v.). Following euthanasia, the right eye of each
animal is enucleated and dissected into front (anterior) and back
(posterior) sections around the lens. Each section is weighed and
homogenised in 500 .mu.L of sterile phosphate buffered saline
followed by 20 minutes centrifugation at 12000 rpm at 4.degree. C.
The resulting supernatant is divided into 3 aliquots and stored at
-80.degree. C. until subsequent cytokine analysis by R&D DuoSet
ELISA.
[0655] Summary of In Vitro and In Vivo Screening Results
[0656] Studies conducted by LeadHunter Discover Services (DiscoveRx
Corporation, Fremont, Calif.) using the KINOMEscan.TM. technology
determined that compound of Example 2 did not have any effect on
the binding of the kinases B-Raf and B-Raf (V600e) to their
standard ligands.
TABLE-US-00003 TABLE 3 KinomeScan Selectivity score data for the
Reference Compound and the compound of Example 2 at 50 and 500 nM
KinomeScan Selectivity Scores/number of hits 50 nM 500 nM Compound
S(35) S(10) S(1) S(35) S(10) S(1) Reference 0.174/67 0.083/32
0.018/7 0.370/143 0.272/105 0.117/45 Compound Ex. 2 0.081/32
0.020/8 0.000/0 0.233/92 0.099/39 0.010/4
[0657] The in vitro profile of the compound examples of the present
invention, as determined using the protocols described above, are
presented below (Tables 3a and 3b).
TABLE-US-00004 TABLE 3a The p38 MAPK (Method 2), c-Src, Syk and
GSK3.alpha. (Method 2) Enzyme Profiles of Compound Examples Test
Compound IC.sub.50 Values for Enzyme Inhibition (nM) Example No.
p38 MAPK.alpha. c-Src Syk GSK3.alpha. 1 25 30 370 12773 2 52 11 50
3849 3 39 14 30 12159 4 50 19 46 9547 5 33 13 34 13006 6 42 17 96
1695 7 88 18 237 2020 8 104 20 120 2890 9 98 15 35 12107 10 110 25
48 12034 11 766 >1212 >1212 12122 12 NT NT NT 12485 13 370 21
123 2129 14 88 4 20 402 15 34 18 57 3196 16 NT 15 27 646 17 NT NT
NT 12093
TABLE-US-00005 TABLE 3b Inhibition of cytokine release in
stimulated cells (assays (a), (b), (c) and (d) above) IC.sub.50
Values for Inhibition of Cytokine Release (nM) Test HT29 Compound
dU937 cells PBMCs cells Example No. IL-8 TNF.alpha. IL-8 TNF.alpha.
IL-2 IFN.gamma. IL-8 1 NT NT 1.6 NT NT NT NT 2 0.5 0.5 2.0 0.7 44.2
2.5 3.3 3 NT NT 1.2 NT 7.5 2.0 NT 4 NT NT 1.4 NT 37.4 2.4 5.3 5 NT
NT 1.2 NT 52.1 1.7 NT 6 NT NT 2.3 NT 123.3 2.9 2.4 7 NT NT 2.4 NT
91.0 3.7 1.6 8 NT NT 1.6 NT 55.0 8.5 3.2 9 NT NT 2.9 NT NT 8.4 3.5
10 NT NT 3.3 NT NT 2.7 4.8 11 NT NT 4.3 NT NT NT 6.2 12 NT NT 11.8
NT NT NT 10.9 13 NT NT 4.6 NT NT NT 3.6 14 NT NT 1.5 NT NT NT 1.5
15 NT NT 1.2 NT NT NT 2.0 16 NT NT 2.7 NT NT NT NT 17 NT NT 5.0 NT
NT NT NT
[0658] In addition to the above: [0659] when studied in assay (e)
above, the compound of Example 2 exhibited IC.sub.50 values of 2.1
and 2.8 nM for inhibition of release of IL-8 and IL-6,
respectively; [0660] when studied in assay (g) above, the compound
of Example 2 exhibited an IC.sub.50 values of 2.7 nM for inhibition
of T cell proliferation; and [0661] when studied in assay (p) above
(neutrophil degranulation), the compound of Example 2 exhibited an
IC.sub.50 of 42.7 nM (an average of 3 experiments).
[0662] As illustrated in Table 4a, compounds of the examples of the
present invention are markedly less active than the Reference
Compound in assay (i) above, which measures impact on cell division
(mitosis) in PBMCs.
TABLE-US-00006 TABLE 4a Effect of compounds of the examples on cell
division in PBMCs (NT = not tested) Test compound % Inhibition of
mitosis Reference at 5 .mu.g/mL compound 87.8.sup.a 1 3.6 2 18.7 3
2.1 4 38.8 5 10.4 6 10.2 7 9.1 8 6.1 9 NT 10 NT 11 NT 12 NT 13 NT
14 NT 15 NT 16 NT 17 NT .sup.aSee, for example, the value reported
in WO 2013/050757.
[0663] As illustrated in Table 4b, compounds of the examples of the
present invention did not elicit any significant .beta.-catenin
induction when studied in assay (m) above. Thus, the potential of
those compounds to increase cellular concentrations of
.beta.-catenin was found to be negative in that their inductive
effect at various test concentrations was substantially less than
the effect produced by the Reference Compound at 1 .mu.g/mL.
TABLE-US-00007 TABLE 4b Effect of compounds of the examples on
.beta.-catenin induction (NT = not tested) % .beta.-catenin
induction Concentration of test compound Test compound 1 .mu.g/mL 5
.mu.g/mL 10 .mu.g/mL Reference compound 100 NT NT 1 -14 -13 -17 2 0
2 0 3 1 6 6 4 5 12 NT 5 8 2 3 6 3 3 -1 7 0 -2 -5 8 6 3 2 9 1 2 4 10
4 2 2 11 NT NT NT 12 NT NT NT 13 -5 -2 -4 14 NT NT NT 15 4 11 27 16
NT NT NT 17 NT NT NT
[0664] When studied in assay (q) above (cell cytotoxicity),
percentage cell viability relative to DMSO control was measured as
101% at 5 .mu.g/mL and 103% at 1 .mu.g/mL of the compound of
Example 2. Thus, that compound does not exhibit any cytotoxicity in
assay (q). By comparison, percentage cell viability relative to
DMSO control was measured for the Reference Compound as 43% at 5
.mu.g/mL and 49% at 1 .mu.g/mL.
[0665] As illustrated in Tables 5a, 5b1 and 5b2 below, the compound
of Example 2 was also screened in human biopsy assay (h) and in
vivo assay (C) above, as conducted over 2 days. Histopathology
analysis revealed that the compound of Example 2 displayed
significant activity in the in vivo model of colonic inflammation.
In particular, that compound, when dosed orally at 5 mg/kg,
demonstrated marked improvements in ulcer grade and epithelial
repair compared to the vehicle control. In addition, the compound
of Example 2 produced marked reduction in inflammatory cell
infiltrate in the reticular and lamina propria zones. The compound
of Example 2 also demonstrated marked anti-inflammatory effects in
biopsies from ulcerative colitis (UC) patients. In contrast to
healthy volunteers, intestinal mucosal biopsies from UC patients
have been shown to spontaneously release pro-inflammatory cytokines
in vitro (Onken, J. E. et al., J Clin Immunol, 2008, 126(3):
345-352). Addition of the compound of Example 2 to biopsies in
vitro markedly reduced IL-1.beta., IL-6 and IL-8 release.
TABLE-US-00008 TABLE 5a Summary of results from studies on
TNBS-induced colitis in mice. Experiment TNBS no. Treatment group n
Ulcer grade LP inflammation 1 Non-diseased 6 0.0 .+-. 0.0 0.2 .+-.
0.2 1 TNBS + Vehicle 24 4.4 .+-. 0.2# 4.5 .+-. 0.2# 1 TNBS +
Example 2 12 3.5 .+-. 0.4 2.9 .+-. 0.3* (1 mg/kg) 1 TNBS + Example
2 12 3.0 .+-. 0.5* 2.2 .+-. 0.4* (5 mg/kg) #P > 0.001 compared
to non-diseased animals *p < 0.05 relative to vheicle
control
TABLE-US-00009 TABLE 5b1 Summary of results from assays using
intestinal mucosa biopsies from the inflamed regions of the colon
of various patients suffering from ulcerative colitis (a form of
IBD). Cytokine release from biopsies of UC patients (% release
relative to DMSO control) Treatment IL-1.beta. IL-6 IL-8 group n
release n release n release DMSO control 100% 100% 100% Example 2
(1 .mu.g/mL) 4 4 .+-. 10 6 29 .+-. 30 6 21 .+-. 21
TABLE-US-00010 TABLE 5b2 Summary of results from further assays
using intestinal mucosa biopsies from the inflamed regions of the
colon of various patients suffering from ulcerative colitis (a form
of IBD). Cytokine release from biopsies of UC patients (% release
relative to DMSO control) Treatment TNF.alpha. IL-1.beta. IL-6 IL-8
group n release n release n release n release DMSO control 100%
100% 100% 100% Example 2 (1000 ng/mL) 2 10 .+-. 3 2 9 .+-. 5 4 6
.+-. 3 4 .sup. 3 .+-. 0.1 Example 2 (100 ng/mL) 2 17 .+-. 1 2 .sup.
2 .+-. 0.1 4 18 .+-. 4 4 19 .+-. 7 Example 2 (10 ng/mL) 2 27 .+-.
17 2 2 .+-. 2 4 40 .+-. 23 4 71 .+-. 30 Example 2 (3 ng/mL) 2 48
.+-. 9 2 34 .+-. 4 4 34 .+-. 9 4 41 .+-. 14
[0666] As illustrated in Tables 5c and 5d below, the compound of
Example 2 was also screened in cellular assays (n) and (o) above.
In these assays, the compound of Example 2 displayed significant
inhibition of cytokines from cells isolated from diseased (IBD)
patients. Negative values reported in Table 5d are indicative of
inhibition of the basal expression of cytokines by the compound of
Example 2.
TABLE-US-00011 TABLE 5c Summary of results from assays using LPMCs
from IBD patients. Cytokine release from LPMCs of IBD patients (%
release relative to DMSO control) Treatment group n IFN.gamma.
release n TNF.alpha. release DMSO control 100 100 Example 2 (1000
ng/mL) 1 2 1 0 Example 2 (100 ng/mL) 1 1 1 2 Example 2 (10 ng/mL) 1
9 1 2 Example 2 (1 ng/mL) 1 8 1 12 Example 2 (0.3 ng/mL) 1 20 1
35
TABLE-US-00012 TABLE 5D Summary of results from assays using LPMCs
from IBD patients. Cytokine release from myofibroblasts of IBD
patients (% release relative to DMSO control) Treatment group n
IL-8 release n IL-6 release DMSO control 100 100 Example 2 (100
ng/mL) 2 -72 .+-. 34 2 -21 .+-. 8 Example 2 (10 ng/mL) 2 -52 .+-.
22 2 -12 .+-. 4 Example 2 (1 ng/mL) 2 66 .+-. 147 2 82 .+-. 105
[0667] As illustrated in Table 6 below, the compound of Example 2
was also screened in the in vivo (adoptive transfer) assay (D)
above. Histopathology analysis, as well as analysis of the relative
inhibition of cytokine release revealed that the compound of
Example 2 also displayed significant activity in this further in
vivo model of colonic inflammation.
TABLE-US-00013 TABLE 5 Summary of results from adoptive transfer
mouse model. Dose of compound of Example 2 (mg/kg) 5 1 0.2 0.04 %
Inhibition of colon weight: length 61%* 43%# 23% 25%# % inhibition
of IL-8 release 90%# 36%# 39% 34%# % inhibition of overall
histopathology score 46% 33% 5% 2% *P < 0.05 ANOVA to vehicle #p
< 0.05 T-test to vehicle
[0668] Summary of Additional Studies
[0669] Determination of Pharmacokinetic Parameters
[0670] (i) Studies in Mice
[0671] A study was conducted by Sai Life Sciences (Hinjewadi, Pune,
India) to investigate the pharmacokinetics and total colon tissue
distribution of the compound of Example 2 in male C57BL/6 mice
following a single oral administration.
[0672] A group of twenty one male mice were dosed with a suspension
formulation (in peanut oil) of the compound of Example 2, at a dose
of 5 mg/kg. Blood samples (approximately 60 .mu.L) were collected
from retro orbital plexus such that the samples were obtained at 1,
2, 4, 6, 8, 12 and 24 hr. The blood samples were collected from a
set of three mice at each time point in labelled micro centrifuge
tube containing K.sub.2EDTA as anticoagulant. Plasma samples were
separated by centrifugation at 4000 rpm for 10 min of whole blood
and stored below -70.degree. C. until bioanalysis. After collection
of blood sample, animals were humanely euthanized by carbon dioxide
asphyxiation to collect total colon tissues. The colons were
flushed with cold phosphate buffer saline (pH 7.4) to remove
contents. The total colon tissues were homogenized with cold
phosphate buffer saline (pH 7.4) of twice the weight of colon
tissue and stored below -70.degree. C. Total volume was three times
the total colon tissue weights. All samples were processed for
analysis by protein precipitation using acetonitrile and analyzed
with developed LC-MS/MS method (LLOQ: 2.02 ng/mL in plasma and 1.01
ng/mL in colon tissue). Pharmacokinetic parameters were calculated
using the non-compartmental analysis tool of Phoenix WinNonlin.RTM.
software (version 6.3).
[0673] (II) Studies in Rats
[0674] A study was conducted by Sai Life Sciences (Hinjewadi, Pune,
India) to investigate the pharmacokinetics, as well as plasma and
total colon tissue distribution of the compound of Example 2 in
male Wistar rats following a single intravenous or oral
administration.
[0675] 30 male Wistar rats were divided into two groups: Group I
(p.o.: 5 mg/kg) and Group II (i.v.: 0.25 mg/kg). Animals in Group I
were administered orally with an aqueous suspension formulation
(having 2% HPMC and 0.5% Tween 80) of the compound of Example 2, at
a dose of 5 mg/kg. Animals in Group II were administered
intravenously with a solution formulation (in 5% v/v DMSO, 7.5% w/v
Solutol HS 15 and 87.5% saline (0.9% w/v NaCl)) of the compound of
Example 2 at a dose of 0.25 mg/kg. From each rat, blood samples
(approximately 120 .mu.L) were collected from retro orbital plexus
such that samples were obtained at pre-dose, 0.05, 0.13, 0.25, 0.5,
1, 2, 4, 8, and 24 hr (i.v.) and pre-dose, 0.5, 1, 2, 4, 6, 8, 12
and 24 hr (p.o.). Immediately after collection, plasma was
harvested from blood by centrifugation and stored at -70.degree. C.
until analysis. Following collection of blood sample, the animals
(Group I) were humanely euthanized by carbon dioxide asphyxiation.
The total colon was isolated, flushed with cold phosphate buffer
saline (pH 7.4) to remove contents and weighed. The total colon
tissues homogenized with ice-cold phosphate buffered saline, pH
7.4. Buffer volume to be used for homogenization was twice the
weight of tissue. All the samples were stored below -70.degree. C.
until bioanalysis. Total colon tissue homogenate volume was three
times. Plasma and total colon tissue samples were quantified by
LC-MS/MS method (LLOQ in plasma and total colon tissue=0.5
ng/mL).
[0676] (II) Studies in Beagle Dogs
[0677] A study was conducted by Sai Life Sciences (Hinjewadi, Pune,
India) to investigate the plasma pharmacokinetics of the compound
of Example 2 in male beagle dogs following a single intravenous or
oral administration.
[0678] A group of three male beagle dogs were administered orally
with an aqueous suspension formulation (having 2% HPMC and 0.5%
Tween 80) of the compound of Example 2, at a dose of 1 mg/kg. A
group of three male beagle dogs were administered intravenously
with a solution formulation (in 5% v/v DMSO, 7.5% w/v Solutol HS 15
and 87.5% saline (0.9% w/v NaCl)) of the compound of Example 2, at
a dose of 0.05 mg/kg. Blood samples (approximately 1.5 mL) were
collected from jugular vein such that the samples were obtained at
pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hr (p.o.) and pre-dose,
0.08, 0.25, 0.5, 1, 2, 4, 8, 12, 24 and 32 hr (i.v.) post dose. The
blood samples were collected from a set of three dogs at each time
point in labelled micro centrifuge tube containing K.sub.2EDTA as
anticoagulant. Plasma samples were separated by centrifugation at
2500 g for 10 min of whole blood and stored below -70.degree. C.
until bioanalysis. All samples were processed for analysis by
protein precipitation using acetonitrile and analyzed with LC-MS/MS
method (LLOQ=0.50 ng/mL). Pharmacokinetic parameters were
calculated using the non-compartmental analysis tool of Phoenix
WinNonlin.RTM. (Version 6.3).
TABLE-US-00014 TABLE 7a Pharmacokinetic parameters determined from
studies involving oral administration of the compound of Example 2.
Mouse Rat Dog Dose & route 5 mg/kg p.o. 5 mg/kg p.o. 1 mg/kg
p.o. Bio matrix Plasma Total colon Plasma Total colon Plasma
T.sub.max (h) 1 8 4 8 -- C.sub.max (ng/mL) 12 13,671 2.7 2,005 --
AUC.sub.LAST 49 117,473 4.8 15,528 -- (h ng/mL) AUC.sub.INF NR
117,565 NC 15,761 -- (h ng/mL) F.sub.po (%) -- -- 0.04 -- 0 NR--Not
reported since the AUC.sub.INF is 20% greater than AUC.sub.LAST.
NC--Not calculated due to insufficient elimination phase.
TABLE-US-00015 TABLE 7b Pharmacokinetic parameters determined from
studies involving intravenous administration of the compound of
Example 2. Rat Dog Dose 0.25 mg/kg 0.05 mg/kg C.sub.0 (ng/mL) 5,364
1,370 .+-. 1,175 AUC.sub.LAST (h ng/mL) 682 218 .+-. 90 AUC.sub.INF
(h ng/mL) 691 223 .+-. 92 T.sub.1/2 (h) 2.2 1.9 .+-. 0.4 CL
(mL/min/kg) 6.3 4.1 .+-. 1.4 V.sub.d (L/kg) 0.3 0.2 .+-. 0.1
TABLE-US-00016 TABLE 7c Concentrations of the compound of Example 2
determined at different time points in the mouse pharmacokinetic
study Mean concentration of the compound of Example 2 (average of 3
experiments) Plasma Colon Time (hr) (ng/mL) (ng/g) 1 11.7 884 2 8.5
2807 4 5.1 4235 6 4.55 (n = 2) 1395 8 5.1 13671 12 0.0 7489 24 0.0
31.6
TABLE-US-00017 TABLE 7d Concentrations of the compound of Example 2
determined at different time points in the rat pharmacokinetic
study Mean concentration of the compound of Example 2 (average of 3
experiments) Plasma Colon Time (hr) (ng/mL) (ng/g) Pre-dose 0.0 0.0
0.8 3.3 1 0.9 1.9 (n = 2) 2 0.6 4.0 (n = 2) 4 2.7 339 6 1.7 1862 8
0.6 2005 12 0.7 597 24 1.8 53.9
[0679] Determination of ADME Parameters
[0680] Assessment of certain in vitro ADME (absorption,
distribution, metabolism, and excretion) parameters for the
compound of Example 2 was conducted by BioFocus (Saffron Walden,
UK).
[0681] (i) Metabolic Stability
[0682] Hepatic Microsomal Stability [0683] Microsomal stability
assays were performed with incubations of test compounds at 0.1
.mu.M (n=2, final DMSO concentration 0.25%), and carried out using
pooled human, dog, rat and Cynomolgus macaque hepatic microsomes
from Xenotech (Lots 1210153, 0810143 and 1110042, respectively) at
0.25 mg protein/mL in the presence of co-factor, NADPH. The
incubations were performed at 37.degree. C. with 100 .mu.L aliquots
taken from the incubation, at 0, 2, 5, 10 and 20 minutes (and, in
the case of Cynomolgus macaque hepatic microsomes, 40 minutes) and
reactions terminated by addition of 100 .mu.L of acetonitrile
containing carbamazepine as analytical internal standard. Samples
were centrifuged and the supernatant fractions analysed by
LC-MS/MS. [0684] The instrument responses (peak heights) were
referenced to the zero time-point samples (as 100%) in order to
determine the percentage of compound remaining. [0685] Ln plots of
the % remaining, for each compound, were used to determine the
half-life for the microsomal incubations. Half-life values were
calculated from the relationship
[0685] T.sub.1/2(min)=-0.693/.lamda. [0686] where .lamda. was the
slope of the Ln concentration vs time curve. [0687] The in vitro
intrinsic clearance, Cl.sub.int (mL/min/kg), was calculated and
scaled to hepatic extraction ratios using the following scaling
parameters and formulae. [0688] Parameters
TABLE-US-00018 [0688] Value Parameter Human Dog Rat Monkey
Microsomal protein concentration 0.25 0.25 0.25 0.25 in incubation
(mg/mL) microsomes/g liver (mg) 52 78 45 32 liver weight/kg body
weight (g) 25 32 50 32 hepatic blood flow (mL/min/kg) 21 31 60
44
[0689] Formulae
[0689] Cl.sub.int(tissue
clearance)mL/min/kg=[0.693/t1/2(min)].times.[1/microsomal protein
concentration mg/mL].times.[mg microsomes/g liver].times.[g
liver/kg body weight]
Cl.sub.int(hepatic clearance)mL/min/kg=hepatic blood
flow.times.Cl.sub.int/(hepatic blood flow+Cl.sub.int)
Hepatic extraction ratio(Eh)=Cl.sub.int(hepatic
clearance)mL/min/kg/hepatic blood flow(mL/min/kg)
[0690] Cryopreserved Hepatocyte Stability [0691] Hepatocyte
stability assays were performed with incubations of test compounds
(0.1 .mu.M initial concentration, n=2) carried out with pooled
human, dog, rat and Cynomolgus macaque cryopreserved hepatocytes
from Celsis (Lot numbers RRW, KLI and WAP, respectively) at a cell
density of 0.5 million cells/mL. The incubations were performed at
37.degree. C. with 100 .mu.L samples taken from the incubation, at
0, 10, 20, 45 and 90 minutes, and reactions terminated by addition
of 100 .mu.L of acetonitrile containing carbamazepine as analytical
internal standard. Samples were centrifuged and the supernatant
fractions analysed by LC-MS/MS. [0692] The instrument responses
(peak heights) were referenced to the zero time-point samples (as
100%) in order to determine the percentage of compound remaining.
[0693] Ln plots of the % remaining, for each compound, were used to
determine the half-life for the hepatocyte incubations. Half-life
values were calculated from the relationship
[0693] T.sub.1/2(min)=-0.693/.lamda. [0694] where .DELTA. was the
slope of the Ln concentration vs time curve. [0695] Standard
compounds testosterone, midazolam and 4-methylumbelliferone are
included in the assay design. These compounds give an indication of
the metabolic capacity of the cryopreserved preparations for both
Phase I and Phase II reactions. [0696] In vitro intrinsic clearance
(Cl.sub.int), as .mu.L/min/million cells was calculated by applying
the following formula to the half-life values:
[0696] Cl.sub.int=0.693/T1/2(min).times.incubation
volume(.mu.L)/million cells [0697] The half-life values were also
scaled to hepatic extraction ratios using the scaling factors and
formulae below. [0698] Parameters
TABLE-US-00019 [0698] Value Parameter Human Dog Rat Monkey
Hepatocyte concentration in incubation 0.5 0.5 0.5 0.5 (million
cells/mL) Hepatocellularity (million cells/g liver) 120 240 120 120
liver weight/kg body weight (g) 25 32 50 32 hepatic blood flow
(mL/min/kg) 21 31 60 44
Cl.sub.int(Tissue
Clearance)mL/min/kg=[0.693/t1/2(min)].times.[1/hepatocyte
concentration (million cells/mL)].times.[million cells/g
liver].times.[g liver/kg body weight]
Cl.sub.int(Hepatic clearance)mL/min/kg=hepatic blood
flow.times.Cl.sub.int/(hepatic blood flow+Cl.sub.int)
Hepatic extraction ratio(Eh)=Cl.sub.int(Hepatic
clearance)mL/min/kg/hepatic blood flow(mL/min/kg)
[0699] The results catalogued in Tables 8a and 8b indicate that the
compound of Example 2 exhibits high hepatic clearance, a feature
resulting in lower systemic exposures in an in vivo setting.
TABLE-US-00020 TABLE 8a Summary of hepatic microsome stability
tests for the compound of Example 2 (results reported are the
arithmeticmean of two experiments). Source of hepatic Mean
intrinsic clearance Mean hepatic extraction microsomes
(.mu.L/min/mg protein) ratio (Eh) Human >554 >0.97 Dog
>554 >0.98 Rat 199 0.88 Cynomolgus macaque 445 0.91
TABLE-US-00021 TABLE 8b Summary of hepatocyte stability tests for
the compound of Example 2 (results reported are the arithmetic
meanof two experiments). Mean intrinsic clearance Mean hepatic
extraction Source of hepatocytes (.mu.L/min/million cells) ratio
(Eh) Human 37 0.84 Dog 46 0.92 Rat 49 0.83 Cynomolgus macaque 43
0.80
[0700] (ii) Time-Dependent Inhibition of Cytochromes
[0701] CYP450 time-dependent inhibition (TDI) assays were performed
with test compound at six test concentrations, 0.062 .mu.M to 15
.mu.M (n=2). The test compounds was pre-incubated for 30 minutes
with pooled human hepatic microsomes in 0.1 M Tris buffer, pH 7.4,
at 37.degree. C. in the presence of cofactor NADPH. A parallel
series of incubations (n=2) were prepared with no pre-incubation.
Probe substrates were then added (with additional cofactor) and
further incubated for the times specified. Concentrations of probe
substrates used in the incubations have been optimised to maintain
first order reaction conditions.
[0702] Reactions were terminated with acetonitrile containing
analytical internal standard (carbamazepine), samples then
centrifuged to remove microsomal protein and analysed using
optimised LC/MS-MS conditions. The MS data were normalized to
internal standard and compared to the appropriate solvent controls
to determine the amount of metabolite formed from the probe
substrate relative to the "uninhibited" controls. The results are
quoted as % inhibition. These values were then plotted using the
sigmoidal dose response equation (shown below) and IC.sub.50's
calculated.
Y=bottom+((top-bottom)/1+10 ((Log IC.sub.50-X)*Hill slope)) [0703]
X=Log concentration [0704] Y=response
[0705] IC.sub.50 is quoted in .mu.M, i.e. the point at which the
inhibition is 50% of the control value.
[0706] Positive and negative time-dependent inhibitors were
included to demonstrate the potential for specific and potent
interactions under the conditions used. Variation in probe turnover
between plate wells means that inhibition values recorded below
10-15% may not be significant.
[0707] A summary of the specific conditions are shown in the table
below.
TABLE-US-00022 Cytochrome Microsome Probe substrate P450 conc.
Conc. Incubation isoform (mg/mL) Identity (.mu.M) Metabolite time
(min) 3A4 0.25 Midazolam 7 1'-OH- 15 midazolam 2C9 0.25 Diclofenac
15 1'-OH- 15 diclofenac
TABLE-US-00023 TABLE 9 Summary of CYP inhibition studies for the
compound of Example 2 (results reported are the arithmetic mean of
two experiments). Cytochrome P450 0 min preincubation 30 min
preincubation isoform 15 .mu.M % Inh IC.sub.50 (.mu.M) 15 .mu.M %
Inh IC.sub.50 (.mu.M) CYP3A4 2 >15 52 7.7 CYP2C9 35 >15 37
>15
[0708] Analysis of Metabolites
[0709] Studies were conducted by BioFocus (Saffron Walden, UK) to
determine the metabolic fate of the compound of Example 2 following
incubation with rat, dog, Cynomolgus macaque or human
hepatocytes.
[0710] Separate incubations (n=3) of the compound of Example 2 (10
.mu.M initial concentration) or DMSO control, were performed with
cryopreserved hepatocytes from each species (0.5 million cell/mL)
at 37.degree. C. for 0, 60 and 90 minutes before termination of
reactions and compound extraction with acetonitrile. Sample
replicates were pooled prior to analysis.
[0711] Potential metabolites were identified using time-of-flight
(TOF) and triple quadruple (TQ) mass spectrometers.
[0712] For all types of hepatocytes tested, putative metabolites of
the compound of Example 2 were observed at very low levels compared
to the abundance of parent compound. The low signal intensity of
some metabolites made interpretation and structural assignment
problematic. Additionally, the close relationship of the products,
and their chromatographic proximity, produced complex mass spectra
from which it was not always possible to assign fragment ions to
one putative metabolite or another. The high degree of mass
resolution afforded by the time-of-flight instrument did, however,
provide confidence in the empirical formulae of the structures
postulated.
[0713] A total of nine metabolites were identified in all studies.
Six of the nine metabolites identified, including all of those in
human hepatocytes, had empirical formulae that were consistent with
oxidative breakdown of the polyethylene glycol (PEG) side-chain of
the compound of Example 2. The other three metabolites were
observed in studies with either dog or Cynomolgus macaque
hepatocytes only.
[0714] hERG Inhibition Studies
[0715] The compound of Example 2 was tested for inhibition of the
human ether a go-go (hERG) channel using IonWorks.TM. patch clamp
electrophysiology at Essen Bioscience (Welwyn Garden City,
England). Eight-point concentration curves were generated using
serial 3-fold dilutions from the maximum final assay concentration
(3 .mu.M). Electrophysiological recordings were made from a Chinese
Hamster Lung cell line stably expressing the full length hERG
channel. Single cell ionic currents were measured in the perforated
patch clamp configuration (100 .mu.g/mL) amphotericin) at room
temperature (21-23.degree. C.) using an IonWorks Quattro
instrument. The internal solution contained (mM): 140 KCl, 1
MgCl.sub.2, 1 EGTA, 20 HEPES and was buffered to pH 7.3. The
external solution contained (mM):138 NaCl, 2.7 KCl, 0.9 CaCl.sub.2,
0.5 MgCl.sub.2, 8 Na.sub.2HPO.sub.4, 1.5 KH.sub.2PO.sub.4, also
buffered to pH 7.3. Cells were clamped at a holding potential of
-70 mV for 30 s and then stepped to +40 mV for 1 s. This was
followed by a hyperpolarising step of 1 s to -30 mV to evoke the
hERG tail current. This sequence was repeated 5 times at a
frequency of 0.25 Hz. Currents were measured from the tail step at
the 5th pulse, and referenced to the holding current. Compounds
were then incubated for 6-7 minutes prior to a second measurement
of the hERG signal using an identical pulse train. Eight-point
concentration curves were generated using serial 3-fold dilutions
from the maximum final assay concentration (3 .mu.M). These studies
determined that the compound of Example 2 has an IC.sub.50 value
for the hERG channel of greater than 3 .mu.M (0.+-.4% inhibition of
the channel being observed at 3 .mu.M concentration of the compound
of Example 2).
[0716] Diversity Profile
[0717] Studies were conducted by Cerep (Celle-Levescault, France)
to investigate the binding of the compound of Example 2 to a
diverse selection of receptors and to investigate either the
inhibition or activation of a selection of enzymes (the "Diversity
Profile" comprising a total of 71 receptors and 26 enzymes).
[0718] When studied at a concentration of 300 nM the compound of
Example 2 did not significantly bind to any of the receptors or
inhibit/activate the enzymes tested (i.e. it inhibited the control
specific binding in the receptor binding assays or enzyme assays by
less than 25%, as assessed using a suitable radioligand for each
receptor or a suitable reference substrate for each enzyme).
[0719] Mutagenicity Assessment (Bacterial Reverse Mutation
Screen)
[0720] Studies were conducted by Sequani (Ledbury, Herefordshire,
UK) to assess the compound of Example 2 in vitro for its ability to
induce mutations in two histidine dependent auxotrophic mutants of
Salmonella typhimurium, strains TA98 and TA100.
[0721] The mutation screen was conducted using the plate
incorporation method and was performed in both the presence and
absence of S-9 mix (a liver post-mitochondrial fraction derived
from the livers of Aroclor 1254 treated rats). The bacteria were
exposed to the compound of Example 2 dissolved in
dimethylsulphoxide, which solvent was also used as the negative
control. The dose levels used were 0.32, 1.6, 8, 40, 200, 1000 or
5000 .mu.g/plate.
[0722] Analysable treatment levels of the compound of Example 2
were limited by insolubility to 1000 .mu.g/plate, as heavy
precipitation observed at 5000 .mu.g/plate affected the scoring of
the colonies. Precipitation was also noted in both strains at 1000
.mu.g/plate in the presence and absence of S-9 mix.
[0723] The compound of Example 2 showed no dose-related or
statistically significant increases in revertant colonies in either
Salmonella typhimurium strain in the presence or absence of S-9
mix. This indicates the absence of any mutagenic effects for the
compound of Example 2 in the Salmonella typhimurium strains
studied.
[0724] Hydrolytic Stability Study
[0725] Chemical stability of the compound of Example 2 was assessed
in a mixture of DMSO and water (3:1) at a test compound
concentration of 1 mg/mL [0726] General HPLC Procedure [0727]
Agilent, Waters X-Select C18, 2.5 .mu.m, 4.6.times.30 mm column, 4
min method, 5-95% [0728] MeCN/water (0.1% formic acid). [0729] Flow
rate 2.5 ml/min. [0730] Column Oven Temperature 40.degree. C.
[0731] Detection 254 nm. [0732] Sample Preparation [0733] A 1.0 mg
sample of test compound was dissolved in 750 .mu.L of DMSO. Water
(250 .mu.L) was added slowly, ensuring no precipitation occurred.
[0734] Recording Stability [0735] A 50 .mu.L aliquot of the test
solution was removed and analysed in duplicate by 5 .mu.L HPLC
injections. The peak area for the test compound was recorded
following manual integration of the corresponding UV trace. [0736]
The test solution was heated to 60.degree. C., with stirring, and
50 .mu.L aliquots removed for HPLC analysis at 5 and 24 h
timepoints. In all cases, 5 .mu.L injections were used and the
samples analysed in duplicate. [0737] The peak area for the test
compound was recorded at both subsequent timepoints and the %
decomposition calculated from the % change in peak area over time.
[0738] Reference Compound A
(3-ethynyl-5-((4-((4-(3-(3-isopropyl-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)n-
aphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-N-(2-morpholinoethyl)benzamide)
was included in each stability study as a control to validate the
study.
[0739] The results of the study are reported in the table
below.
TABLE-US-00024 Test Compound Time (min) % left Reference Compound A
0 100 300 82 1440 36 Example 2 0 100 300 83 1440 39
[0740] Chemical stability of the compound of Example 2 (in solid
form) was also assessed at 40.degree. C. and 75% relative humidity.
The results of the study are reported in the table below (where
chemical purity was assessed using HPLC).
TABLE-US-00025 Condition 1 month, 40.degree. C./ 3 months,
40.degree. C./ Compound 0 months 75% RH 75% RH Example 2 98.52%
96.88% 94.32%
[0741] Throughout the specification and the claims which follow,
unless the context requires otherwise, the word `comprise`, and
variations such as `comprises` and `comprising`, will be understood
to imply the inclusion of a stated integer, step, group of integers
or group of steps but not to the exclusion of any other integer,
step, group of integers or group of steps.
[0742] All patents and patent applications referred to herein are
incorporated by reference in their entirety.
[0743] The application of which this description and claims forms
part may be used as a basis for priority in respect of any
subsequent application. The claims of such subsequent application
may be directed to any feature or combination of features described
herein. They may take the form of product, composition, process, or
use claims and may include, by way of example and without
limitation, the claims.
* * * * *